These terms and conditions govern your use of the website alphaminr.com and its related services.
These Terms and Conditions (“Terms”) are a binding contract between you and Alphaminr, (“Alphaminr”, “we”, “us” and “service”). You must agree to and accept the Terms. These Terms include the provisions in this document as well as those in the Privacy Policy. These terms may be modified at any time.
Your subscription will be on a month to month basis and automatically renew every month. You may terminate your subscription at any time through your account.
We will provide you with advance notice of any change in fees.
You represent that you are of legal age to form a binding contract. You are responsible for any
activity associated with your account. The account can be logged in at only one computer at a
time.
The Services are intended for your own individual use. You shall only use the Services in a
manner that complies with all laws. You may not use any automated software, spider or system to
scrape data from Alphaminr.
Alphaminr is not a financial advisor and does not provide financial advice of any kind. The service is provided “As is”. The materials and information accessible through the Service are solely for informational purposes. While we strive to provide good information and data, we make no guarantee or warranty as to its accuracy.
TO THE EXTENT PERMITTED BY APPLICABLE LAW, UNDER NO CIRCUMSTANCES SHALL ALPHAMINR BE LIABLE TO YOU FOR DAMAGES OF ANY KIND, INCLUDING DAMAGES FOR INVESTMENT LOSSES, LOSS OF DATA, OR ACCURACY OF DATA, OR FOR ANY AMOUNT, IN THE AGGREGATE, IN EXCESS OF THE GREATER OF (1) FIFTY DOLLARS OR (2) THE AMOUNTS PAID BY YOU TO ALPHAMINR IN THE SIX MONTH PERIOD PRECEDING THIS APPLICABLE CLAIM. SOME STATES DO NOT ALLOW THE EXCLUSION OR LIMITATION OF INCIDENTAL OR CONSEQUENTIAL OR CERTAIN OTHER DAMAGES, SO THE ABOVE LIMITATION AND EXCLUSIONS MAY NOT APPLY TO YOU.
If any provision of these Terms is found to be invalid under any applicable law, such provision shall not affect the validity or enforceability of the remaining provisions herein.
This privacy policy describes how we (“Alphaminr”) collect, use, share and protect your personal information when we provide our service (“Service”). This Privacy Policy explains how information is collected about you either directly or indirectly. By using our service, you acknowledge the terms of this Privacy Notice. If you do not agree to the terms of this Privacy Policy, please do not use our Service. You should contact us if you have questions about it. We may modify this Privacy Policy periodically.
When you register for our Service, we collect information from you such as your name, email address and credit card information.
Like many other websites we use “cookies”, which are small text files that are stored on your computer or other device that record your preferences and actions, including how you use the website. You can set your browser or device to refuse all cookies or to alert you when a cookie is being sent. If you delete your cookies, if you opt-out from cookies, some Services may not function properly. We collect information when you use our Service. This includes which pages you visit.
We use Google Analytics and we use Stripe for payment processing. We will not share the information we collect with third parties for promotional purposes. We may share personal information with law enforcement as required or permitted by law.
þ
|
Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
|
o
|
Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
|
Delaware
|
|
75-3108137
|
State of Incorporation
|
|
IRS Employer Identification No.
|
|
|
|
11825 N. Pennsylvania Street
|
|
|
Carmel, Indiana 46032
|
|
(317) 817-6100
|
Address of principal executive offices
|
|
Telephone
|
Title of each class
|
|
Name of Each Exchange on which Registered
|
Common Stock, par value $0.01 per share
|
|
New York Stock Exchange
|
Rights to purchase Series C Junior Participating Preferred Stock
|
|
New York Stock Exchange
|
PART I
|
|
Page
|
Item 1.
|
||
Item 1A.
|
||
Item 1B.
|
||
Item 2.
|
||
Item 3.
|
||
Item 4.
|
||
|
||
|
|
|
PART II
|
|
|
Item 5.
|
||
Item 6.
|
||
Item 7.
|
||
Item 7A.
|
||
Item 8.
|
||
Item 9.
|
||
Item 9A.
|
||
Item 9B.
|
||
|
|
|
PART III
|
|
|
Item 10.
|
||
Item 11.
|
||
Item 12.
|
||
Item 13.
|
||
Item 14.
|
||
|
|
|
PART IV
|
|
|
Item 15.
|
||
Item 16.
|
•
|
Bankers Life,
which markets and distributes Medicare supplement insurance, interest-sensitive life insurance, traditional life insurance, fixed annuities and long-term care insurance products to the middle-income senior market through a dedicated field force of career agents, financial and investment advisors, and sales managers supported by a network of community-based sales offices. The Bankers Life segment includes primarily the business of Bankers Life and Casualty Company ("Bankers Life"). Bankers Life also has various distribution and marketing agreements with other insurance companies to use Bankers Life's career agents to distribute Medicare Advantage and prescription drug plans ("PDP") products in exchange for a fee.
|
•
|
Washington National,
which markets and distributes supplemental health (including specified disease, accident and hospital indemnity insurance products) and life insurance to middle-income consumers at home and at the worksite. These products are marketed through Performance Matters Associates, Inc. ("PMA", a wholly owned subsidiary) and through independent marketing organizations and insurance agencies including worksite marketing. The products being marketed are underwritten by Washington National Insurance Company ("Washington National"). This segment's business also includes certain closed blocks of annuities and Medicare supplement policies which are no longer being actively marketed by this segment and were primarily issued or acquired by Washington National.
|
•
|
Colonial Penn
,
which markets primarily graded benefit and simplified issue life insurance directly to customers in the senior middle-income market through television advertising, direct mail, the internet and telemarketing. The Colonial Penn segment includes primarily the business of Colonial Penn Life Insurance Company ("Colonial Penn").
|
•
|
Long-term care in run-off
consists of the long-term care business that was recaptured due to the termination of certain reinsurance agreements effective September 30, 2016. This business is not actively marketed and was issued or acquired by Washington National and Bankers Conseco Life Insurance Company ("BCLIC").
|
•
|
Maximize our product portfolio to ensure it meets our customers’ needs for integrated products and advice covering a broad range of their financial needs
|
•
|
Position marketing and our distribution channels to better respond to evolving customer preferences
|
•
|
Expand and enhance elements of our broker-dealer and registered investment advisor program
|
•
|
Expand our reach within certain demographics of the middle-income market based on our improved customer segmentation analytics
|
•
|
Maintain our strong capital position and favorable financial metrics
|
•
|
Work to increase our return on equity
|
•
|
Maintain pricing discipline
|
•
|
Active enterprise risk management process
|
•
|
Continue to cost effectively repurchase our common stock, absent compelling alternatives
|
•
|
Maintain a competitive dividend payout ratio
|
•
|
Reduce relative legacy long-term care exposure
|
•
|
Leverage our recent investments to identify opportunities, drive increased productivity, improve efficiencies and profitability, and increase the speed-to-market for new products
|
•
|
Create a strong enterprise data strategy using our platforms and state-of-the-art tools to drive growth on a cost-effective basis
|
•
|
Continue to invest in technology partnerships that will support our field force and relationships with our customers, and leverage data to run our business profitably
|
•
|
Pilot various models across the agent lifecycle to drive increased growth, productivity and retention
|
•
|
Attract, retain and develop the best talent to help us drive sustainable growth, and provide them with development opportunities
|
•
|
Recruit, develop and retain our agent force
|
|
2016
|
|
2015
|
|
2014
|
||||||
Health:
|
|
|
|
|
|
||||||
Bankers Life
|
$
|
1,235.3
|
|
|
$
|
1,242.3
|
|
|
$
|
1,275.1
|
|
Washington National
|
628.4
|
|
|
619.6
|
|
|
603.0
|
|
|||
Colonial Penn
|
2.4
|
|
|
3.0
|
|
|
3.4
|
|
|||
Long-term care in run-off
|
4.7
|
|
|
—
|
|
|
—
|
|
|||
Total health
|
1,870.8
|
|
|
1,864.9
|
|
|
1,881.5
|
|
|||
Annuities:
|
|
|
|
|
|
||||||
Bankers Life
|
970.0
|
|
|
803.0
|
|
|
782.3
|
|
|||
Washington National
|
1.5
|
|
|
2.4
|
|
|
2.6
|
|
|||
Total annuities
|
971.5
|
|
|
805.4
|
|
|
784.9
|
|
|||
Life:
|
|
|
|
|
|
||||||
Bankers Life
|
461.1
|
|
|
446.0
|
|
|
424.9
|
|
|||
Washington National
|
29.4
|
|
|
27.7
|
|
|
25.9
|
|
|||
Colonial Penn
|
277.8
|
|
|
259.9
|
|
|
241.7
|
|
|||
Total life
|
768.3
|
|
|
733.6
|
|
|
692.5
|
|
|||
Total premium collections from business segments excluding the business of CLIC prior to being sold
|
3,610.6
|
|
|
3,403.9
|
|
|
3,358.9
|
|
|||
Premium collections related to business of CLIC prior to being sold (primarily life products)
|
—
|
|
|
—
|
|
|
71.2
|
|
|||
Total premium collections
|
$
|
3,610.6
|
|
|
$
|
3,403.9
|
|
|
$
|
3,430.1
|
|
|
2016
|
|
2015
|
|
2014
|
||||||
Medicare supplement:
|
|
|
|
|
|
||||||
Bankers Life
|
$
|
739.3
|
|
|
$
|
739.4
|
|
|
$
|
743.3
|
|
Washington National
|
61.0
|
|
|
72.6
|
|
|
85.2
|
|
|||
Colonial Penn
|
2.3
|
|
|
2.7
|
|
|
3.2
|
|
|||
Total
|
802.6
|
|
|
814.7
|
|
|
831.7
|
|
|||
Long-term care:
|
|
|
|
|
|
||||||
Bankers Life
|
468.6
|
|
|
476.6
|
|
|
500.6
|
|
|||
Long-term care in run-off
|
4.7
|
|
|
—
|
|
|
—
|
|
|||
Total
|
473.3
|
|
|
476.6
|
|
|
500.6
|
|
|||
Prescription Drug Plan products included in Bankers Life
|
—
|
|
|
—
|
|
|
6.8
|
|
|||
Supplemental health:
|
|
|
|
|
|
||||||
Bankers Life
|
21.2
|
|
|
19.2
|
|
|
16.3
|
|
|||
Washington National
|
565.5
|
|
|
544.8
|
|
|
515.4
|
|
|||
Total
|
586.7
|
|
|
564.0
|
|
|
531.7
|
|
|||
Other:
|
|
|
|
|
|
||||||
Bankers Life
|
6.2
|
|
|
7.1
|
|
|
8.1
|
|
|||
Washington National
|
1.9
|
|
|
2.2
|
|
|
2.4
|
|
|||
Colonial Penn
|
.1
|
|
|
.3
|
|
|
.2
|
|
|||
Total
|
8.2
|
|
|
9.6
|
|
|
10.7
|
|
|||
Total health premium collections
|
$
|
1,870.8
|
|
|
$
|
1,864.9
|
|
|
$
|
1,881.5
|
|
|
|
|
|
|
|
|
2016
|
|
2015
|
|
2014
|
||||||
Fixed index annuity:
|
|
|
|
|
|
||||||
Bankers Life
|
$
|
868.1
|
|
|
$
|
706.6
|
|
|
$
|
646.2
|
|
Washington National
|
1.2
|
|
|
1.9
|
|
|
2.0
|
|
|||
Total fixed index annuity premium collections
|
869.3
|
|
|
708.5
|
|
|
648.2
|
|
|||
Other fixed interest annuity:
|
|
|
|
|
|
||||||
Bankers Life
|
101.9
|
|
|
96.4
|
|
|
136.1
|
|
|||
Washington National
|
.3
|
|
|
.5
|
|
|
.6
|
|
|||
Total fixed interest annuity premium collections
|
102.2
|
|
|
96.9
|
|
|
136.7
|
|
|||
Total annuity premium collections from business segments excluding the business of CLIC prior to being sold
|
971.5
|
|
|
805.4
|
|
|
784.9
|
|
|||
Premium collections related to business of CLIC prior to being sold
|
—
|
|
|
—
|
|
|
.2
|
|
|||
Total annuity premium collections
|
$
|
971.5
|
|
|
$
|
805.4
|
|
|
$
|
785.1
|
|
•
|
The index to be used.
|
•
|
The time period during which the change in the index is measured. At the end of the time period, the change in the index is applied to the account value. The time period of the contract ranges from 1 to 4 years.
|
•
|
The method used to measure the change in the index.
|
•
|
The measured change in the index is multiplied by a "participation rate" (percentage of change in the index) before the credit is applied. Some policies guarantee the initial participation rate for the life of the contract, and some vary the rate for each period.
|
•
|
The measured change in the index may also be limited by a "cap" before the credit is applied. Some policies guarantee the initial cap for the life of the contract, and some vary the cap for each period.
|
•
|
The measured change in the index may also be limited to the excess in the measured change over a "margin" before the credit is applied. Some policies guarantee the initial margin for the life of the contract, and some vary the margin for each period.
|
|
2016
|
|
2015
|
|
2014
|
||||||
Interest-sensitive life products:
|
|
|
|
|
|
||||||
Bankers Life
|
$
|
175.0
|
|
|
$
|
169.1
|
|
|
$
|
169.8
|
|
Washington National
|
18.0
|
|
|
15.6
|
|
|
13.0
|
|
|||
Colonial Penn
|
.3
|
|
|
.2
|
|
|
.4
|
|
|||
Total interest-sensitive life premium collections
|
193.3
|
|
|
184.9
|
|
|
183.2
|
|
|||
Traditional life:
|
|
|
|
|
|
||||||
Bankers Life
|
286.1
|
|
|
276.9
|
|
|
255.1
|
|
|||
Washington National
|
11.4
|
|
|
12.1
|
|
|
12.9
|
|
|||
Colonial Penn
|
277.5
|
|
|
259.7
|
|
|
241.3
|
|
|||
Total traditional life premium collections
|
575.0
|
|
|
548.7
|
|
|
509.3
|
|
|||
Total life premium collections from business segments excluding the business of CLIC prior to being sold
|
768.3
|
|
|
733.6
|
|
|
692.5
|
|
|||
Premium collections related to business of CLIC prior to being sold on July 1, 2014:
|
|
|
|
|
|
||||||
Interest-sensitive life
|
—
|
|
|
—
|
|
|
61.3
|
|
|||
Traditional life
|
—
|
|
|
—
|
|
|
9.7
|
|
|||
Total premium collections related to business of CLIC prior to being sold
|
—
|
|
|
—
|
|
|
71.0
|
|
|||
Total life insurance premium collections
|
$
|
768.3
|
|
|
$
|
733.6
|
|
|
$
|
763.5
|
|
•
|
provide largely stable investment income from a diversified high quality fixed income portfolio;
|
•
|
maximize and maintain a stable spread between our investment income and the yields we pay on insurance products;
|
•
|
sustain adequate liquidity levels to meet operating cash requirements, including a margin for potential adverse developments;
|
•
|
continually monitor and manage the relationship between our investment portfolio and the financial characteristics of our insurance liabilities such as durations and cash flows; and
|
•
|
maximize total return through active investment management.
|
•
|
purchasing options on equity indices with similar payoff characteristics; and
|
•
|
adjusting the participation rate to reflect the change in the cost of such options (such cost varies based on market conditions).
|
Name of Reinsurer
|
Reinsurance receivables
|
|
Ceded life insurance inforce
|
|
A.M. Best rating
|
||||
Jackson National Life Insurance Company ("Jackson") (a)
|
$
|
1,482.4
|
|
|
$
|
755.1
|
|
|
A+
|
Wilton Reassurance Company ("Wilton Re")
|
320.2
|
|
|
1,309.0
|
|
|
A
|
||
RGA Reinsurance Company (b)
|
200.3
|
|
|
102.6
|
|
|
A+
|
||
Munich American Reassurance Company
|
3.4
|
|
|
476.6
|
|
|
A+
|
||
Swiss Re Life and Health America Inc.
|
3.0
|
|
|
611.0
|
|
|
A+
|
||
SCOR Global Life USA Reinsurance Company
|
1.4
|
|
|
95.0
|
|
|
A
|
||
All others (c)
|
249.7
|
|
|
254.7
|
|
|
|
||
|
$
|
2,260.4
|
|
|
$
|
3,604.0
|
|
|
|
(a)
|
In addition to the life insurance business, Jackson has assumed certain annuity business from our insurance subsidiaries through a coinsurance agreement. Such business had total insurance policy liabilities of $1.1 billion at
December 31, 2016
.
|
(b)
|
RGA Reinsurance Company has assumed a portion of the long-term care business of Bankers Life on a coinsurance basis.
|
(c)
|
No other single reinsurer represents more than 3 percent of the reinsurance receivables balance or has assumed greater than 2 percent of the total ceded life insurance business inforce.
|
•
|
grant and revoke business licenses;
|
•
|
regulate and supervise sales practices and market conduct;
|
•
|
establish guaranty associations;
|
•
|
license agents;
|
•
|
approve policy forms;
|
•
|
approve premium rates and premium rate increases for some lines of business such as long-term care and Medicare supplement;
|
•
|
establish reserve requirements;
|
•
|
prescribe the form and content of required financial statements and reports;
|
•
|
determine the reasonableness and adequacy of statutory capital and surplus;
|
•
|
perform financial, market conduct and other examinations;
|
•
|
define acceptable accounting principles; and
|
•
|
regulate the types and amounts of permitted investments.
|
•
|
reserve requirements;
|
•
|
risk-based capital ("RBC") standards;
|
•
|
codification of insurance accounting principles;
|
•
|
investment restrictions;
|
•
|
restrictions on an insurance company's ability to pay dividends;
|
•
|
credit for reinsurance; and
|
•
|
product illustrations.
|
•
|
statutory net gain from operations or statutory net income for the prior year; or
|
•
|
10 percent of statutory capital and surplus at the end of the preceding year.
|
•
|
between the current year and the prior year; and
|
•
|
for the average of the last 3 years.
|
Guaranteed
|
|
Fixed interest and fixed
|
|
Universal
|
|
|
||||||
rate
|
|
index annuities
|
|
life
|
|
Total
|
||||||
> 5.0% to 6.0%
|
|
$
|
.3
|
|
|
$
|
14.4
|
|
|
$
|
14.7
|
|
> 4.0% to 5.0%
|
|
35.3
|
|
|
288.6
|
|
|
323.9
|
|
|||
> 3.0% to 4.0%
|
|
1,018.8
|
|
|
50.0
|
|
|
1,068.8
|
|
|||
> 2.0% to 3.0%
|
|
2,406.4
|
|
|
196.0
|
|
|
2,602.4
|
|
|||
> 1.0% to 2.0%
|
|
882.3
|
|
|
18.5
|
|
|
900.8
|
|
|||
1.0% and under
|
|
3,866.2
|
|
|
297.3
|
|
|
4,163.5
|
|
|||
|
|
$
|
8,209.3
|
|
|
$
|
864.8
|
|
|
$
|
9,074.1
|
|
Weighted average
|
|
1.91
|
%
|
|
2.91
|
%
|
|
2.01
|
%
|
•
|
The first hypothetical scenario assumes immediate and permanent reductions to current interest rate spreads on interest-sensitive products. We estimate that a pre-tax charge of approximately $35 million would occur if assumed spreads related to our interest-sensitive life and annuity products immediately and permanently decreased by 10 basis points.
|
•
|
A second scenario assumes that new money rates remain at their current level indefinitely. We estimate that this scenario would result in a pre-tax charge of approximately $20 million related to an increase in deficiency reserves related to the long-term care block in run-off and life contingent payout annuities.
|
•
|
The third hypothetical scenario assumes current new money rates increase such that our current portfolio yield remains level. We estimate that this scenario would result in a pre-tax charge of approximately $15 million related to an increase in deficiency reserves related to the long-term care in run-off block and life contingent payout annuities.
|
•
|
One scenario assumes that the new money rates available to invest cash flows from our long-term care block in the Bankers Life segment remain at their current level of 5.42 percent indefinitely. This scenario would reduce margins by approximately $110 million but would not result in a charge because margins would continue to be positive (based on our 2016 comprehensive actuarial review).
|
•
|
An additional scenario assumes that current new money rates available to invest cash flows from our long-term care block in the Bankers Life segment immediately decrease to approximately 3.5 percent and remain at that level indefinitely. This scenario would reduce margins in this block by approximately $405 million and would result in a pre-tax charge of approximately $85 million (based on our 2016 comprehensive actuarial review).
|
•
|
The value of our investment portfolio has been materially affected in the past by changes in market conditions which resulted in substantial changes in realized and/or unrealized losses. Future adverse capital market conditions could result in additional realized and/or unrealized losses.
|
•
|
Changes in interest rates also affect our investment portfolio. In periods of increasing interest rates, life insurance policy loans, surrenders and withdrawals could increase as policyholders seek higher returns. This could require us to sell invested assets at a time when their prices may be depressed by the increase in interest rates, which could cause us to realize investment losses. Conversely, during periods of declining interest rates, we could experience increased premium payments on products with flexible premium features, repayment of policy loans and increased percentages of policies remaining inforce. We could obtain lower returns on investments made with these cash flows. In addition, prepayment rates on investments may increase so that we might have to reinvest those proceeds in lower-yielding investments. As a consequence of these factors, we could experience a decrease in the spread between the returns on our investment portfolio and amounts to be credited to policyholders and contractholders, which could adversely affect our profitability.
|
•
|
The attractiveness of certain of our insurance products may decrease because they are linked to the equity markets and assessments of our financial strength, resulting in lower profits. Increasing consumer concerns about the returns and features of our insurance products or our financial strength may cause existing customers to surrender policies or withdraw assets, and diminish our ability to sell policies and attract assets from new and existing customers, which would result in lower sales and fee revenues.
|
•
|
changes in interest rates and credit spreads, which can reduce the value of our investments as further discussed in the risk factor entitled "Changing interest rates may adversely affect our results of operations";
|
•
|
changes in patterns of relative liquidity in the capital markets for various asset classes;
|
•
|
changes in the perceived or actual ability of issuers to make timely repayments, which can reduce the value of our investments. This risk is significantly greater with respect to below-investment grade securities, which comprised 16 percent of the cost basis of our available for sale fixed maturity investments as of
December 31, 2016
; and
|
•
|
changes in the estimated timing of receipt of cash flows. For example, our structured securities, which comprised
26 percent
of our available for sale fixed maturity investments at
December 31, 2016
, are subject to variable prepayment on the assets underlying such securities, such as mortgage loans. When asset-backed securities, collateralized debt obligations, commercial mortgage-backed securities, mortgage pass-through securities and collateralized mortgage obligations (collectively referred to as "structured securities") prepay faster than expected, investment income may be adversely affected due to the acceleration of the amortization of purchase premiums or the inability to reinvest at comparable yields in lower interest rate environments.
|
•
|
subsidiary debt;
|
•
|
liens;
|
•
|
restrictive agreements;
|
•
|
restricted payments during the continuance of an event of default;
|
•
|
disposition of assets and sale and leaseback transactions;
|
•
|
transactions with affiliates;
|
•
|
change in business;
|
•
|
fundamental changes;
|
•
|
modification of certain agreements; and
|
•
|
changes to fiscal year.
|
•
|
non-payment;
|
•
|
breach of representations, warranties or covenants;
|
•
|
cross-default and cross-acceleration;
|
•
|
bankruptcy and insolvency events;
|
•
|
judgment defaults;
|
•
|
actual or asserted invalidity of documentation with respect to the Revolving Credit Agreement;
|
•
|
change of control; and
|
•
|
customary ERISA defaults.
|
•
|
incur certain subsidiary indebtedness without also guaranteeing the Notes;
|
•
|
create liens;
|
•
|
enter into sale and leaseback transactions;
|
•
|
issue, sell, transfer or otherwise dispose of any shares of capital stock of any Insurance Subsidiary (as defined in the Indenture); and
|
•
|
consolidate or merge with or into other companies or transfer all or substantially all of the Company’s assets.
|
•
|
statutory net gain from operations or statutory net income for the prior year, or
|
•
|
10 percent of statutory capital and surplus as of the end of the preceding year.
|
Officer
|
With CNO
|
Positions with CNO, Principal
|
Name and Age (a)
|
Since
|
Occupation and Business Experience (b)
|
Bruce Baude, 52
|
2012
|
Since July 2012, executive vice president, chief operations and technology officer. From 2008 to 2012, Mr. Baude was chief operating officer at Univita Health.
|
Gary C. Bhojwani, 49
|
2016
|
Since April 2016, president of CNO. From April 2015 until joining CNO, chief executive officer of GCB, LLC, an insurance and financial services consulting company that he founded. Mr. Bhojwani served as a member of the board of management at Allianz SE, Chairman of Allianz of America, Allianz Life Insurance Company, and Fireman’s Fund Insurance Company from 2012 to January 1, 2015. From 2007 to 2012, he served as president of Allianz Life Insurance Company of North America.
|
Edward J. Bonach, 62
|
2007
|
Since October 2011, chief executive officer. From May 2007 to January 2012, chief financial officer of CNO.
|
Erik M. Helding, 44
|
2004
|
Since April 2016, executive vice president and chief financial officer. From August 2012 to April 2016, senior vice president, treasury and investor relations. Prior to August 2012, Mr. Helding was vice president, financial planning and analysis and he has held various finance positions since joining CNO in 2004.
|
Eric R. Johnson, 56
|
1997
|
Since September 2003, chief investment officer of CNO and president and chief executive officer of 40|86 Advisors, CNO's wholly-owned registered investment advisor. Mr. Johnson has held various investment management positions since joining CNO in 1997.
|
John R. Kline, 59
|
1990
|
Since July 2002, senior vice president and chief accounting officer. Mr. Kline has served in various accounting and finance capacities with CNO since 1990.
|
Susan L. Menzel, 51
|
2005
|
Since May 2005, executive vice president, human resources.
|
Christopher J. Nickele, 60
|
2005
|
Since August 2014, executive vice president and chief actuary. From October 2005 until August 2014, executive vice president, product management and from May 2010 until March 2014, president, Other CNO Business.
|
Matthew J. Zimpfer, 49
|
1998
|
Since June 2008, executive vice president and general counsel. Mr. Zimpfer has held various legal positions since joining CNO in 1998.
|
(a)
|
The executive officers serve as such at the discretion of the Board of Directors and are elected annually.
|
(b)
|
Business experience is given for at least the last five years.
|
ITEM 5.
|
MARKET FOR REGISTRANT'S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES.
|
Period
|
Market price
|
|
Dividends
|
||||||||
|
High
|
|
Low
|
|
declared and paid
|
||||||
2015:
|
|
|
|
|
|
||||||
First Quarter
|
$
|
17.53
|
|
|
$
|
14.89
|
|
|
$
|
0.06
|
|
Second Quarter
|
19.49
|
|
|
16.88
|
|
|
0.07
|
|
|||
Third Quarter
|
19.28
|
|
|
16.06
|
|
|
0.07
|
|
|||
Fourth Quarter
|
20.88
|
|
|
17.93
|
|
|
0.07
|
|
|||
2016:
|
|
|
|
|
|
||||||
First Quarter
|
$
|
18.71
|
|
|
$
|
14.66
|
|
|
$
|
0.07
|
|
Second Quarter
|
20.55
|
|
|
16.00
|
|
|
0.08
|
|
|||
Third Quarter
|
18.70
|
|
|
14.30
|
|
|
0.08
|
|
|||
Fourth Quarter
|
19.89
|
|
|
14.65
|
|
|
0.08
|
|
|
12/11
|
12/12
|
12/13
|
12/14
|
12/15
|
12/16
|
||||||||||||
CNO Financial Group, Inc.
|
$
|
100.00
|
|
$
|
148.93
|
|
$
|
284.65
|
|
$
|
280.92
|
|
$
|
316.09
|
|
$
|
322.60
|
|
S&P 500 Index
|
100.00
|
|
116.00
|
|
153.57
|
|
174.60
|
|
177.01
|
|
198.18
|
|
||||||
S&P Life & Health Insurance Index
|
100.00
|
|
114.59
|
|
187.33
|
|
190.98
|
|
178.93
|
|
223.41
|
|
||||||
S&P MidCap 400 Index
|
100.00
|
|
117.88
|
|
157.37
|
|
172.74
|
|
168.98
|
|
204.03
|
|
Period (in 2016)
|
|
Total number of shares (or units)
|
|
Average price paid per share (or unit)
|
|
Total number of shares (or units) purchased as part of publicly announced plans or programs
|
|
Maximum number (or approximate dollar value) of shares (or units) that may yet be purchased under the plans or programs(a)
|
||||||
|
|
|
|
|
|
|
|
(dollars in millions)
|
||||||
October 1 through October 31
|
|
—
|
|
|
$
|
—
|
|
|
—
|
|
|
$
|
252.7
|
|
November 1 through November 30
|
|
276
|
|
|
15.06
|
|
|
—
|
|
|
252.7
|
|
||
December 1 through December 31
|
|
936
|
|
|
19.56
|
|
|
—
|
|
|
252.7
|
|
||
Total
|
|
1,212
|
|
|
18.54
|
|
|
—
|
|
|
252.7
|
|
(a)
|
In May 2011, the Company announced a securities repurchase program of up to
$100.0 million
. In February 2012, June 2012, December 2012, December 2013, November 2014 and November 2015, the Company's Board of Directors approved, in aggregate, an additional
$1,600.0 million
to repurchase the Company's outstanding securities.
|
|
|
Number of securities to be issued upon exercise of outstanding options, warrants and rights
|
|
Weighted-average exercise price of outstanding options, warrants and rights
|
|
Number of securities remaining available for future issuance under equity compensation plans (excluding securities reflected in first column)
|
||||
Equity compensation plans approved by security holders
|
|
5,353,758
|
|
|
$
|
14.73
|
|
|
4,620,199
|
|
Equity compensation plans not approved by security holders
|
|
—
|
|
|
—
|
|
|
—
|
|
|
Total
|
|
5,353,758
|
|
|
$
|
14.73
|
|
|
4,620,199
|
|
|
|
Years ended December 31,
|
||||||||||||||||||
|
|
2016
|
|
2015
|
|
2014
|
|
2013
|
|
2012
|
||||||||||
|
|
(Amounts in millions, except per share data)
|
||||||||||||||||||
STATEMENT OF OPERATIONS DATA
|
|
|
|
|
|
|
|
|
|
|
||||||||||
Insurance policy income
|
|
$
|
2,601.1
|
|
|
$
|
2,556.0
|
|
|
$
|
2,629.7
|
|
|
$
|
2,744.7
|
|
|
$
|
2,755.4
|
|
Net investment income
|
|
1,325.2
|
|
|
1,233.6
|
|
|
1,427.4
|
|
|
1,664.0
|
|
|
1,486.4
|
|
|||||
Net realized investment gains (losses)
|
|
8.3
|
|
|
(36.6
|
)
|
|
36.7
|
|
|
33.4
|
|
|
81.1
|
|
|||||
Total revenues
|
|
3,985.1
|
|
|
3,811.9
|
|
|
4,144.7
|
|
|
4,476.1
|
|
|
4,342.7
|
|
|||||
Interest expense
|
|
116.4
|
|
|
94.9
|
|
|
92.8
|
|
|
105.3
|
|
|
114.6
|
|
|||||
Total benefits and expenses
|
|
3,631.9
|
|
|
3,444.2
|
|
|
3,969.6
|
|
|
4,171.3
|
|
|
4,187.0
|
|
|||||
Income before income taxes
|
|
353.2
|
|
|
367.7
|
|
|
175.1
|
|
|
304.8
|
|
|
155.7
|
|
|||||
Income tax expense (benefit)
|
|
(5.0
|
)
|
|
97.0
|
|
|
123.7
|
|
|
(173.2
|
)
|
|
(65.3
|
)
|
|||||
Net income
|
|
358.2
|
|
|
270.7
|
|
|
51.4
|
|
|
478.0
|
|
|
221.0
|
|
|||||
PER SHARE DATA
|
|
|
|
|
|
|
|
|
|
|
||||||||||
Net income, basic
|
|
$
|
2.03
|
|
|
$
|
1.40
|
|
|
$
|
.24
|
|
|
$
|
2.16
|
|
|
$
|
.95
|
|
Net income, diluted
|
|
2.01
|
|
|
1.39
|
|
|
.24
|
|
|
2.06
|
|
|
.83
|
|
|||||
Dividends declared per common share
|
|
.31
|
|
|
.27
|
|
|
.24
|
|
|
.11
|
|
|
.06
|
|
|||||
Book value per common share outstanding
|
|
25.82
|
|
|
22.49
|
|
|
23.06
|
|
|
22.49
|
|
|
22.80
|
|
|||||
Weighted average shares outstanding for basic earnings
|
|
176.6
|
|
|
193.1
|
|
|
212.9
|
|
|
221.6
|
|
|
233.7
|
|
|||||
Weighted average shares outstanding for diluted earnings
|
|
178.3
|
|
|
195.2
|
|
|
217.7
|
|
|
232.7
|
|
|
281.4
|
|
|||||
Shares outstanding at period-end
|
|
173.8
|
|
|
184.0
|
|
|
203.3
|
|
|
220.3
|
|
|
221.5
|
|
|||||
BALANCE SHEET DATA
-
AT PERIOD END
|
|
|
|
|
|
|
|
|
|
|
||||||||||
Total investments
|
|
$
|
26,237.6
|
|
|
$
|
24,487.1
|
|
|
$
|
24,908.3
|
|
|
$
|
27,151.7
|
|
|
$
|
27,959.3
|
|
Total assets
|
|
31,975.2
|
|
|
31,125.1
|
|
|
31,155.9
|
|
|
34,750.2
|
|
|
34,103.7
|
|
|||||
Corporate notes payable
|
|
912.9
|
|
|
911.1
|
|
|
780.3
|
|
|
838.0
|
|
|
986.1
|
|
|||||
Total liabilities
|
|
27,488.3
|
|
|
26,986.6
|
|
|
26,467.7
|
|
|
29,795.0
|
|
|
29,054.4
|
|
|||||
Shareholders' equity
|
|
4,486.9
|
|
|
4,138.5
|
|
|
4,688.2
|
|
|
4,955.2
|
|
|
5,049.3
|
|
|||||
STATUTORY DATA - AT PERIOD END (a)
|
|
|
|
|
|
|
|
|
|
|
||||||||||
Statutory capital and surplus
|
|
$
|
1,956.8
|
|
|
$
|
1,739.2
|
|
|
$
|
1,654.4
|
|
|
$
|
1,711.9
|
|
|
$
|
1,560.4
|
|
Asset valuation reserve ("AVR")
|
|
253.3
|
|
|
196.9
|
|
|
203.1
|
|
|
233.9
|
|
|
222.2
|
|
|||||
Total statutory capital and surplus and AVR
|
|
2,210.1
|
|
|
1,936.1
|
|
|
1,857.5
|
|
|
1,945.8
|
|
|
1,782.6
|
|
(a)
|
We have derived the statutory data from statements filed by our insurance subsidiaries with regulatory authorities which are prepared in accordance with statutory accounting principles, which vary in certain respects from GAAP.
|
ITEM 7.
|
MANAGEMENT'S DISCUSSION AND ANALYSIS OF CONSOLIDATED FINANCIAL CONDITION AND RESULTS OF OPERATIONS.
|
•
|
changes in or sustained low interest rates causing reductions in investment income, the margins of our fixed annuity and life insurance businesses, and sales of, and demand for, our products;
|
•
|
expectations of lower future investment earnings may cause us to accelerate amortization, write down the balance of insurance acquisition costs or establish additional liabilities for insurance products;
|
•
|
general economic, market and political conditions and uncertainties, including the performance of the financial markets which may affect the value of our investments as well as our ability to raise capital or refinance existing indebtedness and the cost of doing so;
|
•
|
the ultimate outcome of lawsuits filed against us and other legal and regulatory proceedings to which we are subject;
|
•
|
our ability to make anticipated changes to certain non-guaranteed elements of our life insurance products;
|
•
|
our ability to obtain adequate and timely rate increases on our health products, including our long-term care business;
|
•
|
the receipt of any required regulatory approvals for dividend and surplus debenture interest payments from our insurance subsidiaries;
|
•
|
mortality, morbidity, the increased cost and usage of health care services, persistency, the adequacy of our previous reserve estimates and other factors which may affect the profitability of our insurance products;
|
•
|
changes in our assumptions related to deferred acquisition costs or the present value of future profits;
|
•
|
the recoverability of our deferred tax assets and the effect of potential ownership changes and tax rate changes on their value;
|
•
|
our assumption that the positions we take on our tax return filings will not be successfully challenged by the IRS;
|
•
|
changes in accounting principles and the interpretation thereof;
|
•
|
our ability to continue to satisfy the financial ratio and balance requirements and other covenants of our debt agreements;
|
•
|
our ability to achieve anticipated expense reductions and levels of operational efficiencies including improvements in claims adjudication and continued automation and rationalization of operating systems;
|
•
|
performance and valuation of our investments, including the impact of realized losses (including other-than-temporary impairment charges);
|
•
|
our ability to identify products and markets in which we can compete effectively against competitors with greater market share, higher ratings, greater financial resources and stronger brand recognition;
|
•
|
our ability to generate sufficient liquidity to meet our debt service obligations and other cash needs;
|
•
|
our ability to maintain effective controls over financial reporting;
|
•
|
our ability to continue to recruit and retain productive agents and distribution partners;
|
•
|
customer response to new products, distribution channels and marketing initiatives;
|
•
|
our ability to achieve additional upgrades of the financial strength ratings of CNO and our insurance company subsidiaries as well as the impact of our ratings on our business, our ability to access capital, and the cost of capital;
|
•
|
regulatory changes or actions, including those relating to regulation of the financial affairs of our insurance companies, such as the payment of dividends and surplus debenture interest to us, regulation of the sale, underwriting and pricing of products, and health care regulation affecting health insurance products;
|
•
|
changes in the Federal income tax laws and regulations which may affect or eliminate the relative tax advantages of some of our products or affect the value of our deferred tax assets;
|
•
|
availability and effectiveness of reinsurance arrangements, as well as any defaults or failure of reinsurers to perform;
|
•
|
the amount we may need to pay to a reinsurer in connection with a long-term care reinsurance transaction;
|
•
|
the performance of third party service providers and potential difficulties arising from outsourcing arrangements;
|
•
|
the growth rate of sales, collected premiums, annuity deposits and assets;
|
•
|
interruption in telecommunication, information technology or other operational systems or failure to maintain the security, confidentiality or privacy of sensitive data on such systems;
|
•
|
events of terrorism, cyber attacks, natural disasters or other catastrophic events, including losses from a disease pandemic;
|
•
|
ineffectiveness of risk management policies and procedures in identifying, monitoring and managing risks; and
|
•
|
the risk factors or uncertainties listed from time to time in our filings with the SEC.
|
•
|
Bankers Life,
which markets and distributes Medicare supplement insurance, interest-sensitive life insurance, traditional life insurance, fixed annuities and long-term care insurance products to the middle-income senior market through a dedicated field force of career agents, financial and investment advisors, and sales managers supported by a network of community-based sales offices. The Bankers Life segment includes primarily the business of Bankers Life and Casualty Company. Bankers Life also has various distribution and marketing agreements with other insurance companies to use Bankers Life's career agents to distribute Medicare Advantage and PDP products in exchange for a fee.
|
•
|
Washington National,
which markets and distributes supplemental health (including specified disease, accident and hospital indemnity insurance products) and life insurance to middle-income consumers at home and at the worksite. These products are marketed through PMA and through independent marketing organizations and insurance agencies including worksite marketing. The products being marketed are underwritten by Washington National. This segment's business also includes certain closed blocks of annuities and Medicare supplement policies which are no longer being actively marketed by this segment and were primarily issued or acquired by Washington National.
|
•
|
Colonial Penn
, which markets primarily graded benefit and simplified issue life insurance directly to customers in the senior middle-income market through television advertising, direct mail, the internet and telemarketing. The Colonial Penn segment includes primarily the business of Colonial Penn.
|
•
|
Long-term care in run-off
consists of the long-term care business that was recaptured due to the termination of certain reinsurance agreements effective September 30, 2016. This business is not actively marketed and was issued or acquired by Washington National and BCLIC.
|
|
2016
|
|
2015
|
|
2014
|
||||||
Adjusted EBIT (a non-GAAP financial measure) (a):
|
|
|
|
|
|
||||||
Bankers Life
|
$
|
397.9
|
|
|
$
|
369.6
|
|
|
$
|
386.9
|
|
Washington National
|
102.9
|
|
|
111.5
|
|
|
111.2
|
|
|||
Colonial Penn
|
1.7
|
|
|
5.6
|
|
|
.8
|
|
|||
Long-term care in run-off
|
(3.9
|
)
|
|
—
|
|
|
—
|
|
|||
Adjusted EBIT from business segments
|
498.6
|
|
|
486.7
|
|
|
498.9
|
|
|||
Corporate Operations, excluding corporate interest expense
|
(42.5
|
)
|
|
(18.9
|
)
|
|
(27.6
|
)
|
|||
Adjusted EBIT
|
456.1
|
|
|
467.8
|
|
|
471.3
|
|
|||
Corporate interest expense
|
(45.8
|
)
|
|
(45.0
|
)
|
|
(43.9
|
)
|
|||
Operating earnings before taxes
|
410.3
|
|
|
422.8
|
|
|
427.4
|
|
|||
Tax expense on operating income
|
147.8
|
|
|
148.1
|
|
|
150.5
|
|
|||
Net operating income
|
262.5
|
|
|
274.7
|
|
|
276.9
|
|
|||
Earnings of subsidiary prior to being sold
|
—
|
|
|
—
|
|
|
23.4
|
|
|||
Loss on sale of subsidiary, gain (loss) on reinsurance transactions and transition expenses
|
—
|
|
|
—
|
|
|
(239.8
|
)
|
|||
Net realized investment gains (losses) (net of related amortization)
|
7.6
|
|
|
(36.1
|
)
|
|
32.9
|
|
|||
Fair value changes in embedded derivative liabilities (net of related amortization)
|
9.6
|
|
|
11.9
|
|
|
(36.0
|
)
|
|||
Fair value changes and amendment related to agent deferred compensation plan
|
3.1
|
|
|
15.1
|
|
|
(26.8
|
)
|
|||
Loss on reinsurance transaction (b)
|
(75.4
|
)
|
|
—
|
|
|
—
|
|
|||
Loss on extinguishment or modification of debt
|
—
|
|
|
(32.8
|
)
|
|
(.6
|
)
|
|||
Other
|
(2.0
|
)
|
|
(13.2
|
)
|
|
(5.4
|
)
|
|||
Non-operating income (loss) before taxes
|
(57.1
|
)
|
|
(55.1
|
)
|
|
(252.3
|
)
|
|||
Income tax expense (benefit):
|
|
|
|
|
|
||||||
On non-operating income (loss)
|
(20.0
|
)
|
|
(18.6
|
)
|
|
8.7
|
|
|||
Valuation allowance for deferred tax assets and other tax items
|
(132.8
|
)
|
|
(32.5
|
)
|
|
(35.5
|
)
|
|||
Net non-operating income (loss)
|
95.7
|
|
|
(4.0
|
)
|
|
(225.5
|
)
|
|||
Net income
|
$
|
358.2
|
|
|
$
|
270.7
|
|
|
$
|
51.4
|
|
|
|
|
|
|
|
||||||
Per diluted share:
|
|
|
|
|
|
||||||
Net operating income
|
$
|
1.47
|
|
|
$
|
1.41
|
|
|
$
|
1.27
|
|
Earnings of subsidiary prior to being sold (net of taxes)
|
—
|
|
|
$
|
—
|
|
|
$
|
.07
|
|
|
Loss on sale of subsidiary, gain (loss) on reinsurance transactions and transition expenses (including impact of taxes)
|
—
|
|
|
$
|
—
|
|
|
$
|
(1.24
|
)
|
|
Net realized investment gains (losses) (net of related amortization and taxes)
|
.03
|
|
|
(.12
|
)
|
|
.10
|
|
|||
Fair value changes in embedded derivative liabilities (net of related amortization and taxes)
|
.04
|
|
|
.04
|
|
|
(.11
|
)
|
|||
Fair value changes and amendment related to agent deferred compensation plan (net of taxes)
|
.01
|
|
|
.05
|
|
|
(.08
|
)
|
|||
Loss on reinsurance transaction (net of taxes)
|
(.27
|
)
|
|
—
|
|
|
—
|
|
|||
Loss on extinguishment or modification of debt (net of taxes)
|
—
|
|
|
(.11
|
)
|
|
—
|
|
|||
Valuation allowance for deferred tax assets and other tax items
|
.74
|
|
|
.17
|
|
|
.25
|
|
|||
Other
|
(.01
|
)
|
|
(.05
|
)
|
|
(.02
|
)
|
|||
Net income
|
$
|
2.01
|
|
|
$
|
1.39
|
|
|
$
|
.24
|
|
(a)
|
Management believes that an analysis of net operating income provides a clearer comparison of the operating results of the Company from period to period because it excludes: (i) the loss on the sale of a subsidiary, gain (loss) on reinsurance transactions and transition expenses, including impact of taxes; (ii) the earnings of subsidiary prior to being sold on July 1, 2014, net of taxes;
(iii)
net realized investment gains or losses, net of related amortization and taxes; (iv) fair value changes due to fluctuations in the interest rates used to discount embedded derivative liabilities related to our fixed index annuities, net of related amortization and taxes; (v) fair value changes and amendment related to the agent deferred compensation plan, net of taxes; (vi) loss on extinguishment or modification of debt, net of taxes; (vii) changes in the valuation allowance for deferred tax assets and other tax items; and (viii)
other non-operating items consisting primarily of equity in earnings of certain non-strategic investments and earnings attributable to variable interest entities
. Net realized investment gains or losses include: (i) gains or losses on the sales of investments; (ii) other-than-temporary impairments recognized through net income; and (iii) changes in fair value of certain fixed maturity investments with embedded derivatives. EBIT is presented as net operating income excluding corporate interest expense and income tax expense. The table above reconciles the non-GAAP measure to the corresponding GAAP measure.
|
•
|
Maximize our product portfolio to ensure it meets our customers’ needs for integrated products and advice covering a broad range of their financial needs
|
•
|
Position marketing and our distribution channels to better respond to evolving customer preferences
|
•
|
Expand and enhance elements of our broker-dealer and registered investment advisor program
|
•
|
Expand our reach within certain demographics of the middle-income market based on our improved customer segmentation analytics
|
•
|
Maintain our strong capital position and favorable financial metrics
|
•
|
Work to increase our return on equity
|
•
|
Maintain pricing discipline
|
•
|
Active enterprise risk management process
|
•
|
Continue to cost effectively repurchase our common stock, absent compelling alternatives
|
•
|
Maintain a competitive dividend payout ratio
|
•
|
Reduce relative legacy long-term care exposure
|
•
|
Leverage our recent investments to identify opportunities, drive increased productivity, improve efficiencies and profitability, and increase the speed-to-market for new products
|
•
|
Create a strong enterprise data strategy using our platforms and state-of-the-art tools to drive growth on a cost-effective basis
|
•
|
Continue to invest in technology partnerships that will support our field force and relationships with our customers, and leverage data to run our business profitably
|
•
|
Pilot various models across the agent lifecycle to drive increased growth, productivity and retention
|
•
|
Attract, retain and develop the best talent to help us drive sustainable growth, and provide them with development opportunities
|
•
|
Recruit, develop and retain our agent force
|
•
|
Level 1 – includes assets and liabilities valued using inputs that are unadjusted quoted prices in active markets for identical assets or liabilities. Our Level 1 assets primarily include cash and cash equivalents and exchange traded securities.
|
•
|
Level 2 – includes assets and liabilities valued using inputs that are quoted prices for similar assets in an active market, quoted prices for identical or similar assets in a market that is not active, observable inputs, or observable inputs that can be corroborated by market data. Level 2 assets and liabilities include those financial instruments that are valued by independent pricing services using models or other valuation methodologies. These models consider various inputs such as credit rating, maturity, corporate credit spreads, reported trades and other inputs that are observable or derived from observable information in the marketplace or are supported by transactions executed in the marketplace. Financial assets in this category primarily include: certain publicly registered and privately placed corporate fixed maturity securities; certain government or agency securities; certain mortgage and asset-backed securities; certain equity securities; most investments held by our consolidated VIEs; certain mutual fund investments; most short-term investments; and non-exchange-traded derivatives such as call options. Financial liabilities in this category include investment borrowings, notes payable and borrowings related to VIEs.
|
•
|
Level 3 – includes assets and liabilities valued using unobservable inputs that are used in model-based valuations that contain management assumptions. Level 3 assets and liabilities include those financial instruments whose fair value is estimated based on broker/dealer quotes, pricing services or internally developed models or methodologies utilizing significant inputs not based on, or corroborated by, readily available market information. Financial assets in this category include certain corporate securities (primarily certain below-investment grade privately placed securities), certain structured securities, mortgage loans, and other less liquid securities. Financial liabilities in this category include our insurance liabilities for interest-sensitive products, which includes embedded derivatives (including embedded derivatives related to our fixed index annuity products and to a modified coinsurance arrangement) since their values include significant unobservable inputs including actuarial assumptions.
|
Change in assumptions
|
|
Estimated adjustment to income before income taxes based on revisions to certain assumptions
|
||
|
|
(dollars in millions)
|
||
Interest-sensitive life products:
|
|
|
||
5% increase to assumed mortality
|
|
$
|
(18
|
)
|
5% decrease to assumed mortality
|
|
19
|
|
|
15% increase to assumed expenses
|
|
(6
|
)
|
|
15% decrease to assumed expenses
|
|
6
|
|
|
10 basis point decrease to assumed spread
|
|
(5
|
)
|
|
10 basis point increase to assumed spread
|
|
5
|
|
|
20% increase to assumed lapses
|
|
(5
|
)
|
|
20% decrease to assumed lapses
|
|
6
|
|
|
Fixed index and fixed interest annuity products:
|
|
|
||
20% increase to assumed surrenders
|
|
(113
|
)
|
|
20% decrease to assumed surrenders
|
|
90
|
|
|
15% increase to assumed expenses
|
|
(6
|
)
|
|
15% decrease to assumed expenses
|
|
6
|
|
|
10 basis point decrease to assumed spread
|
|
(30
|
)
|
|
10 basis point increase to assumed spread
|
|
30
|
|
|
Other than interest-sensitive life and annuity products (a):
|
|
|
||
5% increase to assumed morbidity
|
|
(330
|
)
|
|
50 basis point decrease to investment earnings rate
|
|
(5
|
)
|
|
5% decrease to assumed mortality
|
|
(4
|
)
|
(a)
|
We have excluded the effect of reasonably likely changes in lapse, surrender and expense assumptions for policies other than interest-sensitive life and annuity products.
|
|
Years ended December 31,
|
|||||||
|
2016
|
|
2015
|
|
2014
|
|||
Bankers Life:
|
|
|
|
|
|
|||
Medicare supplement (1)
|
85.9
|
%
|
|
86.3
|
%
|
|
82.8
|
%
|
Long-term care (1)
|
90.0
|
%
|
|
90.4
|
%
|
|
91.1
|
%
|
Fixed index annuities (2)
|
91.5
|
%
|
|
91.2
|
%
|
|
90.8
|
%
|
Other annuities (2)
|
85.8
|
%
|
|
85.1
|
%
|
|
85.2
|
%
|
Life (1)
|
87.1
|
%
|
|
87.3
|
%
|
|
87.3
|
%
|
Washington National:
|
|
|
|
|
|
|||
Medicare supplement (1)
|
85.8
|
%
|
|
83.7
|
%
|
|
84.2
|
%
|
Supplemental health (1)
|
89.2
|
%
|
|
89.0
|
%
|
|
88.4
|
%
|
Life (1)
|
91.2
|
%
|
|
91.8
|
%
|
|
92.5
|
%
|
Colonial Penn:
|
|
|
|
|
|
|||
Life (1)
|
83.0
|
%
|
|
82.6
|
%
|
|
83.2
|
%
|
(1)
|
Based on number of inforce policies.
|
(2)
|
Based on the percentage of the inforce block persisting.
|
|
|
2016
|
|
2015
|
||||
|
|
(Dollars in millions)
|
||||||
Amounts classified as future policy benefits:
|
|
|
|
|
||||
Active life reserves
|
|
$
|
3,816.4
|
|
|
$
|
3,707.8
|
|
Reserves for the present value of amounts not yet due on claims
|
|
1,338.4
|
|
|
1,306.1
|
|
||
Future loss reserves
|
|
191.3
|
|
|
158.3
|
|
||
Amounts classified as liability for policy and contract claims:
|
|
|
|
|
||||
Liability for due and unpaid claims, claims in the course of settlement and incurred but not reported claims
|
|
187.5
|
|
|
194.1
|
|
||
Total
|
|
5,533.6
|
|
|
5,366.3
|
|
||
Reinsurance receivables
|
|
194.3
|
|
|
657.4
|
|
||
Long-term care reserves, net of reinsurance receivables
|
|
$
|
5,339.3
|
|
|
$
|
4,708.9
|
|
•
|
We recognize fee income based on either: (i) a fixed fee per contract sold; or (ii) a percentage of premiums collected. This fee income is recognized over the calendar year term of the contract.
|
•
|
We also pay commissions to our agents who sell the plans. These payments are deferred and amortized over the term of the contract.
|
|
2016
|
|
2015
|
|
2014
|
||||||
Fee revenue:
|
|
|
|
|
|
||||||
Medicare Advantage contracts
|
$
|
23.2
|
|
|
$
|
23.1
|
|
|
$
|
22.4
|
|
PDP contracts
|
3.1
|
|
|
3.2
|
|
|
3.0
|
|
|||
Total revenue
|
26.3
|
|
|
26.3
|
|
|
25.4
|
|
|||
Distribution expenses
|
9.3
|
|
|
9.4
|
|
|
10.4
|
|
|||
Fee revenue, net of distribution expenses
|
$
|
17.0
|
|
|
$
|
16.9
|
|
|
$
|
15.0
|
|
Balance, December 31, 2013
|
$
|
294.8
|
|
|
Decrease in 2014
|
(48.8
|
)
|
(a)
|
|
Balance, December 31, 2014
|
246.0
|
|
|
|
Decrease in 2015
|
(32.5
|
)
|
(b)
|
|
Balance, December 31, 2015
|
213.5
|
|
|
|
Increase in 2016
|
26.7
|
|
(c)
|
|
Balance, December 31, 2016
|
$
|
240.2
|
|
|
(a)
|
The
2014
reduction to the deferred tax valuation allowance primarily resulted from tax examination adjustments and the tax gain on the sale of CLIC.
|
(b)
|
The
2015
reduction to the deferred tax valuation allowance primarily resulted from higher actual and projected non-life income.
|
(c)
|
The
2016
increase to the deferred tax valuation allowance primarily resulted from additional non-life NOLs due to the settlement with the IRS.
|
|
|
Net operating loss
|
||
Year of expiration
|
|
carryforwards
|
||
2023
|
|
$
|
1,936.0
|
|
2025
|
|
85.2
|
|
|
2026
|
|
149.9
|
|
|
2027
|
|
10.8
|
|
|
2028
|
|
80.3
|
|
|
2029
|
|
213.2
|
|
|
2030
|
|
.3
|
|
|
2031
|
|
.2
|
|
|
2032
|
|
44.4
|
|
|
2033
|
|
.6
|
|
|
2034
|
|
1.7
|
|
|
Total federal NOLs
|
|
$
|
2,522.6
|
|
|
Years ended December 31,
|
||||||
|
2016
|
|
2015
|
||||
|
|
|
|
||||
Balance at beginning of year
|
$
|
234.2
|
|
|
$
|
228.7
|
|
Increase based on tax positions taken in prior years
|
3.4
|
|
|
5.5
|
|
||
Decrease in unrecognized tax benefits related to settlements with taxing authorities
|
(237.6
|
)
|
|
—
|
|
||
Balance at end of year
|
$
|
—
|
|
|
$
|
234.2
|
|
•
|
Premium rate increases - If premium rate increases reflect a change in our previous rate increase assumptions, the new assumptions are not reflected prospectively in our reserves. Instead, the additional premium revenue resulting from the rate increase is recognized as earned and original assumptions continue to be used to determine changes to liabilities for insurance products unless a premium deficiency exists.
|
•
|
Benefit reductions - If there is a premium rate increase on one of our long-term care policies, a policyholder may choose reduced coverage with a proportionate reduction in premium, when permitted by our contracts. This option does not require additional underwriting. Benefit reductions are treated as a partial lapse of coverage, and the balance of our reserves and deferred insurance acquisition costs is reduced in proportion to the reduced coverage.
|
•
|
Non-forfeiture benefits offered in conjunction with a rate increase - In some cases, non-forfeiture benefits are offered to policyholders who wish to lapse their policies at the time of a significant rate increase. In these cases, exercise of this option is treated as an extinguishment of the original contract and issuance of a new contract. The balance of our reserves and deferred insurance acquisition costs are released, and a reserve for the new contract is established.
|
|
2016
|
|
2015
|
|
2014
|
||||||
Pre-tax operating earnings (a non-GAAP measure) (a):
|
|
|
|
|
|
||||||
Bankers Life
|
$
|
397.9
|
|
|
$
|
369.6
|
|
|
$
|
386.9
|
|
Washington National
|
102.9
|
|
|
111.5
|
|
|
111.2
|
|
|||
Colonial Penn
|
1.7
|
|
|
5.6
|
|
|
.8
|
|
|||
Long-term care in run-off
|
(3.9
|
)
|
|
—
|
|
|
—
|
|
|||
Corporate operations
|
(88.3
|
)
|
|
(63.9
|
)
|
|
(71.5
|
)
|
|||
|
410.3
|
|
|
422.8
|
|
|
427.4
|
|
|||
Gain (loss) on reinsurance transactions:
|
|
|
|
|
|
||||||
Bankers Life
|
—
|
|
|
—
|
|
|
26.1
|
|
|||
Washington National
|
—
|
|
|
—
|
|
|
3.8
|
|
|||
Corporate operations
|
(75.4
|
)
|
|
—
|
|
|
—
|
|
|||
|
(75.4
|
)
|
|
—
|
|
|
29.9
|
|
|||
Net realized investment gains (losses), net of related amortization:
|
|
|
|
|
|
||||||
Bankers Life
|
(3.6
|
)
|
|
(16.7
|
)
|
|
7.8
|
|
|||
Washington National
|
19.4
|
|
|
(9.6
|
)
|
|
33.9
|
|
|||
Colonial Penn
|
(.2
|
)
|
|
1.2
|
|
|
1.1
|
|
|||
Long-term care in run-off
|
(5.3
|
)
|
|
—
|
|
|
—
|
|
|||
Corporate operations
|
(2.7
|
)
|
|
(11.0
|
)
|
|
(9.9
|
)
|
|||
|
7.6
|
|
|
(36.1
|
)
|
|
32.9
|
|
|||
Fair value changes in embedded derivative liabilities, net of related amortization:
|
|
|
|
|
|
||||||
Bankers Life
|
9.4
|
|
|
11.7
|
|
|
(35.6
|
)
|
|||
Washington National
|
.2
|
|
|
.2
|
|
|
(.4
|
)
|
|||
|
9.6
|
|
|
11.9
|
|
|
(36.0
|
)
|
|||
Equity in earnings of certain non-strategic investments and earnings attributable to VIEs:
|
|
|
|
|
|
||||||
Corporate operations
|
(2.0
|
)
|
|
(6.7
|
)
|
|
(8.0
|
)
|
|||
Net revenue pursuant to transition and support services agreements, net of taxes:
|
|
|
|
|
|
||||||
Corporate operations
|
—
|
|
|
2.5
|
|
|
2.6
|
|
|||
Fair value changes and amendment related to agent deferred compensation plan:
|
|
|
|
|
|
||||||
Corporate operations
|
3.1
|
|
|
15.1
|
|
|
(26.8
|
)
|
|||
Transition expenses:
|
|
|
|
|
|
||||||
Corporate operations
|
—
|
|
|
(9.0
|
)
|
|
—
|
|
|||
Loss on extinguishment or modification of debt:
|
|
|
|
|
|
||||||
Corporate operations
|
—
|
|
|
(32.8
|
)
|
|
(.6
|
)
|
|||
Amounts related to subsidiary prior to being sold:
|
|
|
|
|
|
||||||
Earnings of subsidiary prior to being sold
|
—
|
|
|
—
|
|
|
23.4
|
|
|||
Loss on sale of subsidiary
|
—
|
|
|
—
|
|
|
(269.7
|
)
|
|||
|
—
|
|
|
—
|
|
|
(246.3
|
)
|
|||
Income (loss) before income taxes:
|
|
|
|
|
|
||||||
Bankers Life
|
403.7
|
|
|
364.6
|
|
|
385.2
|
|
|||
Washington National
|
122.5
|
|
|
102.1
|
|
|
148.5
|
|
|||
Colonial Penn
|
1.5
|
|
|
6.8
|
|
|
1.9
|
|
|||
Long-term care in run-off
|
(9.2
|
)
|
|
—
|
|
|
—
|
|
|||
Corporate operations
|
(165.3
|
)
|
|
(105.8
|
)
|
|
(114.2
|
)
|
|||
Amount related to subsidiary prior to being sold
|
—
|
|
|
—
|
|
|
(246.3
|
)
|
|||
Income before income taxes
|
$
|
353.2
|
|
|
$
|
367.7
|
|
|
$
|
175.1
|
|
(a)
|
These non-GAAP measures as presented in the above table and in the following segment financial data and discussions of segment results exclude the loss on the sale of subsidiary and gain (loss) on reinsurance transactions, the earnings of a subsidiary prior to being sold, net realized investment gains (losses), fair value changes in embedded derivative liabilities, net of related amortization, fair value changes and amendment related to the agent deferred compensation plan, equity in earnings of certain non-strategic investments and earnings attributable to VIEs, net revenue (expense) pursuant to transition and support services agreements
,
loss on extinguishment or modification of debt and before income taxes. These are considered non-GAAP financial measures. A non-GAAP measure is a numerical measure of a company's performance, financial position, or cash flows that excludes or includes amounts that are normally excluded or included in the most directly comparable measure calculated and presented in accordance with GAAP.
|
|
2016
|
|
2015
|
|
2014
|
||||||
Premium collections:
|
|
|
|
|
|
||||||
Annuities
|
$
|
970.0
|
|
|
$
|
803.0
|
|
|
$
|
782.3
|
|
Medicare supplement and other supplemental health
|
1,235.3
|
|
|
1,242.3
|
|
|
1,275.1
|
|
|||
Life
|
461.1
|
|
|
446.0
|
|
|
424.9
|
|
|||
Total collections
|
$
|
2,666.4
|
|
|
$
|
2,491.3
|
|
|
$
|
2,482.3
|
|
Average liabilities for insurance products:
|
|
|
|
|
|
|
|||||
Fixed index annuities
|
$
|
4,527.8
|
|
|
$
|
4,075.5
|
|
|
$
|
3,636.7
|
|
Fixed interest annuities
|
3,188.2
|
|
|
3,487.8
|
|
|
3,845.0
|
|
|||
SPIAs and supplemental contracts:
|
|
|
|
|
|
||||||
Mortality based
|
174.9
|
|
|
189.5
|
|
|
202.8
|
|
|||
Deposit based
|
153.7
|
|
|
153.8
|
|
|
149.1
|
|
|||
Health:
|
|
|
|
|
|
||||||
Long-term care
|
4,998.0
|
|
|
4,916.2
|
|
|
4,735.4
|
|
|||
Medicare supplement
|
336.8
|
|
|
331.0
|
|
|
331.0
|
|
|||
Other health
|
50.3
|
|
|
47.7
|
|
|
47.5
|
|
|||
Life:
|
|
|
|
|
|
||||||
Interest sensitive
|
714.6
|
|
|
643.0
|
|
|
564.7
|
|
|||
Non-interest sensitive
|
1,018.0
|
|
|
941.5
|
|
|
782.1
|
|
|||
Total average liabilities for insurance products, net of reinsurance ceded
|
$
|
15,162.3
|
|
|
$
|
14,786.0
|
|
|
$
|
14,294.3
|
|
Revenues:
|
|
|
|
|
|
||||||
Insurance policy income
|
$
|
1,659.1
|
|
|
$
|
1,648.7
|
|
|
$
|
1,651.7
|
|
Net investment income:
|
|
|
|
|
|
||||||
General account invested assets
|
909.5
|
|
|
918.7
|
|
|
895.4
|
|
|||
Fixed index products
|
27.3
|
|
|
(34.0
|
)
|
|
61.9
|
|
|||
Fee revenue and other income
|
34.4
|
|
|
27.7
|
|
|
29.3
|
|
|||
Total revenues
|
2,630.3
|
|
|
2,561.1
|
|
|
2,638.3
|
|
|||
Expenses:
|
|
|
|
|
|
||||||
Insurance policy benefits
|
1,417.4
|
|
|
1,442.5
|
|
|
1,427.7
|
|
|||
Amounts added to policyholder account balances:
|
|
|
|
|
|
||||||
Cost of interest credited to policyholders
|
110.8
|
|
|
118.5
|
|
|
127.2
|
|
|||
Cost of options to fund index credits, net of forfeitures
|
66.1
|
|
|
60.3
|
|
|
49.2
|
|
|||
Market value changes credited to policyholders
|
26.3
|
|
|
(32.9
|
)
|
|
63.5
|
|
|||
Amortization related to operations
|
176.5
|
|
|
187.1
|
|
|
174.7
|
|
|||
Interest expense on investment borrowings
|
13.2
|
|
|
8.8
|
|
|
7.9
|
|
|||
Other operating costs and expenses
|
422.1
|
|
|
407.2
|
|
|
401.2
|
|
|||
Total benefits and expenses
|
2,232.4
|
|
|
2,191.5
|
|
|
2,251.4
|
|
|||
Income before gain on reinsurance transaction, net realized investment gains (losses), net of related amortization, and fair value changes in embedded derivative liabilities, net of related amortization, and income taxes
|
397.9
|
|
|
369.6
|
|
|
386.9
|
|
|||
Gain on reinsurance transaction
|
—
|
|
|
—
|
|
|
26.1
|
|
|||
Net realized investment gains (losses)
|
(3.2
|
)
|
|
(17.2
|
)
|
|
8.3
|
|
|||
Amortization related to net realized investment gains (losses)
|
(.4
|
)
|
|
.5
|
|
|
(.5
|
)
|
|||
Net realized investment gains (losses), net of related amortization
|
(3.6
|
)
|
|
(16.7
|
)
|
|
7.8
|
|
|||
Insurance policy benefits - fair value changes in embedded derivative liabilities
|
10.7
|
|
|
14.9
|
|
|
(47.0
|
)
|
|||
Amortization related to fair value changes in embedded derivative liabilities
|
(1.3
|
)
|
|
(3.2
|
)
|
|
11.4
|
|
|||
Fair value changes in embedded derivative liabilities, net of related amortization
|
9.4
|
|
|
11.7
|
|
|
(35.6
|
)
|
|||
Income before income taxes
|
$
|
403.7
|
|
|
$
|
364.6
|
|
|
$
|
385.2
|
|
|
2016
|
|
2015
|
|
2014
|
||||||
Health benefit ratios:
|
|
|
|
|
|
||||||
All health lines:
|
|
|
|
|
|
||||||
Insurance policy benefits
|
$
|
1,192.3
|
|
|
$
|
1,205.1
|
|
|
$
|
1,190.6
|
|
Benefit ratio (a)
|
95.8
|
%
|
|
96.3
|
%
|
|
92.5
|
%
|
|||
Medicare supplement:
|
|
|
|
|
|
||||||
Insurance policy benefits
|
$
|
556.2
|
|
|
$
|
536.1
|
|
|
$
|
529.3
|
|
Benefit ratio (a)
|
71.9
|
%
|
|
69.6
|
%
|
|
68.4
|
%
|
|||
Long-term care:
|
|
|
|
|
|
||||||
Insurance policy benefits
|
$
|
636.1
|
|
|
$
|
669.0
|
|
|
$
|
656.0
|
|
Benefit ratio (a)
|
135.0
|
%
|
|
139.2
|
%
|
|
129.7
|
%
|
|||
Interest-adjusted benefit ratio (b)
|
76.7
|
%
|
|
82.8
|
%
|
|
77.2
|
%
|
|||
PDP:
|
|
|
|
|
|
||||||
Insurance policy benefits
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
5.3
|
|
Benefit ratio (a)
|
—
|
%
|
|
—
|
%
|
|
77.9
|
%
|
(a)
|
We calculate benefit ratios by dividing the related product's insurance policy benefits by insurance policy income.
|
(b)
|
We calculate the interest-adjusted benefit ratio (a non-GAAP measure) for Bankers Life's long-term care products by dividing such product's insurance policy benefits less the imputed interest income on the accumulated assets backing the insurance liabilities by policy income. These are considered non-GAAP financial measures. A non-GAAP measure is a numerical measure of a company's performance, financial position, or cash flows that excludes or includes amounts that are normally excluded or included in the most directly comparable measure calculated and presented in accordance with GAAP.
|
|
2016
|
|
2015
|
|
2014
|
||||||
Commission expense and agent manager benefits
|
$
|
71.6
|
|
|
$
|
64.4
|
|
|
$
|
57.2
|
|
Other operating expenses
|
350.5
|
|
|
342.8
|
|
|
344.0
|
|
|||
Total
|
$
|
422.1
|
|
|
$
|
407.2
|
|
|
$
|
401.2
|
|
|
2016
|
|
2015
|
|
2014
|
||||||
Premium collections:
|
|
|
|
|
|
||||||
Supplemental health and other health
|
$
|
567.4
|
|
|
$
|
547.0
|
|
|
$
|
517.8
|
|
Medicare supplement
|
61.0
|
|
|
72.6
|
|
|
85.2
|
|
|||
Life
|
29.4
|
|
|
27.7
|
|
|
25.9
|
|
|||
Annuity
|
1.5
|
|
|
2.4
|
|
|
2.6
|
|
|||
Total collections
|
$
|
659.3
|
|
|
$
|
649.7
|
|
|
$
|
631.5
|
|
Average liabilities for insurance products:
|
|
|
|
|
|
|
|||||
Fixed index annuities
|
$
|
350.2
|
|
|
$
|
386.0
|
|
|
$
|
421.5
|
|
Fixed interest annuities
|
107.0
|
|
|
119.1
|
|
|
130.2
|
|
|||
SPIAs and supplemental contracts:
|
|
|
|
|
|
||||||
Mortality based
|
248.6
|
|
|
258.4
|
|
|
245.4
|
|
|||
Deposit based
|
267.2
|
|
|
260.5
|
|
|
252.6
|
|
|||
Separate Accounts
|
4.7
|
|
|
5.2
|
|
|
8.5
|
|
|||
Health:
|
|
|
|
|
|
||||||
Supplemental health
|
2,604.4
|
|
|
2,494.0
|
|
|
2,387.9
|
|
|||
Medicare supplement
|
28.3
|
|
|
30.9
|
|
|
35.2
|
|
|||
Other health
|
14.1
|
|
|
15.0
|
|
|
14.9
|
|
|||
Life:
|
|
|
|
|
|
||||||
Interest sensitive life
|
150.3
|
|
|
151.9
|
|
|
159.4
|
|
|||
Non-interest sensitive life
|
179.8
|
|
|
185.9
|
|
|
192.0
|
|
|||
Total average liabilities for insurance products, net of reinsurance ceded
|
$
|
3,954.6
|
|
|
$
|
3,906.9
|
|
|
$
|
3,847.6
|
|
Revenues:
|
|
|
|
|
|
||||||
Insurance policy income
|
$
|
655.8
|
|
|
$
|
643.8
|
|
|
$
|
626.0
|
|
Net investment income:
|
|
|
|
|
|
||||||
General account invested assets
|
256.2
|
|
|
256.0
|
|
|
266.5
|
|
|||
Fixed index products
|
1.9
|
|
|
(2.2
|
)
|
|
6.3
|
|
|||
Trading account income related to reinsurer accounts
|
—
|
|
|
—
|
|
|
1.4
|
|
|||
Change in value of embedded derivative related to modified coinsurance agreement
|
—
|
|
|
—
|
|
|
(1.4
|
)
|
|||
Trading account income related to policyholder accounts
|
1.2
|
|
|
(.2
|
)
|
|
3.3
|
|
|||
Fee revenue and other income
|
1.3
|
|
|
1.3
|
|
|
1.1
|
|
|||
Total revenues
|
916.4
|
|
|
898.7
|
|
|
903.2
|
|
|||
Expenses:
|
|
|
|
|
|
||||||
Insurance policy benefits
|
538.2
|
|
|
528.4
|
|
|
505.7
|
|
|||
Amounts added to policyholder account balances:
|
|
|
|
|
|
||||||
Cost of interest credited to policyholders
|
13.8
|
|
|
14.6
|
|
|
14.9
|
|
|||
Cost of options to fund index credits, net of forfeitures
|
5.8
|
|
|
6.3
|
|
|
5.6
|
|
|||
Market value changes credited to policyholders
|
3.9
|
|
|
(2.7
|
)
|
|
10.0
|
|
|||
Amortization related to operations
|
59.1
|
|
|
55.2
|
|
|
64.6
|
|
|||
Interest expense on investment borrowings
|
3.7
|
|
|
2.0
|
|
|
1.7
|
|
|||
Other operating costs and expenses
|
189.0
|
|
|
183.4
|
|
|
189.5
|
|
|||
Total benefits and expenses
|
813.5
|
|
|
787.2
|
|
|
792.0
|
|
|||
Income before gain on reinsurance transaction, net realized investment gains (losses) and fair value changes in embedded derivative liabilities, net of related amortization, and income taxes
|
102.9
|
|
|
111.5
|
|
|
111.2
|
|
|||
Gain on reinsurance transaction
|
—
|
|
|
—
|
|
|
3.8
|
|
|||
Net realized investment gains (losses)
|
19.7
|
|
|
(9.6
|
)
|
|
34.4
|
|
|||
Amortization related to net realized investment gains (losses)
|
(.3
|
)
|
|
—
|
|
|
(.5
|
)
|
|||
Net realized investment gains (losses), net of related amortization
|
19.4
|
|
|
(9.6
|
)
|
|
33.9
|
|
|||
Insurance policy benefits - fair value changes in embedded derivative liabilities
|
.6
|
|
|
.8
|
|
|
(1.5
|
)
|
|||
Amortization related to fair value changes in embedded derivative liabilities
|
(.4
|
)
|
|
(.6
|
)
|
|
1.1
|
|
|||
Fair value changes in embedded derivative liabilities, net of related amortization
|
.2
|
|
|
.2
|
|
|
(.4
|
)
|
|||
Income before income taxes
|
$
|
122.5
|
|
|
$
|
102.1
|
|
|
$
|
148.5
|
|
|
2016
|
|
2015
|
|
2014
|
||||||
Health benefit ratios:
|
|
|
|
|
|
||||||
Supplemental health:
|
|
|
|
|
|
||||||
Insurance policy benefits
|
$
|
469.3
|
|
|
$
|
455.3
|
|
|
$
|
408.7
|
|
Benefit ratio (a)
|
83.0
|
%
|
|
84.0
|
%
|
|
80.1
|
%
|
|||
Interest-adjusted benefit ratio (b)
|
59.0
|
%
|
|
59.6
|
%
|
|
54.6
|
%
|
|||
Medicare supplement:
|
|
|
|
|
|
||||||
Insurance policy benefits
|
$
|
42.7
|
|
|
$
|
47.9
|
|
|
$
|
55.2
|
|
Benefit ratio (a)
|
68.4
|
%
|
|
65.0
|
%
|
|
63.3
|
%
|
(a)
|
We calculate benefit ratios by dividing the related product’s insurance policy benefits by insurance policy income.
|
(b)
|
We calculate the interest-adjusted benefit ratio (a non-GAAP measure) for Washington National's supplemental health products by dividing such product’s insurance policy benefits less the imputed interest income on the accumulated assets backing the insurance liabilities by policy income. These are considered non-GAAP financial measures. A non-GAAP measure is a numerical measure of a company's performance, financial position, or cash flows that excludes or includes amounts that are normally excluded or included in the most directly comparable measure calculated and presented in accordance with GAAP.
|
|
2016
|
|
2015
|
|
2014
|
||||||
Premium collections:
|
|
|
|
|
|
||||||
Life
|
$
|
277.8
|
|
|
$
|
259.9
|
|
|
$
|
241.7
|
|
Medicare supplement and other health
|
2.4
|
|
|
3.0
|
|
|
3.4
|
|
|||
Total collections
|
$
|
280.2
|
|
|
$
|
262.9
|
|
|
$
|
245.1
|
|
Average liabilities for insurance products:
|
|
|
|
|
|
|
|||||
SPIAs - mortality based
|
$
|
74.1
|
|
|
$
|
73.1
|
|
|
$
|
69.6
|
|
Health:
|
|
|
|
|
|
||||||
Medicare supplement
|
6.5
|
|
|
7.7
|
|
|
8.3
|
|
|||
Other health
|
4.2
|
|
|
4.4
|
|
|
4.5
|
|
|||
Life:
|
|
|
|
|
|
||||||
Interest sensitive
|
16.2
|
|
|
16.5
|
|
|
17.0
|
|
|||
Non-interest sensitive
|
689.4
|
|
|
670.1
|
|
|
649.8
|
|
|||
Total average liabilities for insurance products, net of reinsurance ceded
|
$
|
790.4
|
|
|
$
|
771.8
|
|
|
$
|
749.2
|
|
Revenues:
|
|
|
|
|
|
||||||
Insurance policy income
|
$
|
281.4
|
|
|
$
|
263.5
|
|
|
$
|
246.0
|
|
Net investment income on general account invested assets
|
44.2
|
|
|
43.0
|
|
|
41.7
|
|
|||
Fee revenue and other income
|
1.1
|
|
|
1.0
|
|
|
1.0
|
|
|||
Total revenues
|
326.7
|
|
|
307.5
|
|
|
288.7
|
|
|||
Expenses:
|
|
|
|
|
|
||||||
Insurance policy benefits
|
201.2
|
|
|
188.3
|
|
|
172.5
|
|
|||
Amounts added to annuity and interest-sensitive life product account balances
|
.7
|
|
|
.7
|
|
|
.7
|
|
|||
Amortization related to operations
|
15.3
|
|
|
14.4
|
|
|
15.3
|
|
|||
Interest expense on investment borrowings
|
.6
|
|
|
.1
|
|
|
—
|
|
|||
Other operating costs and expenses
|
107.2
|
|
|
98.4
|
|
|
99.4
|
|
|||
Total benefits and expenses
|
325.0
|
|
|
301.9
|
|
|
287.9
|
|
|||
Income before net realized investment gains (losses) and income taxes
|
1.7
|
|
|
5.6
|
|
|
.8
|
|
|||
Net realized investment gains (losses)
|
(.2
|
)
|
|
1.2
|
|
|
1.1
|
|
|||
Income before income taxes
|
$
|
1.5
|
|
|
$
|
6.8
|
|
|
$
|
1.9
|
|
|
2016
|
|
2015
|
|
2014
|
||||||
Adjusted EBIT from Inforce Business
|
|
|
|
|
|
||||||
Revenues:
|
|
|
|
|
|
||||||
Insurance policy income
|
$
|
226.5
|
|
|
$
|
212.0
|
|
|
$
|
200.3
|
|
Net investment income and other
|
45.3
|
|
|
44.0
|
|
|
42.7
|
|
|||
Total revenues
|
271.8
|
|
|
256.0
|
|
|
243.0
|
|
|||
Benefits and expenses:
|
|
|
|
|
|
||||||
Insurance policy benefits
|
168.5
|
|
|
159.4
|
|
|
146.9
|
|
|||
Amortization
|
14.5
|
|
|
13.7
|
|
|
14.9
|
|
|||
Other expenses
|
34.4
|
|
|
29.3
|
|
|
31.6
|
|
|||
Total benefits and expenses
|
217.4
|
|
|
202.4
|
|
|
193.4
|
|
|||
Adjusted EBIT from Inforce Business
|
$
|
54.4
|
|
|
$
|
53.6
|
|
|
$
|
49.6
|
|
|
|
|
|
|
|
||||||
Adjusted EBIT from New Business
|
|
|
|
|
|
||||||
Revenues:
|
|
|
|
|
|
||||||
Insurance policy income
|
$
|
54.9
|
|
|
$
|
51.5
|
|
|
$
|
45.7
|
|
Net investment income and other
|
—
|
|
|
—
|
|
|
—
|
|
|||
Total revenues
|
54.9
|
|
|
51.5
|
|
|
45.7
|
|
|||
Benefits and expenses:
|
|
|
|
|
|
||||||
Insurance policy benefits
|
33.4
|
|
|
29.6
|
|
|
26.3
|
|
|||
Amortization
|
.8
|
|
|
.7
|
|
|
.4
|
|
|||
Other expenses
|
73.4
|
|
|
69.2
|
|
|
67.8
|
|
|||
Total benefits and expenses
|
107.6
|
|
|
99.5
|
|
|
94.5
|
|
|||
Adjusted EBIT from New Business
|
$
|
(52.7
|
)
|
|
$
|
(48.0
|
)
|
|
$
|
(48.8
|
)
|
|
|
|
|
|
|
||||||
Adjusted EBIT from Inforce and New Business
|
|
|
|
|
|
||||||
Revenues:
|
|
|
|
|
|
||||||
Insurance policy income
|
$
|
281.4
|
|
|
$
|
263.5
|
|
|
$
|
246.0
|
|
Net investment income and other
|
45.3
|
|
|
44.0
|
|
|
42.7
|
|
|||
Total revenues
|
326.7
|
|
|
307.5
|
|
|
288.7
|
|
|||
Benefits and expenses:
|
|
|
|
|
|
||||||
Insurance policy benefits
|
201.9
|
|
|
189.0
|
|
|
173.2
|
|
|||
Amortization
|
15.3
|
|
|
14.4
|
|
|
15.3
|
|
|||
Other expenses
|
107.8
|
|
|
98.5
|
|
|
99.4
|
|
|||
Total benefits and expenses
|
325.0
|
|
|
301.9
|
|
|
287.9
|
|
|||
Adjusted EBIT from Inforce and New Business
|
$
|
1.7
|
|
|
$
|
5.6
|
|
|
$
|
.8
|
|
|
2016
|
||
Premium collections:
|
|
||
Long-term care (all renewal)
|
$
|
4.7
|
|
|
|
||
Average liabilities for insurance products:
|
|
||
Average liabilities for long-term care products, net of reinsurance ceded
|
$
|
138.4
|
|
|
|
||
Revenues:
|
|
||
Insurance policy income
|
$
|
4.8
|
|
Net investment income on general account invested assets
|
9.4
|
|
|
Total revenues
|
14.2
|
|
|
Expenses:
|
|
||
Insurance policy benefits
|
17.6
|
|
|
Other operating costs and expenses
|
.5
|
|
|
Total benefits and expenses
|
18.1
|
|
|
Loss before net realized investment losses and income taxes
|
(3.9
|
)
|
|
Net realized investment losses
|
(5.3
|
)
|
|
Loss before income taxes
|
$
|
(9.2
|
)
|
|
2016
|
||
Health benefit ratios:
|
|
||
Long-term care:
|
|
||
Insurance policy benefits
|
$
|
17.6
|
|
Benefit ratio (a)
|
365.8
|
%
|
|
Interest-adjusted benefit ratio (b)
|
213.5
|
%
|
(a)
|
We calculate benefit ratios by dividing the related product's insurance policy benefits by insurance policy income.
|
(b)
|
We calculate the interest-adjusted benefit ratio (a non-GAAP measure) for long-term care products in this segment by dividing such product's insurance policy benefits less the imputed interest income on the accumulated assets backing the insurance liabilities by policy income. These are considered non-GAAP financial measures. A non-GAAP measure is a numerical measure of a company's performance, financial position, or cash flows that excludes or includes amounts that are normally excluded or included in the most directly comparable measure calculated and presented in accordance with GAAP.
|
|
2016
|
|
2015
|
|
2014
|
||||||
Corporate operations:
|
|
|
|
|
|
||||||
Interest expense on corporate debt
|
$
|
(45.8
|
)
|
|
$
|
(45.0
|
)
|
|
$
|
(43.9
|
)
|
Net investment income (loss):
|
|
|
|
|
|
||||||
General investment portfolio
|
4.8
|
|
|
6.9
|
|
|
8.5
|
|
|||
Other special-purpose portfolios:
|
|
|
|
|
|
||||||
COLI
|
(.3
|
)
|
|
(6.4
|
)
|
|
(1.3
|
)
|
|||
Investments held in a rabbi trust
|
1.1
|
|
|
(.1
|
)
|
|
.4
|
|
|||
Investments in certain hedge funds
|
—
|
|
|
—
|
|
|
(2.8
|
)
|
|||
Other trading account activities
|
11.0
|
|
|
10.9
|
|
|
10.1
|
|
|||
Fee revenue and other income
|
10.0
|
|
|
8.6
|
|
|
6.7
|
|
|||
Interest expense on investment borrowings
|
—
|
|
|
(.2
|
)
|
|
(.1
|
)
|
|||
Other operating costs and expenses
|
(69.1
|
)
|
|
(38.6
|
)
|
|
(49.1
|
)
|
|||
Loss before net realized investment losses, equity in earnings of certain non-strategic investments and earnings attributable to non-controlling interests, fair value changes and amendment related to agent deferred compensation plan, loss on reinsurance transaction, net revenue pursuant to transition and support services agreements, transition expenses, loss on extinguishment or modification of debt and income taxes
|
(88.3
|
)
|
|
(63.9
|
)
|
|
(71.5
|
)
|
|||
Net realized investment losses
|
(2.7
|
)
|
|
(11.0
|
)
|
|
(9.9
|
)
|
|||
Equity in earnings of certain non-strategic investments and earnings attributable to non-controlling interests
|
(2.0
|
)
|
|
(6.7
|
)
|
|
(8.0
|
)
|
|||
Fair value changes and amendment related to agent deferred compensation plan
|
3.1
|
|
|
15.1
|
|
|
(26.8
|
)
|
|||
Loss on reinsurance transaction
|
(75.4
|
)
|
|
—
|
|
|
—
|
|
|||
Net revenue pursuant to transition and support services agreements
|
—
|
|
|
2.5
|
|
|
2.6
|
|
|||
Transition expenses
|
—
|
|
|
(9.0
|
)
|
|
—
|
|
|||
Loss on extinguishment or modification of debt
|
—
|
|
|
(32.8
|
)
|
|
(.6
|
)
|
|||
Loss before income taxes
|
$
|
(165.3
|
)
|
|
$
|
(105.8
|
)
|
|
$
|
(114.2
|
)
|
|
2014
|
||
Premium collections:
|
|
||
Annuities
|
$
|
.2
|
|
Life
|
71.0
|
|
|
Total collections
|
$
|
71.2
|
|
Average liabilities for insurance products:
|
|
||
Fixed index annuities
|
$
|
—
|
|
Fixed interest annuities
|
—
|
|
|
SPIAs and supplemental contracts:
|
|
||
Mortality based
|
—
|
|
|
Deposit based
|
—
|
|
|
Health:
|
|
||
Supplemental health
|
—
|
|
|
Medicare supplement
|
—
|
|
|
Other health
|
—
|
|
|
Life:
|
|
||
Interest sensitive
|
—
|
|
|
Non-interest sensitive
|
—
|
|
|
Total average liabilities for insurance products, net of reinsurance ceded
|
$
|
—
|
|
Revenues:
|
|
||
Insurance policy income
|
$
|
106.0
|
|
Net investment income:
|
|
||
General account invested assets
|
100.7
|
|
|
Fixed index products
|
1.3
|
|
|
Fee revenue and other income
|
—
|
|
|
Total revenues
|
208.0
|
|
|
Expenses:
|
|
||
Insurance policy benefits
|
115.8
|
|
|
Amounts added to policyholder account balances:
|
|
||
Cost of interest credited to policyholders
|
43.2
|
|
|
Cost of options to fund index credits, net of forfeitures
|
.8
|
|
|
Market value changes credited to policyholders
|
.9
|
|
|
Amortization related to operations
|
4.3
|
|
|
Interest expense on investment borrowings
|
9.1
|
|
|
Other operating costs and expenses
|
13.3
|
|
|
Total benefits and expenses
|
187.4
|
|
|
Income (loss) before net realized investment gains (losses), loss on sale of CLIC and income taxes
|
20.6
|
|
|
Net realized investment gains (losses)
|
2.8
|
|
|
Amortization related to net realized investment gains (losses)
|
—
|
|
|
Net realized investment gains (losses), net of related amortization
|
2.8
|
|
|
Earnings of CLIC prior to being sold
|
23.4
|
|
|
Loss on sale of CLIC
|
(269.7
|
)
|
|
Income (loss) before income taxes
|
$
|
(246.3
|
)
|
|
2016
|
|
2015
|
|
2014 (a)
|
||||||
First year:
|
|
|
|
|
|
||||||
Bankers Life
|
$
|
1,211.8
|
|
|
$
|
1,065.7
|
|
|
$
|
1,080.8
|
|
Washington National
|
78.2
|
|
|
80.2
|
|
|
77.6
|
|
|||
Colonial Penn
|
54.8
|
|
|
51.5
|
|
|
45.7
|
|
|||
Total first year
|
1,344.8
|
|
|
1,197.4
|
|
|
1,204.1
|
|
|||
|
|
|
|
|
|
||||||
Renewal:
|
|
|
|
|
|
||||||
Bankers Life
|
1,454.6
|
|
|
1,425.6
|
|
|
1,401.5
|
|
|||
Washington National
|
581.1
|
|
|
569.5
|
|
|
553.9
|
|
|||
Colonial Penn
|
225.4
|
|
|
211.4
|
|
|
199.4
|
|
|||
Long-term care in run-off
|
4.7
|
|
|
—
|
|
|
—
|
|
|||
Total renewal
|
2,265.8
|
|
|
2,206.5
|
|
|
2,154.8
|
|
|||
Total premiums collected
|
$
|
3,610.6
|
|
|
$
|
3,403.9
|
|
|
$
|
3,358.9
|
|
|
2016
|
|
2015
|
|
2014
|
||||||
Premiums collected by product:
|
|
|
|
|
|
||||||
Annuities:
|
|
|
|
|
|
||||||
Fixed index (first-year)
|
$
|
868.1
|
|
|
$
|
706.6
|
|
|
$
|
646.2
|
|
Other fixed interest (first-year)
|
95.7
|
|
|
89.6
|
|
|
129.1
|
|
|||
Other fixed interest (renewal)
|
6.2
|
|
|
6.8
|
|
|
7.0
|
|
|||
Subtotal - other fixed interest annuities
|
101.9
|
|
|
96.4
|
|
|
136.1
|
|
|||
Total annuities
|
970.0
|
|
|
803.0
|
|
|
782.3
|
|
|||
Health:
|
|
|
|
|
|
||||||
Medicare supplement (first-year)
|
75.6
|
|
|
80.3
|
|
|
88.6
|
|
|||
Medicare supplement (renewal)
|
663.7
|
|
|
659.1
|
|
|
654.7
|
|
|||
Subtotal - Medicare supplement
|
739.3
|
|
|
739.4
|
|
|
743.3
|
|
|||
Long-term care (first-year)
|
17.4
|
|
|
16.7
|
|
|
16.8
|
|
|||
Long-term care (renewal)
|
451.2
|
|
|
459.9
|
|
|
483.8
|
|
|||
Subtotal - long-term care
|
468.6
|
|
|
476.6
|
|
|
500.6
|
|
|||
PDP (renewal)
|
—
|
|
|
—
|
|
|
6.8
|
|
|||
Supplemental health (first-year)
|
5.5
|
|
|
6.1
|
|
|
7.6
|
|
|||
Supplemental health (renewal)
|
15.7
|
|
|
13.1
|
|
|
8.7
|
|
|||
Subtotal – supplemental health
|
21.2
|
|
|
19.2
|
|
|
16.3
|
|
|||
Other health (first-year)
|
.1
|
|
|
.1
|
|
|
.7
|
|
|||
Other health (renewal)
|
6.1
|
|
|
7.0
|
|
|
7.4
|
|
|||
Subtotal - other health
|
6.2
|
|
|
7.1
|
|
|
8.1
|
|
|||
Total health
|
1,235.3
|
|
|
1,242.3
|
|
|
1,275.1
|
|
|||
Life insurance:
|
|
|
|
|
|
||||||
Traditional (first-year)
|
78.8
|
|
|
83.0
|
|
|
91.6
|
|
|||
Traditional (renewal)
|
207.3
|
|
|
193.9
|
|
|
163.5
|
|
|||
Subtotal - traditional
|
286.1
|
|
|
276.9
|
|
|
255.1
|
|
|||
Interest-sensitive (first-year)
|
70.6
|
|
|
83.3
|
|
|
100.2
|
|
|||
Interest-sensitive (renewal)
|
104.4
|
|
|
85.8
|
|
|
69.6
|
|
|||
Subtotal - interest-sensitive
|
175.0
|
|
|
169.1
|
|
|
169.8
|
|
|||
Total life insurance
|
461.1
|
|
|
446.0
|
|
|
424.9
|
|
|||
Collections on insurance products:
|
|
|
|
|
|
||||||
Total first-year premium collections on insurance products
|
1,211.8
|
|
|
1,065.7
|
|
|
1,080.8
|
|
|||
Total renewal premium collections on insurance products
|
1,454.6
|
|
|
1,425.6
|
|
|
1,401.5
|
|
|||
Total collections on insurance products
|
$
|
2,666.4
|
|
|
$
|
2,491.3
|
|
|
$
|
2,482.3
|
|
|
2016
|
|
2015
|
|
2014
|
||||||
Premiums collected by product:
|
|
|
|
|
|
||||||
Health:
|
|
|
|
|
|
||||||
Medicare supplement (renewal)
|
$
|
61.0
|
|
|
$
|
72.6
|
|
|
$
|
85.2
|
|
Supplemental health (first-year)
|
72.2
|
|
|
74.9
|
|
|
72.8
|
|
|||
Supplemental health (renewal)
|
493.3
|
|
|
469.9
|
|
|
442.6
|
|
|||
Subtotal – supplemental health
|
565.5
|
|
|
544.8
|
|
|
515.4
|
|
|||
Other health (first-year)
|
.2
|
|
|
.2
|
|
|
.2
|
|
|||
Other health (renewal)
|
1.7
|
|
|
2.0
|
|
|
2.2
|
|
|||
Subtotal – other health
|
1.9
|
|
|
2.2
|
|
|
2.4
|
|
|||
Total health
|
628.4
|
|
|
619.6
|
|
|
603.0
|
|
|||
Life insurance:
|
|
|
|
|
|
||||||
Traditional (first-year)
|
.9
|
|
|
.7
|
|
|
.6
|
|
|||
Traditional (renewal)
|
10.5
|
|
|
11.4
|
|
|
12.3
|
|
|||
Subtotal - traditional
|
11.4
|
|
|
12.1
|
|
|
12.9
|
|
|||
Interest-sensitive (first-year)
|
4.7
|
|
|
4.3
|
|
|
3.8
|
|
|||
Interest-sensitive (renewal)
|
13.3
|
|
|
11.3
|
|
|
9.2
|
|
|||
Subtotal - interest-sensitive
|
18.0
|
|
|
15.6
|
|
|
13.0
|
|
|||
Total life insurance
|
29.4
|
|
|
27.7
|
|
|
25.9
|
|
|||
Annuities:
|
|
|
|
|
|
||||||
Fixed index (first-year)
|
.2
|
|
|
.1
|
|
|
.2
|
|
|||
Fixed index (renewal)
|
1.0
|
|
|
1.8
|
|
|
1.8
|
|
|||
Subtotal - fixed index annuities
|
1.2
|
|
|
1.9
|
|
|
2.0
|
|
|||
Other fixed interest (renewal)
|
.3
|
|
|
.5
|
|
|
.6
|
|
|||
Total annuities
|
1.5
|
|
|
2.4
|
|
|
2.6
|
|
|||
Collections on insurance products:
|
|
|
|
|
|
||||||
Total first-year premium collections on insurance products
|
78.2
|
|
|
80.2
|
|
|
77.6
|
|
|||
Total renewal premium collections on insurance products
|
581.1
|
|
|
569.5
|
|
|
553.9
|
|
|||
Total collections on insurance products
|
$
|
659.3
|
|
|
$
|
649.7
|
|
|
$
|
631.5
|
|
|
2016
|
|
2015
|
|
2014
|
||||||
Premiums collected by product:
|
|
|
|
|
|
||||||
Life insurance:
|
|
|
|
|
|
||||||
Traditional (first-year)
|
$
|
54.8
|
|
|
$
|
51.5
|
|
|
$
|
45.7
|
|
Traditional (renewal)
|
222.7
|
|
|
208.2
|
|
|
195.6
|
|
|||
Subtotal - traditional
|
277.5
|
|
|
259.7
|
|
|
241.3
|
|
|||
Interest-sensitive (all renewal)
|
.3
|
|
|
.2
|
|
|
.4
|
|
|||
Total life insurance
|
277.8
|
|
|
259.9
|
|
|
241.7
|
|
|||
Health (all renewal):
|
|
|
|
|
|
||||||
Medicare supplement
|
2.3
|
|
|
2.7
|
|
|
3.2
|
|
|||
Other health
|
.1
|
|
|
.3
|
|
|
.2
|
|
|||
Total health
|
2.4
|
|
|
3.0
|
|
|
3.4
|
|
|||
Collections on insurance products:
|
|
|
|
|
|
||||||
Total first-year premium collections on insurance products
|
54.8
|
|
|
51.5
|
|
|
45.7
|
|
|||
Total renewal premium collections on insurance products
|
225.4
|
|
|
211.4
|
|
|
199.4
|
|
|||
Total collections on insurance products
|
$
|
280.2
|
|
|
$
|
262.9
|
|
|
$
|
245.1
|
|
|
2016
|
||
Premiums collected by product:
|
|
||
Health:
|
|
||
Long-term care (renewal)
|
$
|
4.7
|
|
|
Carrying value
|
|
Percent of total investments
|
|||
Fixed maturities, available for sale
|
$
|
21,096.2
|
|
|
80
|
%
|
Equity securities
|
584.2
|
|
|
2
|
|
|
Mortgage loans
|
1,768.0
|
|
|
7
|
|
|
Policy loans
|
112.0
|
|
|
—
|
|
|
Trading securities
|
363.4
|
|
|
1
|
|
|
Investments held by variable interest entities
|
1,724.3
|
|
|
7
|
|
|
Company-owned life insurance
|
165.0
|
|
|
1
|
|
|
Other invested assets
|
424.5
|
|
|
2
|
|
|
Total investments
|
$
|
26,237.6
|
|
|
100
|
%
|
|
Carrying value
|
|
Percent of fixed maturities
|
|
Gross unrealized losses
|
|
Percent of gross unrealized losses
|
||||||
Asset-backed securities
|
$
|
2,710.3
|
|
|
12.8
|
%
|
|
$
|
15.5
|
|
|
8.0
|
%
|
States and political subdivisions
|
1,988.9
|
|
|
9.4
|
|
|
9.6
|
|
|
4.9
|
|
||
Energy
|
1,539.4
|
|
|
7.3
|
|
|
21.4
|
|
|
11.0
|
|
||
Utilities
|
1,538.4
|
|
|
7.3
|
|
|
5.4
|
|
|
2.8
|
|
||
Commercial mortgage-backed securities
|
1,536.2
|
|
|
7.3
|
|
|
27.9
|
|
|
14.4
|
|
||
Insurance
|
1,456.1
|
|
|
6.9
|
|
|
12.7
|
|
|
6.6
|
|
||
Healthcare/pharmaceuticals
|
1,434.5
|
|
|
6.8
|
|
|
19.0
|
|
|
9.8
|
|
||
Banks
|
992.6
|
|
|
4.7
|
|
|
9.5
|
|
|
4.9
|
|
||
Collateralized mortgage obligations
|
915.5
|
|
|
4.3
|
|
|
1.6
|
|
|
.8
|
|
||
Food/beverage
|
894.4
|
|
|
4.2
|
|
|
1.7
|
|
|
.9
|
|
||
Cable/media
|
737.9
|
|
|
3.5
|
|
|
20.3
|
|
|
10.5
|
|
||
Real estate/REITs
|
558.9
|
|
|
2.6
|
|
|
1.0
|
|
|
.5
|
|
||
Capital goods
|
522.5
|
|
|
2.5
|
|
|
3.9
|
|
|
2.0
|
|
||
Transportation
|
455.0
|
|
|
2.2
|
|
|
2.9
|
|
|
1.5
|
|
||
Chemicals
|
421.2
|
|
|
2.0
|
|
|
10.3
|
|
|
5.3
|
|
||
Telecom
|
420.9
|
|
|
2.0
|
|
|
2.6
|
|
|
1.3
|
|
||
Brokerage
|
312.1
|
|
|
1.5
|
|
|
2.5
|
|
|
1.3
|
|
||
Aerospace/defense
|
275.9
|
|
|
1.3
|
|
|
.3
|
|
|
.1
|
|
||
Technology
|
273.4
|
|
|
1.3
|
|
|
3.3
|
|
|
1.7
|
|
||
Business services
|
256.7
|
|
|
1.2
|
|
|
4.2
|
|
|
2.2
|
|
||
Paper
|
245.9
|
|
|
1.2
|
|
|
.6
|
|
|
.3
|
|
||
Autos
|
245.4
|
|
|
1.2
|
|
|
1.4
|
|
|
.7
|
|
||
Collateralized debt obligations
|
230.7
|
|
|
1.1
|
|
|
.3
|
|
|
.2
|
|
||
Other
|
1,133.4
|
|
|
5.4
|
|
|
16.4
|
|
|
8.3
|
|
||
Total fixed maturities, available for sale
|
$
|
21,096.2
|
|
|
100.0
|
%
|
|
$
|
194.3
|
|
|
100.0
|
%
|
|
Investment grade
|
|
Below-investment grade
|
|
|
||||||||||||||
|
AAA/AA/A
|
|
BBB
|
|
BB
|
|
B+ and
below
|
|
Total gross
unrealized
losses |
||||||||||
Commercial mortgage-backed securities
|
$
|
22.3
|
|
|
$
|
4.3
|
|
|
$
|
1.3
|
|
|
$
|
—
|
|
|
$
|
27.9
|
|
Energy
|
.1
|
|
|
10.0
|
|
|
8.5
|
|
|
2.8
|
|
|
21.4
|
|
|||||
Cable/media
|
.2
|
|
|
16.7
|
|
|
3.1
|
|
|
.3
|
|
|
20.3
|
|
|||||
Healthcare/pharmaceuticals
|
2.5
|
|
|
14.5
|
|
|
.2
|
|
|
1.8
|
|
|
19.0
|
|
|||||
Asset-backed securities
|
2.7
|
|
|
6.0
|
|
|
.3
|
|
|
6.5
|
|
|
15.5
|
|
|||||
Insurance
|
2.2
|
|
|
10.5
|
|
|
—
|
|
|
—
|
|
|
12.7
|
|
|||||
Chemicals
|
.8
|
|
|
4.1
|
|
|
5.4
|
|
|
—
|
|
|
10.3
|
|
|||||
States and political subdivisions
|
4.8
|
|
|
3.1
|
|
|
—
|
|
|
1.7
|
|
|
9.6
|
|
|||||
Banks
|
2.6
|
|
|
6.9
|
|
|
—
|
|
|
—
|
|
|
9.5
|
|
|||||
Utilities
|
2.0
|
|
|
3.0
|
|
|
—
|
|
|
.4
|
|
|
5.4
|
|
|||||
Business services
|
—
|
|
|
.1
|
|
|
4.1
|
|
|
—
|
|
|
4.2
|
|
|||||
Capital goods
|
.6
|
|
|
2.8
|
|
|
.2
|
|
|
.3
|
|
|
3.9
|
|
|||||
Retail
|
—
|
|
|
.2
|
|
|
—
|
|
|
3.5
|
|
|
3.7
|
|
|||||
Technology
|
—
|
|
|
3.0
|
|
|
.3
|
|
|
—
|
|
|
3.3
|
|
|||||
Transportation
|
—
|
|
|
2.7
|
|
|
—
|
|
|
.2
|
|
|
2.9
|
|
|||||
Telecom
|
—
|
|
|
1.5
|
|
|
1.0
|
|
|
.1
|
|
|
2.6
|
|
|||||
Brokerage
|
—
|
|
|
1.7
|
|
|
—
|
|
|
.8
|
|
|
2.5
|
|
|||||
Metals and mining
|
—
|
|
|
.3
|
|
|
1.3
|
|
|
.3
|
|
|
1.9
|
|
|||||
Food/beverage
|
—
|
|
|
1.7
|
|
|
—
|
|
|
—
|
|
|
1.7
|
|
|||||
Collateralized mortgage obligations
|
.2
|
|
|
—
|
|
|
.3
|
|
|
1.1
|
|
|
1.6
|
|
|||||
Building materials
|
—
|
|
|
—
|
|
|
1.5
|
|
|
—
|
|
|
1.5
|
|
|||||
Autos
|
—
|
|
|
1.4
|
|
|
—
|
|
|
—
|
|
|
1.4
|
|
|||||
Real estate/REITs
|
—
|
|
|
1.0
|
|
|
—
|
|
|
—
|
|
|
1.0
|
|
|||||
Paper
|
—
|
|
|
.6
|
|
|
—
|
|
|
—
|
|
|
.6
|
|
|||||
Debt securities issued by foreign governments
|
—
|
|
|
.4
|
|
|
—
|
|
|
—
|
|
|
.4
|
|
|||||
Consumer products
|
—
|
|
|
.3
|
|
|
—
|
|
|
—
|
|
|
.3
|
|
|||||
Collateralized debt obligations
|
.3
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
.3
|
|
|||||
Aerospace/defense
|
—
|
|
|
—
|
|
|
—
|
|
|
.3
|
|
|
.3
|
|
|||||
Other
|
4.9
|
|
|
.9
|
|
|
1.0
|
|
|
1.8
|
|
|
8.6
|
|
|||||
Total fixed maturities, available for sale
|
$
|
46.2
|
|
|
$
|
97.7
|
|
|
$
|
28.5
|
|
|
$
|
21.9
|
|
|
$
|
194.3
|
|
•
|
Level 1 – includes assets and liabilities valued using inputs that are unadjusted quoted prices in active markets for identical assets or liabilities. Our Level 1 assets primarily include cash and cash equivalents and exchange traded securities.
|
•
|
Level 2 – includes assets and liabilities valued using inputs that are quoted prices for similar assets in an active market, quoted prices for identical or similar assets in a market that is not active, observable inputs, or observable inputs that can be corroborated by market data. Level 2 assets and liabilities include those financial instruments that are valued by independent pricing services using models or other valuation methodologies. These models consider various inputs such as credit rating, maturity, corporate credit spreads, reported trades and other inputs that are observable or derived from observable information in the marketplace or are supported by transactions executed in the marketplace. Financial assets in this category primarily include: certain publicly registered and privately placed corporate fixed maturity securities; certain government or agency securities; certain mortgage and asset-backed securities; certain equity securities; most investments held by our consolidated VIEs; certain mutual fund investments; most short-term investments; and non-exchange-traded derivatives such as call options. Financial liabilities in this category include investment borrowings, notes payable and borrowings related to VIEs.
|
•
|
Level 3 – includes assets and liabilities valued using unobservable inputs that are used in model-based valuations that contain management assumptions. Level 3 assets and liabilities include those financial instruments whose fair value is estimated based on broker/dealer quotes, pricing services or internally developed models or methodologies utilizing significant inputs not based on, or corroborated by, readily available market information. Financial assets in this category include certain corporate securities (primarily certain below-investment grade privately placed securities), certain structured securities, mortgage loans, and other less liquid securities. Financial liabilities in this category include our insurance liabilities for interest-sensitive products, which includes embedded derivatives (including embedded derivatives related to our fixed index annuity products and to a modified coinsurance arrangement) since their values include significant unobservable inputs including actuarial assumptions.
|
•
|
Investments held by VIEs
|
•
|
Other invested assets - derivatives
|
|
Quoted prices in active markets
for identical assets or liabilities (Level 1) |
|
Significant other observable inputs
(Level 2)
|
|
Significant unobservable inputs
(Level 3)
|
|
Total
|
||||||||
Assets:
|
|
|
|
|
|
|
|
||||||||
Fixed maturities, available for sale:
|
|
|
|
|
|
|
|
||||||||
Corporate securities
|
$
|
—
|
|
|
$
|
13,252.4
|
|
|
$
|
258.5
|
|
|
$
|
13,510.9
|
|
United States Treasury securities and obligations of United States government corporations and agencies
|
—
|
|
|
164.3
|
|
|
—
|
|
|
164.3
|
|
||||
States and political subdivisions
|
—
|
|
|
1,988.9
|
|
|
—
|
|
|
1,988.9
|
|
||||
Debt securities issued by foreign governments
|
—
|
|
|
33.0
|
|
|
3.9
|
|
|
36.9
|
|
||||
Asset-backed securities
|
—
|
|
|
2,649.9
|
|
|
60.4
|
|
|
2,710.3
|
|
||||
Collateralized debt obligations
|
—
|
|
|
225.3
|
|
|
5.4
|
|
|
230.7
|
|
||||
Commercial mortgage-backed securities
|
—
|
|
|
1,504.2
|
|
|
32.0
|
|
|
1,536.2
|
|
||||
Mortgage pass-through securities
|
—
|
|
|
2.5
|
|
|
—
|
|
|
2.5
|
|
||||
Collateralized mortgage obligations
|
—
|
|
|
915.5
|
|
|
—
|
|
|
915.5
|
|
||||
Total fixed maturities, available for sale
|
—
|
|
|
20,736.0
|
|
|
360.2
|
|
|
21,096.2
|
|
||||
Equity securities - corporate securities
|
359.9
|
|
|
199.1
|
|
|
25.2
|
|
|
584.2
|
|
||||
Trading securities:
|
|
|
|
|
|
|
|
|
|
|
|
||||
Corporate securities
|
—
|
|
|
19.0
|
|
|
—
|
|
|
19.0
|
|
||||
United States Treasury securities and obligations of United States government corporations and agencies
|
—
|
|
|
.5
|
|
|
—
|
|
|
.5
|
|
||||
Asset-backed securities
|
—
|
|
|
94.3
|
|
|
—
|
|
|
94.3
|
|
||||
Collateralized debt obligations
|
—
|
|
|
2.4
|
|
|
—
|
|
|
2.4
|
|
||||
Commercial mortgage-backed securities
|
—
|
|
|
163.9
|
|
|
—
|
|
|
163.9
|
|
||||
Collateralized mortgage obligations
|
—
|
|
|
78.4
|
|
|
—
|
|
|
78.4
|
|
||||
Equity securities
|
4.9
|
|
|
—
|
|
|
—
|
|
|
4.9
|
|
||||
Total trading securities
|
4.9
|
|
|
358.5
|
|
|
—
|
|
|
363.4
|
|
||||
Investments held by variable interest entities - corporate securities
|
—
|
|
|
1,724.3
|
|
|
—
|
|
|
1,724.3
|
|
||||
Other invested assets - derivatives
|
—
|
|
|
111.9
|
|
|
—
|
|
|
111.9
|
|
||||
Assets held in separate accounts
|
—
|
|
|
4.7
|
|
|
—
|
|
|
4.7
|
|
||||
Total assets carried at fair value by category
|
$
|
364.8
|
|
|
$
|
23,134.5
|
|
|
$
|
385.4
|
|
|
$
|
23,884.7
|
|
|
|
|
|
|
|
|
|
||||||||
Liabilities:
|
|
|
|
|
|
|
|
|
|
|
|
||||
Future policy benefits - embedded derivatives associated with fixed index annuity products
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
1,092.3
|
|
|
$
|
1,092.3
|
|
|
|
December 31, 2016
|
|
|
||||||||||||||||||||||||||||
|
|
Beginning balance as of December 31, 2015
|
|
Purchases, sales, issuances and settlements, net (b)
|
|
Total realized and unrealized gains (losses) included in net income
|
|
Total realized and unrealized gains (losses) included in accumulated other comprehensive income (loss)
|
|
Transfers into Level 3 (a)
|
|
Transfers out of Level 3 (a)
|
|
Ending balance as of December 31, 2016
|
|
Amount of total gains (losses) for the year ended December 31, 2016 included in our net income relating to assets and liabilities still held as of the reporting date
|
||||||||||||||||
Assets:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||||||
Fixed maturities, available for sale:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||||||
Corporate securities
|
|
$
|
170.4
|
|
|
$
|
76.5
|
|
|
$
|
(10.7
|
)
|
|
$
|
9.1
|
|
|
$
|
20.3
|
|
|
$
|
(7.1
|
)
|
|
$
|
258.5
|
|
|
$
|
(10.9
|
)
|
Debt securities issued by foreign governments
|
|
—
|
|
|
4.0
|
|
|
—
|
|
|
(.1
|
)
|
|
—
|
|
|
—
|
|
|
3.9
|
|
|
—
|
|
||||||||
Asset-backed securities
|
|
35.9
|
|
|
9.7
|
|
|
—
|
|
|
2.2
|
|
|
26.3
|
|
|
(13.7
|
)
|
|
60.4
|
|
|
—
|
|
||||||||
Collateralized debt obligations
|
|
—
|
|
|
5.4
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
5.4
|
|
|
—
|
|
||||||||
Commercial mortgage-backed securities
|
|
1.1
|
|
|
16.9
|
|
|
—
|
|
|
.1
|
|
|
13.9
|
|
|
—
|
|
|
32.0
|
|
|
—
|
|
||||||||
Mortgage pass-through securities
|
|
.1
|
|
|
(.1
|
)
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
||||||||
Total fixed maturities, available for sale
|
|
207.5
|
|
|
112.4
|
|
|
(10.7
|
)
|
|
11.3
|
|
|
60.5
|
|
|
(20.8
|
)
|
|
360.2
|
|
|
(10.9
|
)
|
||||||||
Equity securities - corporate securities
|
|
32.0
|
|
|
5.5
|
|
|
(12.7
|
)
|
|
.4
|
|
|
—
|
|
|
—
|
|
|
25.2
|
|
|
(12.7
|
)
|
||||||||
Trading securities - commercial mortgage-backed securities
|
|
39.9
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
(39.9
|
)
|
|
—
|
|
|
—
|
|
||||||||
Liabilities:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||
Future policy benefits - embedded derivatives associated with fixed index annuity products
|
|
(1,057.1
|
)
|
|
(96.0
|
)
|
|
60.8
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
(1,092.3
|
)
|
|
60.8
|
|
(a)
|
Transfers into Level 3 are the result of unobservable inputs utilized within valuation methodologies for assets that were previously valued using observable inputs. Transfers out of Level 3 are due to the use of observable inputs in valuation methodologies as well as the utilization of pricing service information for certain assets that the Company is able to validate.
|
(b)
|
Purchases, sales, issuances and settlements, net, represent the activity that occurred during the period that results in a change of the asset or liability but does not represent changes in fair value for the instruments held at the beginning of the period. Such activity primarily consists of purchases and sales of fixed maturity and equity securities and changes to embedded derivative instruments related to insurance products resulting from the issuance of new contracts, or changes to existing contracts. In addition, such activity includes the investments received upon the recapture of reinsurance agreements with BRe on September 29, 2016. The following summarizes such activity for the year ended
December 31, 2016
(dollars in millions):
|
|
Purchases
|
|
Received in reinsurance recapture
|
|
Sales
|
|
Issuances
|
|
Settlements
|
|
Purchases, sales, issuances and settlements, net
|
||||||||||||
Assets:
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||
Fixed maturities, available for sale:
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||
Corporate securities
|
$
|
18.5
|
|
|
$
|
89.2
|
|
|
$
|
(31.2
|
)
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
76.5
|
|
Debt securities issued by foreign governments
|
4.0
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
4.0
|
|
||||||
Asset-backed securities
|
16.9
|
|
|
—
|
|
|
(7.2
|
)
|
|
—
|
|
|
—
|
|
|
9.7
|
|
||||||
Collateralized debt obligations
|
5.4
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
5.4
|
|
||||||
Commercial mortgage-backed securities
|
17.0
|
|
|
—
|
|
|
(.1
|
)
|
|
—
|
|
|
—
|
|
|
16.9
|
|
||||||
Mortgage pass-through securities
|
—
|
|
|
—
|
|
|
(.1
|
)
|
|
—
|
|
|
—
|
|
|
(.1
|
)
|
||||||
Total fixed maturities, available for sale
|
61.8
|
|
|
89.2
|
|
|
(38.6
|
)
|
|
—
|
|
|
—
|
|
|
112.4
|
|
||||||
Equity securities - corporate securities
|
3.3
|
|
|
2.2
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
5.5
|
|
||||||
Trading securities - corporate securities
|
.2
|
|
|
—
|
|
|
(.2
|
)
|
|
—
|
|
|
—
|
|
|
—
|
|
||||||
Liabilities:
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||
Future policy benefits - embedded derivatives associated with fixed index annuity products
|
(148.3
|
)
|
|
—
|
|
|
21.2
|
|
|
(28.9
|
)
|
|
60.0
|
|
|
(96.0
|
)
|
|
|
|
Estimated fair value
|
|||||||
Investment rating
|
Amortized cost
|
|
Amount
|
|
Percent of fixed maturities
|
|||||
AAA
|
$
|
992.4
|
|
|
$
|
1,026.2
|
|
|
5
|
%
|
AA
|
1,434.8
|
|
|
1,569.0
|
|
|
7
|
|
||
A
|
5,009.2
|
|
|
5,505.3
|
|
|
26
|
|
||
BBB+
|
2,668.7
|
|
|
2,922.0
|
|
|
14
|
|
||
BBB
|
3,353.1
|
|
|
3,530.0
|
|
|
17
|
|
||
BBB-
|
3,274.9
|
|
|
3,395.9
|
|
|
16
|
|
||
Investment grade
|
16,733.1
|
|
|
17,948.4
|
|
|
85
|
|
||
BB+
|
210.3
|
|
|
206.2
|
|
|
1
|
|
||
BB
|
333.7
|
|
|
330.3
|
|
|
2
|
|
||
BB-
|
330.8
|
|
|
329.0
|
|
|
1
|
|
||
B+ and below
|
2,195.2
|
|
|
2,282.3
|
|
|
11
|
|
||
Below-investment grade
|
3,070.0
|
|
|
3,147.8
|
|
|
15
|
|
||
Total fixed maturity securities
|
$
|
19,803.1
|
|
|
$
|
21,096.2
|
|
|
100
|
%
|
|
2016
|
|
2015
|
|
2014
|
||||||
Weighted average general account invested assets at amortized cost
|
$
|
22,539.5
|
|
|
$
|
21,624.6
|
|
|
$
|
22,939.9
|
|
Net investment income on general account invested assets
|
1,219.3
|
|
|
1,217.7
|
|
|
1,304.3
|
|
|||
Yield earned
|
5.41
|
%
|
|
5.63
|
%
|
|
5.69
|
%
|
|
Par
value
|
|
Amortized
cost
|
|
Estimated
fair value
|
||||||
Below 4 percent
|
$
|
1,993.9
|
|
|
$
|
1,523.5
|
|
|
$
|
1,535.4
|
|
4 percent – 5 percent
|
1,757.6
|
|
|
1,592.5
|
|
|
1,624.7
|
|
|||
5 percent – 6 percent
|
1,772.2
|
|
|
1,602.2
|
|
|
1,666.7
|
|
|||
6 percent – 7 percent
|
388.1
|
|
|
348.0
|
|
|
364.5
|
|
|||
7 percent – 8 percent
|
55.8
|
|
|
56.2
|
|
|
65.6
|
|
|||
8 percent and above
|
138.7
|
|
|
138.1
|
|
|
138.3
|
|
|||
Total structured securities
|
$
|
6,106.3
|
|
|
$
|
5,260.5
|
|
|
$
|
5,395.2
|
|
|
|
|
Estimated fair value
|
|||||||
Type
|
Amortized
cost
|
|
Amount
|
|
Percent
of fixed
maturities
|
|||||
Pass-throughs, sequential and equivalent securities
|
$
|
664.8
|
|
|
$
|
710.6
|
|
|
3.4
|
%
|
Planned amortization classes, target amortization classes and accretion-directed bonds
|
142.5
|
|
|
156.4
|
|
|
.7
|
|
||
Commercial mortgage-backed securities
|
1,531.0
|
|
|
1,536.2
|
|
|
7.3
|
|
||
Asset-backed securities
|
2,641.5
|
|
|
2,710.3
|
|
|
12.9
|
|
||
Collateralized debt obligations
|
230.0
|
|
|
230.7
|
|
|
1.1
|
|
||
Other
|
50.7
|
|
|
51.0
|
|
|
.2
|
|
||
Total structured securities
|
$
|
5,260.5
|
|
|
$
|
5,395.2
|
|
|
25.6
|
%
|
|
Number of loans
|
|
Carrying value
|
|||
Retail
|
117
|
|
|
$
|
487.9
|
|
Multi-family
|
37
|
|
|
508.4
|
|
|
Office building
|
33
|
|
|
332.8
|
|
|
Industrial
|
29
|
|
|
249.6
|
|
|
Other
|
26
|
|
|
189.3
|
|
|
Total commercial mortgage loans
|
242
|
|
|
$
|
1,768.0
|
|
|
Number of loans
|
|
Carrying value
|
|||
Under $5 million
|
113
|
|
|
$
|
187.7
|
|
$5 million but less than $10 million
|
65
|
|
|
457.9
|
|
|
$10 million but less than $20 million
|
40
|
|
|
546.8
|
|
|
Over $20 million
|
24
|
|
|
575.6
|
|
|
Total commercial mortgage loans
|
242
|
|
|
$
|
1,768.0
|
|
|
Number of loans
|
|
Carrying value
|
|||
2017
|
15
|
|
|
$
|
86.5
|
|
2018
|
30
|
|
|
141.1
|
|
|
2019
|
20
|
|
|
39.8
|
|
|
2020
|
8
|
|
|
32.0
|
|
|
2021
|
14
|
|
|
108.4
|
|
|
after 2021
|
155
|
|
|
1,360.2
|
|
|
Total commercial mortgage loans
|
242
|
|
|
$
|
1,768.0
|
|
|
|
|
Estimated fair
value
|
||||||||
Loan-to-value ratio (a)
|
Carrying value
|
|
Mortgage loans
|
|
Collateral
|
||||||
Less than 60%
|
$
|
976.5
|
|
|
$
|
1,004.2
|
|
|
$
|
2,393.0
|
|
60% to 70%
|
394.7
|
|
|
396.7
|
|
|
596.2
|
|
|||
Greater than 70% to 80%
|
282.3
|
|
|
286.2
|
|
|
385.1
|
|
|||
Greater than 80% to 90%
|
75.3
|
|
|
74.0
|
|
|
89.5
|
|
|||
Greater than 90%
|
39.2
|
|
|
39.0
|
|
|
42.0
|
|
|||
Total
|
$
|
1,768.0
|
|
|
$
|
1,800.1
|
|
|
$
|
3,505.8
|
|
(a)
|
Loan-to-value ratios are calculated as the ratio of: (i) the carrying value of the commercial mortgage loans; to (ii) the estimated fair value of the underlying collateral.
|
|
December 31,
2016 |
|
December 31, 2015
|
||||
Total capital:
|
|
|
|
||||
Corporate notes payable
|
$
|
912.9
|
|
|
$
|
911.1
|
|
Shareholders’ equity:
|
|
|
|
|
|||
Common stock
|
1.7
|
|
|
1.8
|
|
||
Additional paid-in capital
|
3,212.1
|
|
|
3,386.8
|
|
||
Accumulated other comprehensive income
|
622.4
|
|
|
402.8
|
|
||
Retained earnings
|
650.7
|
|
|
347.1
|
|
||
Total shareholders’ equity
|
4,486.9
|
|
|
4,138.5
|
|
||
Total capital
|
$
|
5,399.8
|
|
|
$
|
5,049.6
|
|
|
December 31,
2016 |
|
December 31, 2015
|
||||
Book value per common share
|
$
|
25.82
|
|
|
$
|
22.49
|
|
Book value per common share, excluding accumulated other comprehensive income (a)
|
22.24
|
|
|
20.30
|
|
||
Ratio of earnings to fixed charges
|
2.43X
|
|
|
2.59X
|
|
||
Debt to total capital ratios:
|
|
|
|
||||
Corporate debt to total capital
|
16.9
|
%
|
|
18.0
|
%
|
||
Corporate debt to total capital, excluding accumulated other comprehensive income (a)
|
19.1
|
%
|
|
19.6
|
%
|
(a)
|
This non-GAAP measure differs from the corresponding GAAP measure presented immediately above, because accumulated other comprehensive income has been excluded from the value of capital used to determine this measure. Management believes this non-GAAP measure is useful because it removes the volatility that arises from changes in accumulated other comprehensive income. Such volatility is often caused by changes in the estimated fair value of our investment portfolio resulting from changes in general market interest rates rather than the business decisions made by management. However, this measure does not replace the corresponding GAAP measure.
|
|
|
September 30, 2016 values
|
|
Net cash flows (1)
|
|
Realized losses and impairments (2)
|
|
Other activity (3)
|
|
December 31, 2016 values
|
||||||||||
Investments included in initial scope of audit
|
$
|
62.2
|
|
|
$
|
(13.5
|
)
|
|
$
|
.4
|
|
|
$
|
3.9
|
|
|
$
|
53.0
|
|
|
Investments included in additional scope of audit
|
62.6
|
|
|
(11.6
|
)
|
|
(1.7
|
)
|
|
1.9
|
|
|
51.2
|
|
||||||
Investments not included in scope of audit:
|
|
|
|
|
|
|
|
|
|
|||||||||||
|
Fixed maturities and other invested assets
|
319.4
|
|
|
(299.1
|
)
|
|
(4.0
|
)
|
|
.6
|
|
|
16.9
|
|
|||||
|
Cash and investment purchases subsequent to recapture
|
60.4
|
|
|
324.2
|
|
|
—
|
|
|
(3.9
|
)
|
|
380.7
|
|
|||||
Total investments
|
$
|
504.6
|
|
|
$
|
—
|
|
|
$
|
(5.3
|
)
|
|
$
|
2.5
|
|
|
$
|
501.8
|
|
|
|
Investments included in initial scope of audit
|
|
Investments included in additional scope of audit
|
|
Total investments included in the scope of audit
|
||||||
Lease related investments
|
$
|
—
|
|
|
$
|
27.4
|
|
|
$
|
27.4
|
|
|
Mortgage loans secured by real estate
|
1.0
|
|
|
16.1
|
|
|
17.1
|
|
||||
Senior secured loans to companies in the energy sector (4)
|
13.8
|
|
|
—
|
|
|
13.8
|
|
||||
Senior secured loans to other companies
|
17.6
|
|
|
3.4
|
|
|
21.0
|
|
||||
Life settlement financing
|
6.8
|
|
|
1.0
|
|
|
7.8
|
|
||||
Secured term loan issued by Platinum Partners Credit Opportunity Master Fund L.P.
|
4.4
|
|
|
—
|
|
|
4.4
|
|
||||
Preferred and common stock
|
2.7
|
|
|
.9
|
|
|
3.6
|
|
||||
Other
|
6.7
|
|
|
2.4
|
|
|
9.1
|
|
||||
Total investments
|
$
|
53.0
|
|
|
$
|
51.2
|
|
|
$
|
104.2
|
|
(1)
|
Net cash flows from sales, redemptions and investment purchases during the quarter ended December 31, 2016.
|
(2)
|
Includes $4.6 million of impairment charges and $.7 million of net realized losses recognized on the sale of transferred investments.
|
(3)
|
Includes amortization of discount and premium and changes in estimated fair values of investments during the quarter ended December 31, 2016.
|
(4)
|
Includes: (i) $5.0 million of loans issued by Golden Gate Oil, LLC with a par value of $11.6 million; and (ii) $6.7 million of loans issued by the parent of Agera Energy LLC with a par value of $10.9 million. The issuers of this debt have been referred to in recent articles regarding Platinum.
|
Market value of investments
|
$
|
504.7
|
|
Insurance liabilities
|
(552.2
|
)
|
|
Write-off of reinsurance receivables
|
(17.9
|
)
|
|
Estimated transaction expenses
|
(10.0
|
)
|
|
Pre-tax loss
|
$
|
(75.4
|
)
|
Impact on surplus:
|
|
||
Market value of investments
|
$
|
504.7
|
|
Write-off of estimated receivable due from BRe
|
(17.9
|
)
|
|
Insurance liabilities
|
(587.2
|
)
|
|
Expenses incurred
|
(10.0
|
)
|
|
Statutory earnings impact
|
(110.4
|
)
|
|
Impact on admitted investments
|
(11.0
|
)
|
|
Impact on admitted deferred tax assets
|
(14.5
|
)
|
|
Statutory surplus impact
|
$
|
(135.9
|
)
|
|
|
|
Payment due in
|
||||||||||||||||
|
Total
|
|
2017
|
|
2018-2019
|
|
2020-2021
|
|
Thereafter
|
||||||||||
Insurance liabilities (a)
|
$
|
57,475.3
|
|
|
$
|
3,650.9
|
|
|
$
|
7,406.8
|
|
|
$
|
7,231.6
|
|
|
$
|
39,186.0
|
|
Notes payable (b)
|
1,206.6
|
|
|
43.9
|
|
|
185.9
|
|
|
384.9
|
|
|
591.9
|
|
|||||
Investment borrowings (c)
|
1,842.0
|
|
|
186.6
|
|
|
723.5
|
|
|
858.9
|
|
|
73.0
|
|
|||||
Borrowings related to variable interest
entities (d)
|
2,180.5
|
|
|
68.7
|
|
|
104.5
|
|
|
103.3
|
|
|
1,904.0
|
|
|||||
Postretirement plans (e)
|
266.8
|
|
|
7.0
|
|
|
14.9
|
|
|
15.6
|
|
|
229.3
|
|
|||||
Operating leases and certain other contractual commitments (f)
|
303.8
|
|
|
118.6
|
|
|
152.7
|
|
|
26.6
|
|
|
5.9
|
|
|||||
Total
|
$
|
63,275.0
|
|
|
$
|
4,075.7
|
|
|
$
|
8,588.3
|
|
|
$
|
8,620.9
|
|
|
$
|
41,990.1
|
|
(a)
|
These cash flows represent our estimates of the payments we expect to make to our policyholders, without consideration of future premiums or reinsurance recoveries. These estimates are based on numerous assumptions (depending on the product type) related to mortality, morbidity, lapses, withdrawals, future premiums, future deposits, interest rates on investments, credited rates, expenses and other factors which affect our future payments. The cash flows presented are undiscounted for interest. As a result, total outflows for all years exceed the corresponding liabilities of
$22.7 billion
|
•
|
For products such as immediate annuities and structured settlement annuities without life contingencies, the payment obligation is fixed and determinable based on the terms of the policy.
|
•
|
For products such as universal life, ordinary life, long-term care, supplemental health and fixed rate annuities, the future payments are not due until the occurrence of an insurable event (such as death or disability) or a triggering event (such as a surrender or partial withdrawal). We estimated these payments using actuarial models based on historical experience and our expectation of the future payment patterns.
|
•
|
For short-term insurance products such as Medicare supplement insurance, the future payments relate only to amounts necessary to settle all outstanding claims, including those that have been incurred but not reported as of the balance sheet date. We estimated these payments based on our historical experience and our expectation of future payment patterns.
|
•
|
The average interest rate we assumed would be credited to our total insurance liabilities (excluding interest rate bonuses for the first policy year only and excluding the effect of credited rates attributable to variable or fixed index products) over the term of the contracts was 4.5 percent.
|
(b)
|
Includes projected interest payments based on interest rates, as applicable, as of
December 31, 2016
. Refer to the note to the consolidated financial statements entitled "Notes Payable - Direct Corporate Obligations" for additional information on notes payable.
|
(c)
|
These borrowings primarily represent collateralized borrowings from the FHLB.
|
(d)
|
These borrowings represent the securities issued by VIEs and include projected interest payments based on interest rates, as applicable, as of
December 31, 2016
.
|
(e)
|
Includes benefits expected to be paid pursuant to our deferred compensation plan and postretirement plans based on numerous actuarial assumptions and interest credited at
4.25 percent
.
|
(f)
|
Includes amounts related to noncancellable operating leases, sponsorship agreements and commitments to purchase investments. Also included are obligations with third parties for information technology services, software maintenance and license agreements and consulting services.
|
•
|
An adverse decision in pending or future litigation.
|
•
|
An inability to obtain rate increases on certain of our insurance products.
|
•
|
Worse than anticipated claims experience.
|
•
|
Lower than expected dividends and/or surplus debenture interest payments from our insurance subsidiaries (resulting from inadequate earnings or capital or regulatory requirements).
|
•
|
An inability to meet and/or maintain the covenants in our Revolving Credit Agreement.
|
•
|
A significant increase in policy surrender levels.
|
•
|
A significant increase in investment defaults.
|
•
|
An inability of our reinsurers to meet their financial obligations.
|
Amount
|
|
Maturity
|
|
Interest rate at
|
||
borrowed
|
|
date
|
|
December 31, 2016
|
||
$
|
50.0
|
|
|
January 2018
|
|
Variable rate – 1.226%
|
50.0
|
|
|
January 2018
|
|
Variable rate – 1.222%
|
|
50.0
|
|
|
February 2018
|
|
Variable rate – 1.191%
|
|
50.0
|
|
|
February 2018
|
|
Variable rate – 1.001%
|
|
22.0
|
|
|
February 2018
|
|
Variable rate – 1.267%
|
|
100.0
|
|
|
May 2018
|
|
Variable rate – 1.206%
|
|
50.0
|
|
|
July 2018
|
|
Variable rate – 1.360%
|
|
50.0
|
|
|
August 2018
|
|
Variable rate – 1.022%
|
|
10.0
|
|
|
December 2018
|
|
Variable rate – 1.266%
|
|
50.0
|
|
|
January 2019
|
|
Variable rate – 1.300%
|
|
50.0
|
|
|
February 2019
|
|
Variable rate – 1.001%
|
|
100.0
|
|
|
March 2019
|
|
Variable rate – 1.216%
|
|
21.8
|
|
|
July 2019
|
|
Variable rate – 1.234%
|
|
15.0
|
|
|
October 2019
|
|
Variable rate – 1.399%
|
|
50.0
|
|
|
May 2020
|
|
Variable rate – 1.224%
|
|
21.8
|
|
|
June 2020
|
|
Fixed rate – 1.960%
|
|
25.0
|
|
|
September 2020
|
|
Variable rate – 1.622%
|
|
100.0
|
|
|
September 2020
|
|
Variable rate – 1.416%
|
|
50.0
|
|
|
September 2020
|
|
Variable rate – 1.416%
|
|
75.0
|
|
|
September 2020
|
|
Variable rate – 1.118%
|
|
100.0
|
|
|
October 2020
|
|
Variable rate – 1.109%
|
|
50.0
|
|
|
December 2020
|
|
Variable rate – 1.335%
|
|
100.0
|
|
|
July 2021
|
|
Variable rate – 1.431%
|
|
57.7
|
|
|
July 2021
|
|
Variable rate – 1.411%
|
|
100.0
|
|
|
August 2021
|
|
Variable rate – 1.400%
|
|
28.2
|
|
|
August 2021
|
|
Fixed rate – 2.550%
|
|
125.0
|
|
|
August 2021
|
|
Variable rate – 1.236%
|
|
50.0
|
|
|
September 2021
|
|
Variable rate – 1.477%
|
|
25.4
|
|
|
March 2023
|
|
Fixed rate – 2.160%
|
|
20.5
|
|
|
June 2025
|
|
Fixed rate – 2.940%
|
|
$
|
1,647.4
|
|
|
|
|
|
|
Years ended December 31,
|
||||||||||
|
2016
|
|
2015
|
|
2014
|
||||||
Dividends from insurance subsidiaries, net of contributions
|
$
|
74.3
|
|
|
$
|
265.7
|
|
|
$
|
174.0
|
|
Surplus debenture interest
|
56.0
|
|
|
60.6
|
|
|
63.3
|
|
|||
Fees for services provided pursuant to service agreements
|
78.6
|
|
|
70.1
|
|
|
92.5
|
|
|||
Total dividends and other distributions paid by insurance subsidiaries
|
$
|
208.9
|
|
|
$
|
396.4
|
|
|
$
|
329.8
|
|
Subsidiary of CLTX
|
|
Earned surplus (deficit)
|
|
Additional information
|
||
Bankers Life
|
|
$
|
541.7
|
|
|
(a)
|
Colonial Penn
|
|
(296.1
|
)
|
|
(b)
|
(a)
|
Bankers Life paid dividends of $143.7 million to CLTX in
2016
.
|
(b)
|
The deficit is primarily due to transactions which occurred several years ago, including a tax planning transaction and the fee paid to recapture a block of business previously ceded to an unaffiliated insurer.
|
|
Principal
|
|
Interest (a)
|
||||
2017
|
$
|
—
|
|
|
$
|
43.9
|
|
2018
|
—
|
|
|
43.9
|
|
||
2019
|
100.0
|
|
|
42.0
|
|
||
2020
|
325.0
|
|
|
33.6
|
|
||
2021
|
—
|
|
|
26.3
|
|
||
2022 and thereafter
|
500.0
|
|
|
91.9
|
|
||
|
$
|
925.0
|
|
|
$
|
281.6
|
|
(a)
|
Based on interest rates as of
December 31, 2016
.
|
Index to Consolidated Financial Statements
|
|
|
Page
|
|
2016
|
|
2015
|
||||
|
|
|
|
||||
Investments:
|
|
|
|
||||
Fixed maturities, available for sale, at fair value (amortized cost: 2016 - $19,803.1; 2015 - $18,947.0)
|
$
|
21,096.2
|
|
|
$
|
19,882.9
|
|
Equity securities at fair value (cost: 2016 - $580.7; 2015 - $447.4)
|
584.2
|
|
|
463.0
|
|
||
Mortgage loans
|
1,768.0
|
|
|
1,721.0
|
|
||
Policy loans
|
112.0
|
|
|
109.4
|
|
||
Trading securities
|
363.4
|
|
|
262.1
|
|
||
Investments held by variable interest entities
|
1,724.3
|
|
|
1,633.6
|
|
||
Other invested assets
|
589.5
|
|
|
415.1
|
|
||
Total investments
|
26,237.6
|
|
|
24,487.1
|
|
||
Cash and cash equivalents - unrestricted
|
478.9
|
|
|
432.3
|
|
||
Cash and cash equivalents held by variable interest entities
|
189.3
|
|
|
364.4
|
|
||
Accrued investment income
|
239.6
|
|
|
237.0
|
|
||
Present value of future profits
|
401.8
|
|
|
449.0
|
|
||
Deferred acquisition costs
|
1,044.7
|
|
|
1,083.3
|
|
||
Reinsurance receivables
|
2,260.4
|
|
|
2,859.3
|
|
||
Income tax assets, net
|
789.7
|
|
|
898.8
|
|
||
Assets held in separate accounts
|
4.7
|
|
|
4.7
|
|
||
Other assets
|
328.5
|
|
|
309.2
|
|
||
Total assets
|
$
|
31,975.2
|
|
|
$
|
31,125.1
|
|
|
2016
|
|
2015
|
||||
|
|
|
|
||||
Liabilities:
|
|
|
|
||||
Liabilities for insurance products:
|
|
|
|
||||
Policyholder account balances
|
$
|
10,912.7
|
|
|
$
|
10,762.3
|
|
Future policy benefits
|
10,953.3
|
|
|
10,602.1
|
|
||
Liability for policy and contract claims
|
500.6
|
|
|
487.8
|
|
||
Unearned and advanced premiums
|
282.5
|
|
|
286.3
|
|
||
Liabilities related to separate accounts
|
4.7
|
|
|
4.7
|
|
||
Other liabilities
|
611.4
|
|
|
707.8
|
|
||
Investment borrowings
|
1,647.4
|
|
|
1,548.1
|
|
||
Borrowings related to variable interest entities
|
1,662.8
|
|
|
1,676.4
|
|
||
Notes payable – direct corporate obligations
|
912.9
|
|
|
911.1
|
|
||
Total liabilities
|
27,488.3
|
|
|
26,986.6
|
|
||
Commitments and Contingencies
|
|
|
|
|
|
||
Shareholders' equity:
|
|
|
|
|
|
||
Common stock ($0.01 par value, 8,000,000,000 shares authorized, shares issued and outstanding: 2016 - 173,753,614; 2015 - 184,028,511)
|
1.7
|
|
|
1.8
|
|
||
Additional paid-in capital
|
3,212.1
|
|
|
3,386.8
|
|
||
Accumulated other comprehensive income
|
622.4
|
|
|
402.8
|
|
||
Retained earnings
|
650.7
|
|
|
347.1
|
|
||
Total shareholders' equity
|
4,486.9
|
|
|
4,138.5
|
|
||
Total liabilities and shareholders' equity
|
$
|
31,975.2
|
|
|
$
|
31,125.1
|
|
|
|
2016
|
|
2015
|
|
2014
|
||||||
Revenues:
|
|
|
|
|
|
|
||||||
Insurance policy income
|
|
$
|
2,601.1
|
|
|
$
|
2,556.0
|
|
|
$
|
2,629.7
|
|
Net investment income:
|
|
|
|
|
|
|
|
|
|
|||
General account assets
|
|
1,204.1
|
|
|
1,203.6
|
|
|
1,301.0
|
|
|||
Policyholder and reinsurer accounts and other special-purpose portfolios
|
|
121.1
|
|
|
30.0
|
|
|
126.4
|
|
|||
Realized investment gains (losses):
|
|
|
|
|
|
|
|
|
|
|||
Net realized investment gains (losses), excluding impairment losses
|
|
47.9
|
|
|
(8.0
|
)
|
|
64.0
|
|
|||
Other-than-temporary impairments:
|
|
|
|
|
|
|
|
|
|
|||
Total other-than-temporary impairment losses
|
|
(35.9
|
)
|
|
(42.9
|
)
|
|
(27.3
|
)
|
|||
Portion of other-than-temporary impairment losses recognized in accumulated other comprehensive income
|
|
3.6
|
|
|
3.0
|
|
|
—
|
|
|||
Net impairment losses recognized
|
|
(32.3
|
)
|
|
(39.9
|
)
|
|
(27.3
|
)
|
|||
Gain (loss) on dissolution of variable interest entities
|
|
(7.3
|
)
|
|
11.3
|
|
|
—
|
|
|||
Total realized gains (losses)
|
|
8.3
|
|
|
(36.6
|
)
|
|
36.7
|
|
|||
Fee revenue and other income
|
|
50.5
|
|
|
58.9
|
|
|
50.9
|
|
|||
Total revenues
|
|
3,985.1
|
|
|
3,811.9
|
|
|
4,144.7
|
|
|||
Benefits and expenses:
|
|
|
|
|
|
|
||||||
Insurance policy benefits
|
|
2,390.5
|
|
|
2,308.3
|
|
|
2,586.2
|
|
|||
Loss on sale of subsidiary, (gain) loss on reinsurance transactions and transition expenses
|
|
75.4
|
|
|
9.0
|
|
|
239.8
|
|
|||
Interest expense
|
|
116.4
|
|
|
94.9
|
|
|
92.8
|
|
|||
Amortization
|
|
253.3
|
|
|
260.0
|
|
|
247.4
|
|
|||
Loss on extinguishment or modification of debt
|
|
—
|
|
|
32.8
|
|
|
.6
|
|
|||
Other operating costs and expenses
|
|
796.3
|
|
|
739.2
|
|
|
802.8
|
|
|||
Total benefits and expenses
|
|
3,631.9
|
|
|
3,444.2
|
|
|
3,969.6
|
|
|||
Income before income taxes
|
|
353.2
|
|
|
367.7
|
|
|
175.1
|
|
|||
Income tax expense (benefit):
|
|
|
|
|
|
|
||||||
Tax expense on period income
|
|
127.8
|
|
|
129.5
|
|
|
159.2
|
|
|||
Valuation allowance for deferred tax assets and other tax items
|
|
(132.8
|
)
|
|
(32.5
|
)
|
|
(35.5
|
)
|
|||
Net income
|
|
$
|
358.2
|
|
|
$
|
270.7
|
|
|
$
|
51.4
|
|
Earnings per common share:
|
|
|
|
|
|
|
||||||
Basic:
|
|
|
|
|
|
|
||||||
Weighted average shares outstanding
|
|
176,638,000
|
|
|
193,054,000
|
|
|
212,917,000
|
|
|||
Net income
|
|
$
|
2.03
|
|
|
$
|
1.40
|
|
|
$
|
.24
|
|
Diluted:
|
|
|
|
|
|
|
||||||
Weighted average shares outstanding
|
|
178,323,000
|
|
|
195,166,000
|
|
|
217,655,000
|
|
|||
Net income
|
|
$
|
2.01
|
|
|
$
|
1.39
|
|
|
$
|
.24
|
|
|
2016
|
|
2015
|
|
2014
|
||||||
Net income
|
$
|
358.2
|
|
|
$
|
270.7
|
|
|
$
|
51.4
|
|
Other comprehensive income, before tax:
|
|
|
|
|
|
||||||
Unrealized gains (losses) for the period
|
424.4
|
|
|
(1,337.6
|
)
|
|
942.9
|
|
|||
Amortization of present value of future profits and deferred acquisition costs
|
(27.9
|
)
|
|
157.9
|
|
|
(113.5
|
)
|
|||
Amount related to premium deficiencies assuming the net unrealized gains (losses) had been realized
|
(46.9
|
)
|
|
495.3
|
|
|
(624.6
|
)
|
|||
Reclassification adjustments:
|
|
|
|
|
|
||||||
For net realized investment (gains) losses included in net income
|
(18.6
|
)
|
|
29.6
|
|
|
(59.0
|
)
|
|||
For amortization of the present value of future profits and deferred acquisition costs related to net realized investment gains (losses) included in net income
|
.7
|
|
|
(.5
|
)
|
|
1.0
|
|
|||
Unrealized gains (losses) on investments
|
331.7
|
|
|
(655.3
|
)
|
|
146.8
|
|
|||
Change related to deferred compensation plan
|
8.6
|
|
|
(.1
|
)
|
|
(1.4
|
)
|
|||
Other comprehensive income (loss) before tax
|
340.3
|
|
|
(655.4
|
)
|
|
145.4
|
|
|||
Income tax (expense) benefit related to items of accumulated other comprehensive income
|
(120.7
|
)
|
|
232.9
|
|
|
(51.9
|
)
|
|||
Other comprehensive income (loss), net of tax
|
219.6
|
|
|
(422.5
|
)
|
|
93.5
|
|
|||
Comprehensive income (loss)
|
$
|
577.8
|
|
|
$
|
(151.8
|
)
|
|
$
|
144.9
|
|
|
Common stock and
additional
paid-in capital
|
|
Accumulated other
comprehensive income
|
|
Retained earnings
|
|
Total
|
||||||||
Balance, December 31, 2013
|
$
|
4,095.0
|
|
|
$
|
731.8
|
|
|
$
|
128.4
|
|
|
$
|
4,955.2
|
|
Net income
|
—
|
|
|
—
|
|
|
51.4
|
|
|
51.4
|
|
||||
Change in unrealized appreciation (depreciation) of investments (net of applicable income tax expense of $52.3)
|
—
|
|
|
94.2
|
|
|
—
|
|
|
94.2
|
|
||||
Change in noncredit component of impairment losses on fixed maturities, available for sale (net of applicable income tax benefit of $.4)
|
—
|
|
|
(.7
|
)
|
|
—
|
|
|
(.7
|
)
|
||||
Cost of common stock and warrants repurchased
|
(376.5
|
)
|
|
—
|
|
|
—
|
|
|
(376.5
|
)
|
||||
Dividends on common stock
|
—
|
|
|
—
|
|
|
(51.3
|
)
|
|
(51.3
|
)
|
||||
Stock options, restricted stock and performance units
|
15.9
|
|
|
—
|
|
|
—
|
|
|
15.9
|
|
||||
Balance, December 31, 2014
|
3,734.4
|
|
|
825.3
|
|
|
128.5
|
|
|
4,688.2
|
|
||||
Net income
|
—
|
|
|
—
|
|
|
270.7
|
|
|
270.7
|
|
||||
Change in unrealized appreciation (depreciation) of investments (net of applicable income tax benefit of $231.7)
|
—
|
|
|
(420.4
|
)
|
|
—
|
|
|
(420.4
|
)
|
||||
Change in noncredit component of impairment losses on fixed maturities, available for sale (net of applicable income tax benefit of $1.2)
|
—
|
|
|
(2.1
|
)
|
|
—
|
|
|
(2.1
|
)
|
||||
Cost of common stock repurchased
|
(365.2
|
)
|
|
—
|
|
|
—
|
|
|
(365.2
|
)
|
||||
Dividends on common stock
|
—
|
|
|
—
|
|
|
(52.1
|
)
|
|
(52.1
|
)
|
||||
Stock options, restricted stock and performance units
|
19.4
|
|
|
—
|
|
|
—
|
|
|
19.4
|
|
||||
Balance, December 31, 2015
|
3,388.6
|
|
|
402.8
|
|
|
347.1
|
|
|
4,138.5
|
|
||||
Net income
|
—
|
|
|
—
|
|
|
358.2
|
|
|
358.2
|
|
||||
Change in unrealized appreciation (depreciation) of investments (net of applicable income tax expense of $121.5)
|
—
|
|
|
221.1
|
|
|
—
|
|
|
221.1
|
|
||||
Change in noncredit component of impairment losses on fixed maturities, available for sale (net of applicable income tax benefit of $.8)
|
—
|
|
|
(1.5
|
)
|
|
—
|
|
|
(1.5
|
)
|
||||
Cost of common stock repurchased
|
(203.0
|
)
|
|
—
|
|
|
—
|
|
|
(203.0
|
)
|
||||
Dividends on common stock
|
—
|
|
|
—
|
|
|
(54.6
|
)
|
|
(54.6
|
)
|
||||
Stock options, restricted stock and performance units
|
28.2
|
|
|
—
|
|
|
—
|
|
|
28.2
|
|
||||
Balance, December 31, 2016
|
$
|
3,213.8
|
|
|
$
|
622.4
|
|
|
$
|
650.7
|
|
|
$
|
4,486.9
|
|
|
2016
|
|
2015
|
|
2014
|
|
||||||
Cash flows from operating activities:
|
|
|
|
|
|
|
||||||
Insurance policy income
|
$
|
2,457.0
|
|
|
$
|
2,423.4
|
|
|
$
|
2,407.9
|
|
|
Net investment income
|
1,201.0
|
|
|
1,205.9
|
|
|
1,279.0
|
|
|
|||
Fee revenue and other income
|
50.5
|
|
|
58.9
|
|
|
50.9
|
|
|
|||
Cash and cash equivalents received upon recapture of reinsurance
|
73.6
|
|
|
—
|
|
|
—
|
|
|
|||
Insurance policy benefits
|
(1,916.0
|
)
|
|
(1,879.4
|
)
|
|
(1,968.4
|
)
|
|
|||
Payment to reinsurer pursuant to long-term care business reinsured
|
—
|
|
|
—
|
|
|
(590.3
|
)
|
|
|||
Interest expense
|
(106.0
|
)
|
|
(90.0
|
)
|
|
(81.7
|
)
|
|
|||
Deferrable policy acquisition costs
|
(242.7
|
)
|
|
(246.4
|
)
|
|
(242.8
|
)
|
|
|||
Other operating costs
|
(751.2
|
)
|
|
(724.4
|
)
|
|
(728.8
|
)
|
|
|||
Income taxes
|
(6.7
|
)
|
|
(4.1
|
)
|
|
(4.0
|
)
|
|
|||
Net cash from operating activities
|
759.5
|
|
|
743.9
|
|
|
121.8
|
|
(a)
|
|||
Cash flows from investing activities:
|
|
|
|
|
|
|
|
|
||||
Sales of investments
|
2,841.8
|
|
|
2,177.6
|
|
|
2,090.0
|
|
|
|||
Maturities and redemptions of investments
|
2,507.2
|
|
|
1,853.4
|
|
|
1,618.2
|
|
|
|||
Purchases of investments
|
(6,159.8
|
)
|
|
(4,767.2
|
)
|
|
(3,731.6
|
)
|
|
|||
Net sales (purchases) of trading securities
|
(84.2
|
)
|
|
(12.3
|
)
|
|
4.9
|
|
|
|||
Change in cash and cash equivalents held by variable interest entities
|
175.1
|
|
|
(296.1
|
)
|
|
36.0
|
|
|
|||
Cash and cash equivalents held by subsidiary prior to being sold
|
—
|
|
|
—
|
|
|
(164.7
|
)
|
|
|||
Proceeds from sale of subsidiary
|
—
|
|
|
—
|
|
|
231.0
|
|
|
|||
Other
|
(22.5
|
)
|
|
(25.0
|
)
|
|
(27.5
|
)
|
|
|||
Net cash provided (used) by investing activities
|
(742.4
|
)
|
|
(1,069.6
|
)
|
|
56.3
|
|
|
|||
Cash flows from financing activities:
|
|
|
|
|
|
|
|
|
||||
Issuance of notes payable, net
|
—
|
|
|
910.0
|
|
|
—
|
|
|
|||
Payments on notes payable
|
—
|
|
|
(797.1
|
)
|
|
(62.9
|
)
|
|
|||
Expenses related to extinguishment or modification of debt
|
—
|
|
|
(17.8
|
)
|
|
(.6
|
)
|
|
|||
Issuance of common stock
|
8.4
|
|
|
6.3
|
|
|
5.0
|
|
|
|||
Payments to repurchase common stock and warrants
|
(206.7
|
)
|
|
(361.5
|
)
|
|
(376.5
|
)
|
|
|||
Common stock dividends paid
|
(54.8
|
)
|
|
(52.0
|
)
|
|
(51.0
|
)
|
|
|||
Amounts received for deposit products
|
1,386.7
|
|
|
1,241.9
|
|
|
1,295.4
|
|
|
|||
Withdrawals from deposit products
|
(1,181.6
|
)
|
|
(1,225.0
|
)
|
|
(1,347.3
|
)
|
|
|||
Issuance of investment borrowings:
|
|
|
|
|
|
|
||||||
Federal Home Loan Bank
|
432.7
|
|
|
475.0
|
|
|
350.0
|
|
|
|||
Related to variable interest entities
|
493.2
|
|
|
544.7
|
|
|
358.5
|
|
|
|||
Payments on investment borrowings:
|
|
|
|
|
|
|
||||||
Federal Home Loan Bank
|
(333.5
|
)
|
|
(425.7
|
)
|
|
(367.7
|
)
|
|
|||
Related to variable interest entities and other
|
(514.9
|
)
|
|
(132.0
|
)
|
|
(88.8
|
)
|
|
|||
Investment borrowings - repurchase agreements, net
|
—
|
|
|
(20.4
|
)
|
|
20.4
|
|
|
|||
Net cash provided (used) by financing activities
|
29.5
|
|
|
146.4
|
|
|
(265.5
|
)
|
|
|||
Net increase (decrease) in cash and cash equivalents
|
46.6
|
|
|
(179.3
|
)
|
|
(87.4
|
)
|
|
|||
Cash and cash equivalents, beginning of year
|
432.3
|
|
|
611.6
|
|
|
699.0
|
|
|
|||
Cash and cash equivalents, end of year
|
$
|
478.9
|
|
|
$
|
432.3
|
|
|
$
|
611.6
|
|
|
(a)
|
Cash flows from operating activities reflect outflows in 2014 due to the payment to reinsurer to transfer certain long-term care business.
|
•
|
Bankers Life,
which markets and distributes Medicare supplement insurance, interest-sensitive life insurance, traditional life insurance, fixed annuities and long-term care insurance products to the middle-income senior market through a dedicated field force of career agents, financial and investment advisors, and sales managers supported by a network of community-based sales offices. The Bankers Life segment includes primarily the business of Bankers Life and Casualty Company ("Bankers Life"). Bankers Life also has various distribution and marketing agreements with other insurance companies to use Bankers Life's career agents to distribute Medicare Advantage and prescription drug plan products in exchange for a fee.
|
•
|
Washington National,
which markets and distributes supplemental health (including specified disease, accident and hospital indemnity insurance products) and life insurance to middle-income consumers at home and at the worksite. These products are marketed through Performance Matters Associates, Inc. and through independent marketing organizations and insurance agencies including worksite marketing. The products being marketed are underwritten by Washington National Insurance Company ("Washington National"). This segment's business also includes certain closed blocks of annuities and Medicare supplement policies which are no longer being actively marketed by this segment and were primarily issued or acquired by Washington National.
|
•
|
Colonial Penn
, which markets primarily graded benefit and simplified issue life insurance directly to customers in the senior middle-income market through television advertising, direct mail, the internet and telemarketing. The Colonial Penn segment includes primarily the business of Colonial Penn Life Insurance Company ("Colonial Penn").
|
•
|
Long-term care in run-off
consists of the long-term care business that was recaptured due to the termination of certain reinsurance agreements effective September 30, 2016. This business is not actively marketed and was issued or acquired by Washington National and Bankers Conseco Life Insurance Company ("BCLIC").
|
•
|
Premium rate increases - If premium rate increases reflect a change in our previous rate increase assumptions, the new assumptions are not reflected prospectively in our reserves. Instead, the additional premium revenue resulting from the rate increase is recognized as earned and original assumptions continue to be used to determine changes to liabilities for insurance products unless a premium deficiency exists.
|
•
|
Benefit reductions - A policyholder may choose reduced coverage with a proportionate reduction in premium, when permitted by our contracts. This option does not require additional underwriting. Benefit reductions are treated as a partial lapse of coverage, and the balance of our reserves and deferred insurance acquisition costs is reduced in proportion to the reduced coverage.
|
•
|
Non-forfeiture benefits offered in conjunction with a rate increase - In some cases, non-forfeiture benefits are offered to policyholders who wish to lapse their policies at the time of a significant rate increase. In these cases, exercise of this option is treated as an extinguishment of the original contract and issuance of a new contract. The balance of our reserves and deferred insurance acquisition costs are released, and a reserve for the new contract is established.
|
•
|
We recognize distribution income based on either: (i) a fixed fee per contract sold; or (ii) a percentage of premiums collected. This fee income is recognized over the calendar year term of the contract.
|
•
|
We also pay commissions to our agents who sell the plans. These payments are deferred and amortized over the term of the contract.
|
Market value of investments
|
$
|
504.7
|
|
Insurance liabilities
|
(552.2
|
)
|
|
Write-off of reinsurance receivables
|
(17.9
|
)
|
|
Estimated transaction expenses
|
(10.0
|
)
|
|
Pre-tax loss
|
(75.4
|
)
|
|
Tax benefit
|
26.4
|
|
|
Increase in valuation allowance for deferred tax assets
|
(4.1
|
)
|
|
After-tax loss
|
$
|
(53.1
|
)
|
Amount
|
|
Maturity
|
|
Interest rate at
|
||
borrowed
|
|
date
|
|
December 31, 2016
|
||
$
|
50.0
|
|
|
January 2018
|
|
Variable rate – 1.226%
|
50.0
|
|
|
January 2018
|
|
Variable rate – 1.222%
|
|
50.0
|
|
|
February 2018
|
|
Variable rate – 1.191%
|
|
50.0
|
|
|
February 2018
|
|
Variable rate – 1.001%
|
|
22.0
|
|
|
February 2018
|
|
Variable rate – 1.267%
|
|
100.0
|
|
|
May 2018
|
|
Variable rate – 1.206%
|
|
50.0
|
|
|
July 2018
|
|
Variable rate – 1.360%
|
|
50.0
|
|
|
August 2018
|
|
Variable rate – 1.022%
|
|
10.0
|
|
|
December 2018
|
|
Variable rate – 1.266%
|
|
50.0
|
|
|
January 2019
|
|
Variable rate – 1.300%
|
|
50.0
|
|
|
February 2019
|
|
Variable rate – 1.001%
|
|
100.0
|
|
|
March 2019
|
|
Variable rate – 1.216%
|
|
21.8
|
|
|
July 2019
|
|
Variable rate – 1.234%
|
|
15.0
|
|
|
October 2019
|
|
Variable rate – 1.399%
|
|
50.0
|
|
|
May 2020
|
|
Variable rate – 1.224%
|
|
21.8
|
|
|
June 2020
|
|
Fixed rate – 1.960%
|
|
25.0
|
|
|
September 2020
|
|
Variable rate – 1.622%
|
|
100.0
|
|
|
September 2020
|
|
Variable rate – 1.416%
|
|
50.0
|
|
|
September 2020
|
|
Variable rate – 1.416%
|
|
75.0
|
|
|
September 2020
|
|
Variable rate – 1.118%
|
|
100.0
|
|
|
October 2020
|
|
Variable rate – 1.109%
|
|
50.0
|
|
|
December 2020
|
|
Variable rate – 1.335%
|
|
100.0
|
|
|
July 2021
|
|
Variable rate – 1.431%
|
|
57.7
|
|
|
July 2021
|
|
Variable rate – 1.411%
|
|
100.0
|
|
|
August 2021
|
|
Variable rate – 1.400%
|
|
28.2
|
|
|
August 2021
|
|
Fixed rate – 2.550%
|
|
125.0
|
|
|
August 2021
|
|
Variable rate – 1.236%
|
|
50.0
|
|
|
September 2021
|
|
Variable rate – 1.477%
|
|
25.4
|
|
|
March 2023
|
|
Fixed rate – 2.160%
|
|
20.5
|
|
|
June 2025
|
|
Fixed rate – 2.940%
|
|
$
|
1,647.4
|
|
|
|
|
|
(i)
|
Require equity investments (except those accounted for under the equity method of accounting or those that result in consolidation of the investee) to be measured at fair value with changes in fair value recognized in net income. However, an entity may choose to measure equity investments that do not have readily determinable fair values at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer.
|
(ii)
|
Simplify the impairment assessment of equity investments without readily determinable fair values by requiring a qualitative assessment to identify impairment. When a qualitative assessment indicates that impairment exists, an entity is required to measure the investment at fair value.
|
(iii)
|
Eliminate the requirement for public business entities to disclose the method(s) and significant assumptions used to estimate the fair value that is required to be disclosed for financial instruments measured at amortized cost on the balance sheet.
|
(iv)
|
Require public business entities to use the exit price notion when measuring the fair value of financial instruments for disclosure purposes.
|
(v)
|
Require an entity to present separately in other comprehensive income the portion of the total change in the fair value of a liability resulting from a change in the instrument-specific credit risk when the entity has elected to measure the liability at fair value in accordance with the fair value option for financial instruments.
|
(vi)
|
Require separate presentation of financial assets and financial liabilities by measurement category and form of financial asset (that is, securities or loans and receivables) on the balance sheet or the accompanying notes to the financial statements.
|
(vii)
|
Clarify that an entity should evaluate the need for a valuation allowance on a deferred tax asset related to available-for-sale securities in combination with the entity’s other deferred tax assets.
|
|
Amortized
cost
|
|
Gross
unrealized
gains
|
|
Gross
unrealized
losses
|
|
Estimated
fair
value
|
|
Other-than-temporary impairments included in accumulated other comprehensive income
|
||||||||||
Investment grade (a):
|
|
|
|
|
|
|
|
|
|
||||||||||
Corporate securities
|
$
|
11,582.6
|
|
|
$
|
1,073.9
|
|
|
$
|
(99.8
|
)
|
|
$
|
12,556.7
|
|
|
$
|
—
|
|
United States Treasury securities and obligations of United States government corporations and agencies
|
143.8
|
|
|
20.5
|
|
|
—
|
|
|
164.3
|
|
|
—
|
|
|||||
States and political subdivisions
|
1,798.2
|
|
|
186.7
|
|
|
(7.9
|
)
|
|
1,977.0
|
|
|
—
|
|
|||||
Debt securities issued by foreign governments
|
37.1
|
|
|
.2
|
|
|
(.4
|
)
|
|
36.9
|
|
|
—
|
|
|||||
Asset-backed securities
|
1,169.6
|
|
|
29.2
|
|
|
(8.7
|
)
|
|
1,190.1
|
|
|
—
|
|
|||||
Collateralized debt obligations
|
227.5
|
|
|
1.0
|
|
|
(.3
|
)
|
|
228.2
|
|
|
—
|
|
|||||
Commercial mortgage-backed securities
|
1,467.2
|
|
|
32.9
|
|
|
(26.6
|
)
|
|
1,473.5
|
|
|
—
|
|
|||||
Mortgage pass-through securities
|
2.3
|
|
|
.2
|
|
|
—
|
|
|
2.5
|
|
|
—
|
|
|||||
Collateralized mortgage obligations
|
304.8
|
|
|
14.6
|
|
|
(.2
|
)
|
|
319.2
|
|
|
—
|
|
|||||
Total investment grade fixed maturities, available for sale
|
16,733.1
|
|
|
1,359.2
|
|
|
(143.9
|
)
|
|
17,948.4
|
|
|
—
|
|
|||||
Below-investment grade (a) (b):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||
Corporate securities
|
967.3
|
|
|
26.1
|
|
|
(39.2
|
)
|
|
954.2
|
|
|
(3.6
|
)
|
|||||
States and political subdivisions
|
13.6
|
|
|
—
|
|
|
(1.7
|
)
|
|
11.9
|
|
|
(3.0
|
)
|
|||||
Asset-backed securities
|
1,471.9
|
|
|
55.1
|
|
|
(6.8
|
)
|
|
1,520.2
|
|
|
—
|
|
|||||
Collateralized debt obligations
|
2.5
|
|
|
—
|
|
|
—
|
|
|
2.5
|
|
|
—
|
|
|||||
Commercial mortgage-backed securities
|
63.8
|
|
|
.2
|
|
|
(1.3
|
)
|
|
62.7
|
|
|
—
|
|
|||||
Collateralized mortgage obligations
|
550.9
|
|
|
46.8
|
|
|
(1.4
|
)
|
|
596.3
|
|
|
(1.4
|
)
|
|||||
Total below-investment grade fixed maturities, available for sale
|
3,070.0
|
|
|
128.2
|
|
|
(50.4
|
)
|
|
3,147.8
|
|
|
(8.0
|
)
|
|||||
Total fixed maturities, available for sale
|
$
|
19,803.1
|
|
|
$
|
1,487.4
|
|
|
$
|
(194.3
|
)
|
|
$
|
21,096.2
|
|
|
$
|
(8.0
|
)
|
Equity securities
|
$
|
580.7
|
|
|
$
|
11.5
|
|
|
$
|
(8.0
|
)
|
|
$
|
584.2
|
|
|
|
(a)
|
Investment ratings – Investment ratings are assigned the second lowest rating by Nationally Recognized Statistical Rating Organizations ("NRSROs") (Moody's Investor Services, Inc. ("Moody's"), S&P Global Ratings ("S&P") or Fitch Ratings ("Fitch")), or if not rated by such firms, the rating assigned by the National Association of Insurance Commissioners (the "NAIC"). NAIC designations of "1" or "2" include fixed maturities generally rated investment grade (rated "Baa3" or higher by Moody's or rated "BBB-" or higher by S&P and Fitch). NAIC designations of "3" through "6" are referred to as below-investment grade (which generally are rated "Ba1" or lower by Moody's or rated "BB+" or lower by S&P and Fitch). References to investment grade or below-investment grade throughout our consolidated financial statements are determined as described above.
|
(b)
|
Certain structured securities rated below-investment grade by NRSROs may be assigned a NAIC 1 or NAIC 2 designation based on the cost basis of the security relative to estimated recoverable amounts as determined by the
|
NAIC Designation
|
|
NRSRO Equivalent Rating
|
1
|
|
AAA/AA/A
|
2
|
|
BBB
|
3
|
|
BB
|
4
|
|
B
|
5
|
|
CCC and lower
|
6
|
|
In or near default
|
NAIC designation
|
|
Amortized cost
|
|
Estimated fair value
|
|
Percentage of total estimated fair value
|
|||||
1
|
|
$
|
9,715.7
|
|
|
$
|
10,463.2
|
|
|
49.6
|
%
|
2
|
|
8,973.1
|
|
|
9,526.4
|
|
|
45.2
|
|
||
Total NAIC 1 and 2 (investment grade)
|
|
18,688.8
|
|
|
19,989.6
|
|
|
94.8
|
|
||
3
|
|
711.7
|
|
|
705.4
|
|
|
3.3
|
|
||
4
|
|
233.0
|
|
|
229.4
|
|
|
1.1
|
|
||
5
|
|
141.3
|
|
|
138.3
|
|
|
.6
|
|
||
6
|
|
28.3
|
|
|
33.5
|
|
|
.2
|
|
||
Total NAIC 3,4,5 and 6 (below-investment grade)
|
|
1,114.3
|
|
|
1,106.6
|
|
|
5.2
|
|
||
|
|
$
|
19,803.1
|
|
|
$
|
21,096.2
|
|
|
100.0
|
%
|
|
Amortized
cost
|
|
Gross
unrealized
gains
|
|
Gross
unrealized
losses
|
|
Estimated
fair
value
|
|
Other-than-temporary impairments included in accumulated other comprehensive income
|
||||||||||
Investment grade:
|
|
|
|
|
|
|
|
|
|
||||||||||
Corporate securities
|
$
|
11,477.5
|
|
|
$
|
929.4
|
|
|
$
|
(262.9
|
)
|
|
$
|
12,144.0
|
|
|
$
|
—
|
|
United States Treasury securities and obligations of United States government corporations and agencies
|
172.5
|
|
|
22.3
|
|
|
(.3
|
)
|
|
194.5
|
|
|
—
|
|
|||||
States and political subdivisions
|
1,889.6
|
|
|
208.6
|
|
|
(3.7
|
)
|
|
2,094.5
|
|
|
—
|
|
|||||
Debt securities issued by foreign governments
|
18.9
|
|
|
—
|
|
|
(.6
|
)
|
|
18.3
|
|
|
—
|
|
|||||
Asset-backed securities
|
979.8
|
|
|
22.1
|
|
|
(7.2
|
)
|
|
994.7
|
|
|
—
|
|
|||||
Collateralized debt obligations
|
188.5
|
|
|
.4
|
|
|
(2.2
|
)
|
|
186.7
|
|
|
—
|
|
|||||
Commercial mortgage-backed securities
|
1,531.7
|
|
|
41.3
|
|
|
(16.3
|
)
|
|
1,556.7
|
|
|
—
|
|
|||||
Mortgage pass-through securities
|
3.1
|
|
|
.3
|
|
|
—
|
|
|
3.4
|
|
|
—
|
|
|||||
Collateralized mortgage obligations
|
450.9
|
|
|
17.0
|
|
|
(.6
|
)
|
|
467.3
|
|
|
—
|
|
|||||
Total investment grade fixed maturities, available for sale
|
16,712.5
|
|
|
1,241.4
|
|
|
(293.8
|
)
|
|
17,660.1
|
|
|
—
|
|
|||||
Below-investment grade:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||
Corporate securities
|
798.5
|
|
|
8.3
|
|
|
(82.3
|
)
|
|
724.5
|
|
|
—
|
|
|||||
States and political subdivisions
|
13.6
|
|
|
—
|
|
|
(3.9
|
)
|
|
9.7
|
|
|
(3.0
|
)
|
|||||
Debt securities issued by foreign governments
|
2.4
|
|
|
—
|
|
|
—
|
|
|
2.4
|
|
|
—
|
|
|||||
Asset-backed securities
|
838.0
|
|
|
25.7
|
|
|
(6.2
|
)
|
|
857.5
|
|
|
—
|
|
|||||
Commercial mortgage-backed securities
|
49.9
|
|
|
—
|
|
|
(1.3
|
)
|
|
48.6
|
|
|
—
|
|
|||||
Collateralized mortgage obligations
|
532.1
|
|
|
49.0
|
|
|
(1.0
|
)
|
|
580.1
|
|
|
(1.9
|
)
|
|||||
Total below-investment grade fixed maturities, available for sale
|
2,234.5
|
|
|
83.0
|
|
|
(94.7
|
)
|
|
2,222.8
|
|
|
(4.9
|
)
|
|||||
Total fixed maturities, available for sale
|
$
|
18,947.0
|
|
|
$
|
1,324.4
|
|
|
$
|
(388.5
|
)
|
|
$
|
19,882.9
|
|
|
$
|
(4.9
|
)
|
Equity securities
|
$
|
447.4
|
|
|
$
|
18.4
|
|
|
$
|
(2.8
|
)
|
|
$
|
463.0
|
|
|
|
|
2016
|
|
2015
|
||||
Net unrealized appreciation (depreciation) on fixed maturity securities, available for sale, on which an other-than-temporary impairment loss has been recognized
|
$
|
(1.1
|
)
|
|
$
|
1.6
|
|
Net unrealized gains on all other investments
|
1,311.9
|
|
|
903.4
|
|
||
Adjustment to present value of future profits (a)
|
(106.2
|
)
|
|
(121.2
|
)
|
||
Adjustment to deferred acquisition costs
|
(223.5
|
)
|
|
(133.3
|
)
|
||
Adjustment to insurance liabilities
|
(13.5
|
)
|
|
(14.6
|
)
|
||
Unrecognized net loss related to deferred compensation plan
|
—
|
|
|
(8.6
|
)
|
||
Deferred income tax liabilities
|
(345.2
|
)
|
|
(224.5
|
)
|
||
Accumulated other comprehensive income
|
$
|
622.4
|
|
|
$
|
402.8
|
|
(a)
|
The present value of future profits is the value assigned to the right to receive future cash flows from contracts existing at September 10, 2003, the date our Predecessor emerged from bankruptcy.
|
|
Amortized
cost
|
|
Estimated
fair
value
|
||||
|
(Dollars in millions)
|
||||||
Due in one year or less
|
$
|
354.7
|
|
|
$
|
359.8
|
|
Due after one year through five years
|
2,243.8
|
|
|
2,399.5
|
|
||
Due after five years through ten years
|
1,549.1
|
|
|
1,620.8
|
|
||
Due after ten years
|
10,395.0
|
|
|
11,320.9
|
|
||
Subtotal
|
14,542.6
|
|
|
15,701.0
|
|
||
Structured securities
|
5,260.5
|
|
|
5,395.2
|
|
||
Total fixed maturities, available for sale
|
$
|
19,803.1
|
|
|
$
|
21,096.2
|
|
|
2016
|
|
2015
|
|
2014
|
||||||
General account assets:
|
|
|
|
|
|
||||||
Fixed maturities
|
$
|
1,081.4
|
|
|
$
|
1,090.1
|
|
|
$
|
1,175.8
|
|
Equity securities
|
21.5
|
|
|
18.3
|
|
|
13.9
|
|
|||
Mortgage loans
|
91.0
|
|
|
91.4
|
|
|
104.2
|
|
|||
Policy loans
|
7.3
|
|
|
7.3
|
|
|
11.0
|
|
|||
Other invested assets
|
24.3
|
|
|
17.4
|
|
|
17.1
|
|
|||
Cash and cash equivalents
|
2.0
|
|
|
.8
|
|
|
.6
|
|
|||
Policyholder and reinsurer accounts and other special-purpose portfolios:
|
|
|
|
|
|
||||||
Trading securities (a)
|
12.2
|
|
|
10.7
|
|
|
14.8
|
|
|||
Options related to fixed index products:
|
|
|
|
|
|
||||||
Option income (loss)
|
(40.1
|
)
|
|
36.5
|
|
|
118.9
|
|
|||
Change in value of options
|
69.3
|
|
|
(72.7
|
)
|
|
(49.4
|
)
|
|||
Other special-purpose portfolios
|
79.7
|
|
|
55.5
|
|
|
42.1
|
|
|||
Gross investment income
|
1,348.6
|
|
|
1,255.3
|
|
|
1,449.0
|
|
|||
Less investment expenses
|
23.4
|
|
|
21.7
|
|
|
21.6
|
|
|||
Net investment income
|
$
|
1,325.2
|
|
|
$
|
1,233.6
|
|
|
$
|
1,427.4
|
|
(a)
|
Changes in the estimated fair value for trading securities still held as of the end of the respective years and included in net investment income were
$(.2) million
,
$.4 million
and
$3.4 million
for the years ended
December 31, 2016
,
2015
and
2014
, respectively.
|
|
2016
|
|
2015
|
|
2014
|
||||||
Fixed maturity securities, available for sale:
|
|
|
|
|
|
||||||
Gross realized gains on sale
|
$
|
137.7
|
|
|
$
|
95.7
|
|
|
$
|
64.4
|
|
Gross realized losses on sale
|
(95.2
|
)
|
|
(88.4
|
)
|
|
(13.0
|
)
|
|||
Impairments:
|
|
|
|
|
|
||||||
Total other-than-temporary impairment losses
|
(15.2
|
)
|
|
(17.9
|
)
|
|
—
|
|
|||
Other-than-temporary impairment losses recognized in accumulated other comprehensive income
|
3.6
|
|
|
3.0
|
|
|
—
|
|
|||
Net impairment losses recognized
|
(11.6
|
)
|
|
(14.9
|
)
|
|
—
|
|
|||
Net realized investment gains (losses) from fixed maturities
|
30.9
|
|
|
(7.6
|
)
|
|
51.4
|
|
|||
Equity securities
|
20.9
|
|
|
3.7
|
|
|
10.1
|
|
|||
Commercial mortgage loans
|
—
|
|
|
(2.3
|
)
|
|
(.1
|
)
|
|||
Impairments on preferred stock and other investments
|
(20.7
|
)
|
|
(25.0
|
)
|
|
(27.3
|
)
|
|||
Gain (loss) on dissolution of variable interest entities
|
(7.3
|
)
|
|
11.3
|
|
|
—
|
|
|||
Other (a)
|
(15.5
|
)
|
|
(16.7
|
)
|
|
2.6
|
|
|||
Net realized investment gains (losses)
|
$
|
8.3
|
|
|
$
|
(36.6
|
)
|
|
$
|
36.7
|
|
(a)
|
Changes in the estimated fair value of trading securities that we have elected the fair value option (and still held as of the end of the respective periods) were
$(.5) million
,
$(9.2) million
and
$7.8 million
for the years ended
December 31, 2016
,
2015
and
2014
, respectively.
|
|
|
|
At date of sale
|
||||||
|
Number
of issuers |
|
Amortized cost
|
|
Fair value
|
||||
Less than 6 months prior to sale
|
19
|
|
$
|
119.3
|
|
|
$
|
79.2
|
|
Greater than or equal to 6 months and less than 12 months prior to sale
|
7
|
|
76.4
|
|
|
45.6
|
|
||
|
26
|
|
$
|
195.7
|
|
|
$
|
124.8
|
|
|
Year ended
|
||||||||||
|
December 31,
|
||||||||||
|
2016
|
|
2015
|
|
2014
|
||||||
Credit losses on fixed maturity securities, available for sale, beginning of period
|
$
|
(2.6
|
)
|
|
$
|
(1.0
|
)
|
|
$
|
(1.3
|
)
|
Add: credit losses on other-than-temporary impairments not previously recognized
|
(3.0
|
)
|
|
(2.0
|
)
|
|
—
|
|
|||
Less: credit losses on securities sold
|
.1
|
|
|
.4
|
|
|
.3
|
|
|||
Less: credit losses on securities impaired due to intent to sell (a)
|
—
|
|
|
—
|
|
|
—
|
|
|||
Add: credit losses on previously impaired securities
|
—
|
|
|
—
|
|
|
—
|
|
|||
Less: increases in cash flows expected on previously impaired securities
|
—
|
|
|
—
|
|
|
—
|
|
|||
Credit losses on fixed maturity securities, available for sale, end of period
|
$
|
(5.5
|
)
|
|
$
|
(2.6
|
)
|
|
$
|
(1.0
|
)
|
(a)
|
Represents securities for which the amount previously recognized in accumulated other comprehensive income was recognized in earnings because we intend to sell the security or we more likely than not will be required to sell the security before recovery of its amortized cost basis.
|
|
Amortized
cost
|
|
Estimated
fair
value
|
||||
|
(Dollars in millions)
|
||||||
Due in one year or less
|
$
|
35.7
|
|
|
$
|
35.0
|
|
Due after one year through five years
|
150.4
|
|
|
145.9
|
|
||
Due after five years through ten years
|
389.3
|
|
|
370.9
|
|
||
Due after ten years
|
2,262.3
|
|
|
2,136.9
|
|
||
Subtotal
|
2,837.7
|
|
|
2,688.7
|
|
||
Structured securities
|
1,857.2
|
|
|
1,811.9
|
|
||
Total
|
$
|
4,694.9
|
|
|
$
|
4,500.6
|
|
|
Number
of issuers |
|
Cost
basis |
|
Unrealized
loss |
|
Estimated
fair value |
||||||
Less than 6 months
|
4
|
|
$
|
53.8
|
|
|
$
|
(12.1
|
)
|
|
$
|
41.7
|
|
Greater than 12 months
|
1
|
|
.7
|
|
|
(.2
|
)
|
|
.5
|
|
|||
|
|
|
$
|
54.5
|
|
|
$
|
(12.3
|
)
|
|
$
|
42.2
|
|
|
|
Less than 12 months
|
|
12 months or greater
|
|
Total
|
||||||||||||||||||
Description of securities
|
|
Fair
value
|
|
Unrealized
losses
|
|
Fair
value
|
|
Unrealized
losses
|
|
Fair
value
|
|
Unrealized
losses
|
||||||||||||
United States Treasury securities and obligations of United States government corporations and agencies
|
|
$
|
8.0
|
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
8.0
|
|
|
$
|
—
|
|
States and political subdivisions
|
|
176.3
|
|
|
(7.8
|
)
|
|
18.3
|
|
|
(1.8
|
)
|
|
194.6
|
|
|
(9.6
|
)
|
||||||
Debt securities issued by foreign governments
|
|
18.9
|
|
|
(.4
|
)
|
|
—
|
|
|
—
|
|
|
18.9
|
|
|
(.4
|
)
|
||||||
Corporate securities
|
|
1,907.6
|
|
|
(75.5
|
)
|
|
559.6
|
|
|
(63.5
|
)
|
|
2,467.2
|
|
|
(139.0
|
)
|
||||||
Asset-backed securities
|
|
692.9
|
|
|
(8.5
|
)
|
|
262.5
|
|
|
(7.0
|
)
|
|
955.4
|
|
|
(15.5
|
)
|
||||||
Collateralized debt obligations
|
|
38.3
|
|
|
(.1
|
)
|
|
30.8
|
|
|
(.2
|
)
|
|
69.1
|
|
|
(.3
|
)
|
||||||
Commercial mortgage-backed securities
|
|
525.2
|
|
|
(16.6
|
)
|
|
154.0
|
|
|
(11.3
|
)
|
|
679.2
|
|
|
(27.9
|
)
|
||||||
Collateralized mortgage obligations
|
|
73.6
|
|
|
(.6
|
)
|
|
34.6
|
|
|
(1.0
|
)
|
|
108.2
|
|
|
(1.6
|
)
|
||||||
Total fixed maturities, available for sale
|
|
$
|
3,440.8
|
|
|
$
|
(109.5
|
)
|
|
$
|
1,059.8
|
|
|
$
|
(84.8
|
)
|
|
$
|
4,500.6
|
|
|
$
|
(194.3
|
)
|
Equity securities
|
|
$
|
239.4
|
|
|
$
|
(8.0
|
)
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
239.4
|
|
|
$
|
(8.0
|
)
|
|
|
Less than 12 months
|
|
12 months or greater
|
|
Total
|
||||||||||||||||||
Description of securities
|
|
Fair
value
|
|
Unrealized
losses
|
|
Fair
value
|
|
Unrealized
losses
|
|
Fair
value
|
|
Unrealized
losses
|
||||||||||||
United States Treasury securities and obligations of United States government corporations and agencies
|
|
$
|
43.6
|
|
|
$
|
(.3
|
)
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
43.6
|
|
|
$
|
(.3
|
)
|
States and political subdivisions
|
|
156.8
|
|
|
(4.1
|
)
|
|
14.8
|
|
|
(3.5
|
)
|
|
171.6
|
|
|
(7.6
|
)
|
||||||
Debt securities issued by foreign governments
|
|
20.7
|
|
|
(.6
|
)
|
|
—
|
|
|
—
|
|
|
20.7
|
|
|
(.6
|
)
|
||||||
Corporate securities
|
|
2,913.6
|
|
|
(255.7
|
)
|
|
278.9
|
|
|
(89.5
|
)
|
|
3,192.5
|
|
|
(345.2
|
)
|
||||||
Asset-backed securities
|
|
930.3
|
|
|
(11.7
|
)
|
|
98.4
|
|
|
(1.7
|
)
|
|
1,028.7
|
|
|
(13.4
|
)
|
||||||
Collateralized debt obligations
|
|
96.2
|
|
|
(1.8
|
)
|
|
36.3
|
|
|
(.4
|
)
|
|
132.5
|
|
|
(2.2
|
)
|
||||||
Commercial mortgage-backed securities
|
|
556.0
|
|
|
(16.1
|
)
|
|
25.7
|
|
|
(1.5
|
)
|
|
581.7
|
|
|
(17.6
|
)
|
||||||
Mortgage pass-through securities
|
|
—
|
|
|
—
|
|
|
.1
|
|
|
—
|
|
|
.1
|
|
|
—
|
|
||||||
Collateralized mortgage obligations
|
|
97.8
|
|
|
(1.0
|
)
|
|
40.8
|
|
|
(.6
|
)
|
|
138.6
|
|
|
(1.6
|
)
|
||||||
Total fixed maturities, available for sale
|
|
$
|
4,815.0
|
|
|
$
|
(291.3
|
)
|
|
$
|
495.0
|
|
|
$
|
(97.2
|
)
|
|
$
|
5,310.0
|
|
|
$
|
(388.5
|
)
|
Equity securities
|
|
$
|
140.1
|
|
|
$
|
(2.4
|
)
|
|
$
|
2.4
|
|
|
$
|
(.4
|
)
|
|
$
|
142.5
|
|
|
$
|
(2.8
|
)
|
|
Par
value
|
|
Amortized
cost
|
|
Estimated
fair value
|
||||||
Below 4 percent
|
$
|
1,993.9
|
|
|
$
|
1,523.5
|
|
|
$
|
1,535.4
|
|
4 percent – 5 percent
|
1,757.6
|
|
|
1,592.5
|
|
|
1,624.7
|
|
|||
5 percent – 6 percent
|
1,772.2
|
|
|
1,602.2
|
|
|
1,666.7
|
|
|||
6 percent – 7 percent
|
388.1
|
|
|
348.0
|
|
|
364.5
|
|
|||
7 percent – 8 percent
|
55.8
|
|
|
56.2
|
|
|
65.6
|
|
|||
8 percent and above
|
138.7
|
|
|
138.1
|
|
|
138.3
|
|
|||
Total structured securities
|
$
|
6,106.3
|
|
|
$
|
5,260.5
|
|
|
$
|
5,395.2
|
|
|
|
|
Estimated fair value
|
|||||||
Type
|
Amortized
cost
|
|
Amount
|
|
Percent
of fixed
maturities
|
|||||
Pass-throughs, sequential and equivalent securities
|
$
|
664.8
|
|
|
$
|
710.6
|
|
|
3.4
|
%
|
Planned amortization classes, target amortization classes and accretion-directed bonds
|
142.5
|
|
|
156.4
|
|
|
.7
|
|
||
Commercial mortgage-backed securities
|
1,531.0
|
|
|
1,536.2
|
|
|
7.3
|
|
||
Asset-backed securities
|
2,641.5
|
|
|
2,710.3
|
|
|
12.9
|
|
||
Collateralized debt obligations
|
230.0
|
|
|
230.7
|
|
|
1.1
|
|
||
Other
|
50.7
|
|
|
51.0
|
|
|
.2
|
|
||
Total structured securities
|
$
|
5,260.5
|
|
|
$
|
5,395.2
|
|
|
25.6
|
%
|
|
|
|
Estimated fair
value
|
||||||||
Loan-to-value ratio (a)
|
Carrying value
|
|
Mortgage loans
|
|
Collateral
|
||||||
Less than 60%
|
$
|
976.5
|
|
|
$
|
1,004.2
|
|
|
$
|
2,393.0
|
|
60% to 70%
|
394.7
|
|
|
396.7
|
|
|
596.2
|
|
|||
Greater than 70% to 80%
|
282.3
|
|
|
286.2
|
|
|
385.1
|
|
|||
Greater than 80% to 90%
|
75.3
|
|
|
74.0
|
|
|
89.5
|
|
|||
Greater than 90%
|
39.2
|
|
|
39.0
|
|
|
42.0
|
|
|||
Total
|
$
|
1,768.0
|
|
|
$
|
1,800.1
|
|
|
$
|
3,505.8
|
|
(a)
|
Loan-to-value ratios are calculated as the ratio of: (i) the carrying value of the commercial mortgage loans; to (ii) the estimated fair value of the underlying collateral.
|
•
|
Level 1 – includes assets and liabilities valued using inputs that are unadjusted quoted prices in active markets for identical assets or liabilities. Our Level 1 assets primarily include cash and cash equivalents and exchange traded securities.
|
•
|
Level 2 – includes assets and liabilities valued using inputs that are quoted prices for similar assets in an active market, quoted prices for identical or similar assets in a market that is not active, observable inputs, or observable inputs that can be corroborated by market data. Level 2 assets and liabilities include those financial instruments that are valued by independent pricing services using models or other valuation methodologies. These models consider various inputs such as credit rating, maturity, corporate credit spreads, reported trades and other inputs that are observable or derived from observable information in the marketplace or are supported by transactions executed in the marketplace. Financial assets in this category primarily include: certain publicly registered and privately placed corporate fixed maturity securities; certain government or agency securities; certain mortgage and asset-backed securities; certain equity securities; most investments held by our consolidated VIEs; certain mutual fund investments; most short-term investments; and non-exchange-traded derivatives such as call options. Financial liabilities in this category include investment borrowings, notes payable and borrowings related to VIEs.
|
•
|
Level 3 – includes assets and liabilities valued using unobservable inputs that are used in model-based valuations that contain management assumptions. Level 3 assets and liabilities include those financial instruments whose fair value is estimated based on broker/dealer quotes, pricing services or internally developed models or methodologies utilizing significant inputs not based on, or corroborated by, readily available market information. Financial assets in this category include certain corporate securities (primarily certain below-investment grade privately placed securities), certain structured securities, mortgage loans, and other less liquid securities. Financial liabilities in this category include our insurance liabilities for interest-sensitive products, which includes embedded derivatives (including embedded derivatives related to our fixed index annuity products and to a modified coinsurance arrangement) since their values include significant unobservable inputs including actuarial assumptions.
|
•
|
Investments held by VIEs
|
•
|
Other invested assets - derivatives
|
|
Quoted prices in active markets
for identical assets or liabilities (Level 1) |
|
Significant other observable inputs
(Level 2)
|
|
Significant unobservable inputs
(Level 3)
|
|
Total
|
||||||||
Assets:
|
|
|
|
|
|
|
|
||||||||
Fixed maturities, available for sale:
|
|
|
|
|
|
|
|
||||||||
Corporate securities
|
$
|
—
|
|
|
$
|
13,252.4
|
|
|
$
|
258.5
|
|
|
$
|
13,510.9
|
|
United States Treasury securities and obligations of United States government corporations and agencies
|
—
|
|
|
164.3
|
|
|
—
|
|
|
164.3
|
|
||||
States and political subdivisions
|
—
|
|
|
1,988.9
|
|
|
—
|
|
|
1,988.9
|
|
||||
Debt securities issued by foreign governments
|
—
|
|
|
33.0
|
|
|
3.9
|
|
|
36.9
|
|
||||
Asset-backed securities
|
—
|
|
|
2,649.9
|
|
|
60.4
|
|
|
2,710.3
|
|
||||
Collateralized debt obligations
|
—
|
|
|
225.3
|
|
|
5.4
|
|
|
230.7
|
|
||||
Commercial mortgage-backed securities
|
—
|
|
|
1,504.2
|
|
|
32.0
|
|
|
1,536.2
|
|
||||
Mortgage pass-through securities
|
—
|
|
|
2.5
|
|
|
—
|
|
|
2.5
|
|
||||
Collateralized mortgage obligations
|
—
|
|
|
915.5
|
|
|
—
|
|
|
915.5
|
|
||||
Total fixed maturities, available for sale
|
—
|
|
|
20,736.0
|
|
|
360.2
|
|
|
21,096.2
|
|
||||
Equity securities - corporate securities
|
359.9
|
|
|
199.1
|
|
|
25.2
|
|
|
584.2
|
|
||||
Trading securities:
|
|
|
|
|
|
|
|
|
|
|
|
||||
Corporate securities
|
—
|
|
|
19.0
|
|
|
—
|
|
|
19.0
|
|
||||
United States Treasury securities and obligations of United States government corporations and agencies
|
—
|
|
|
.5
|
|
|
—
|
|
|
.5
|
|
||||
Asset-backed securities
|
—
|
|
|
94.3
|
|
|
—
|
|
|
94.3
|
|
||||
Collateralized debt obligations
|
—
|
|
|
2.4
|
|
|
—
|
|
|
2.4
|
|
||||
Commercial mortgage-backed securities
|
—
|
|
|
163.9
|
|
|
—
|
|
|
163.9
|
|
||||
Collateralized mortgage obligations
|
—
|
|
|
78.4
|
|
|
—
|
|
|
78.4
|
|
||||
Equity securities
|
4.9
|
|
|
—
|
|
|
—
|
|
|
4.9
|
|
||||
Total trading securities
|
4.9
|
|
|
358.5
|
|
|
—
|
|
|
363.4
|
|
||||
Investments held by variable interest entities - corporate securities
|
—
|
|
|
1,724.3
|
|
|
—
|
|
|
1,724.3
|
|
||||
Other invested assets - derivatives
|
—
|
|
|
111.9
|
|
|
—
|
|
|
111.9
|
|
||||
Assets held in separate accounts
|
—
|
|
|
4.7
|
|
|
—
|
|
|
4.7
|
|
||||
Total assets carried at fair value by category
|
$
|
364.8
|
|
|
$
|
23,134.5
|
|
|
$
|
385.4
|
|
|
$
|
23,884.7
|
|
|
|
|
|
|
|
|
|
||||||||
Liabilities:
|
|
|
|
|
|
|
|
|
|
|
|
||||
Future policy benefits - embedded derivatives associated with fixed index annuity products
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
1,092.3
|
|
|
$
|
1,092.3
|
|
|
Quoted prices in active markets
for identical assets or liabilities
(Level 1)
|
|
Significant other observable inputs
(Level 2)
|
|
Significant unobservable inputs
(Level 3)
|
|
Total
|
||||||||
Assets:
|
|
|
|
|
|
|
|
||||||||
Fixed maturities, available for sale:
|
|
|
|
|
|
|
|
||||||||
Corporate securities
|
$
|
—
|
|
|
$
|
12,698.1
|
|
|
$
|
170.4
|
|
|
$
|
12,868.5
|
|
United States Treasury securities and obligations of United States government corporations and agencies
|
—
|
|
|
194.5
|
|
|
—
|
|
|
194.5
|
|
||||
States and political subdivisions
|
—
|
|
|
2,104.2
|
|
|
—
|
|
|
2,104.2
|
|
||||
Debt securities issued by foreign governments
|
—
|
|
|
20.7
|
|
|
—
|
|
|
20.7
|
|
||||
Asset-backed securities
|
—
|
|
|
1,816.3
|
|
|
35.9
|
|
|
1,852.2
|
|
||||
Collateralized debt obligations
|
—
|
|
|
186.7
|
|
|
—
|
|
|
186.7
|
|
||||
Commercial mortgage-backed securities
|
—
|
|
|
1,604.2
|
|
|
1.1
|
|
|
1,605.3
|
|
||||
Mortgage pass-through securities
|
—
|
|
|
3.3
|
|
|
.1
|
|
|
3.4
|
|
||||
Collateralized mortgage obligations
|
—
|
|
|
1,047.4
|
|
|
—
|
|
|
1,047.4
|
|
||||
Total fixed maturities, available for sale
|
—
|
|
|
19,675.4
|
|
|
207.5
|
|
|
19,882.9
|
|
||||
Equity securities - corporate securities
|
254.9
|
|
|
176.1
|
|
|
32.0
|
|
|
463.0
|
|
||||
Trading securities:
|
|
|
|
|
|
|
|
|
|
|
|
||||
Corporate securities
|
—
|
|
|
21.5
|
|
|
—
|
|
|
21.5
|
|
||||
United States Treasury securities and obligations of United States government corporations and agencies
|
—
|
|
|
1.9
|
|
|
—
|
|
|
1.9
|
|
||||
Asset-backed securities
|
—
|
|
|
35.5
|
|
|
—
|
|
|
35.5
|
|
||||
Collateralized debt obligations
|
—
|
|
|
2.1
|
|
|
—
|
|
|
2.1
|
|
||||
Commercial mortgage-backed securities
|
—
|
|
|
118.1
|
|
|
39.9
|
|
|
158.0
|
|
||||
Collateralized mortgage obligations
|
—
|
|
|
38.2
|
|
|
—
|
|
|
38.2
|
|
||||
Equity securities
|
4.9
|
|
|
—
|
|
|
—
|
|
|
4.9
|
|
||||
Total trading securities
|
4.9
|
|
|
217.3
|
|
|
39.9
|
|
|
262.1
|
|
||||
Investments held by variable interest entities - corporate securities
|
—
|
|
|
1,633.6
|
|
|
—
|
|
|
1,633.6
|
|
||||
Other invested assets - derivatives
|
1.6
|
|
|
41.0
|
|
|
—
|
|
|
42.6
|
|
||||
Assets held in separate accounts
|
—
|
|
|
4.7
|
|
|
—
|
|
|
4.7
|
|
||||
Total assets carried at fair value by category
|
$
|
261.4
|
|
|
$
|
21,748.1
|
|
|
$
|
279.4
|
|
|
$
|
22,288.9
|
|
|
|
|
|
|
|
|
|
||||||||
Liabilities:
|
|
|
|
|
|
|
|
|
|
|
|
||||
Future policy benefits - embedded derivatives associated with fixed index annuity products
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
1,057.1
|
|
|
$
|
1,057.1
|
|
|
December 31, 2016
|
||||||||||||||||||
|
Quoted prices in active markets for identical assets or liabilities
(Level 1)
|
|
Significant other observable inputs
(Level 2)
|
|
Significant unobservable inputs
(Level 3)
|
|
Total estimated fair value
|
|
Total carrying amount
|
||||||||||
Assets:
|
|
|
|
|
|
|
|
|
|
||||||||||
Mortgage loans
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
1,800.1
|
|
|
$
|
1,800.1
|
|
|
$
|
1,768.0
|
|
Policy loans
|
—
|
|
|
—
|
|
|
112.0
|
|
|
112.0
|
|
|
112.0
|
|
|||||
Other invested assets:
|
|
|
|
|
|
|
|
|
|
||||||||||
Company-owned life insurance
|
—
|
|
|
165.0
|
|
|
—
|
|
|
165.0
|
|
|
165.0
|
|
|||||
Cash and cash equivalents:
|
|
|
|
|
|
|
|
|
|
||||||||||
Unrestricted
|
473.6
|
|
|
5.3
|
|
|
—
|
|
|
478.9
|
|
|
478.9
|
|
|||||
Held by variable interest entities
|
189.3
|
|
|
—
|
|
|
—
|
|
|
189.3
|
|
|
189.3
|
|
|||||
Liabilities:
|
|
|
|
|
|
|
|
|
|
||||||||||
Policyholder account balances
|
—
|
|
|
—
|
|
|
10,912.7
|
|
|
10,912.7
|
|
|
10,912.7
|
|
|||||
Investment borrowings
|
—
|
|
|
1,650.0
|
|
|
—
|
|
|
1,650.0
|
|
|
1,647.4
|
|
|||||
Borrowings related to variable interest entities
|
—
|
|
|
1,675.2
|
|
|
—
|
|
|
1,675.2
|
|
|
1,662.8
|
|
|||||
Notes payable – direct corporate obligations
|
—
|
|
|
931.9
|
|
|
—
|
|
|
931.9
|
|
|
912.9
|
|
|
December 31, 2015
|
||||||||||||||||||
|
Quoted prices in active markets for identical assets or liabilities
(Level 1)
|
|
Significant other observable inputs
(Level 2)
|
|
Significant unobservable inputs
(Level 3)
|
|
Total estimated fair value
|
|
Total carrying amount
|
||||||||||
Assets:
|
|
|
|
|
|
|
|
|
|
||||||||||
Mortgage loans
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
1,772.4
|
|
|
$
|
1,772.4
|
|
|
$
|
1,721.0
|
|
Policy loans
|
—
|
|
|
—
|
|
|
109.4
|
|
|
109.4
|
|
|
109.4
|
|
|||||
Other invested assets:
|
|
|
|
|
|
|
|
|
|
||||||||||
Company-owned life insurance
|
—
|
|
|
158.1
|
|
|
—
|
|
|
158.1
|
|
|
158.1
|
|
|||||
Cash and cash equivalents:
|
|
|
|
|
|
|
|
|
|
||||||||||
Unrestricted
|
432.3
|
|
|
—
|
|
|
—
|
|
|
432.3
|
|
|
432.3
|
|
|||||
Held by variable interest entities
|
364.4
|
|
|
—
|
|
|
—
|
|
|
364.4
|
|
|
364.4
|
|
|||||
Liabilities:
|
|
|
|
|
|
|
|
|
|
||||||||||
Policyholder account balances
|
—
|
|
|
—
|
|
|
10,762.3
|
|
|
10,762.3
|
|
|
10,762.3
|
|
|||||
Investment borrowings
|
—
|
|
|
1,549.8
|
|
|
—
|
|
|
1,549.8
|
|
|
1,548.1
|
|
|||||
Borrowings related to variable interest entities
|
—
|
|
|
1,673.6
|
|
|
—
|
|
|
1,673.6
|
|
|
1,676.4
|
|
|||||
Notes payable – direct corporate obligations
|
—
|
|
|
937.8
|
|
|
—
|
|
|
937.8
|
|
|
911.1
|
|
|
|
December 31, 2016
|
|
|
||||||||||||||||||||||||||||
|
|
Beginning balance as of December 31, 2015
|
|
Purchases, sales, issuances and settlements, net (b)
|
|
Total realized and unrealized gains (losses) included in net income
|
|
Total realized and unrealized gains (losses) included in accumulated other comprehensive income (loss)
|
|
Transfers into Level 3 (a)
|
|
Transfers out of Level 3 (a)
|
|
Ending balance as of December 31, 2016
|
|
Amount of total gains (losses) for the year ended December 31, 2016 included in our net income relating to assets and liabilities still held as of the reporting date
|
||||||||||||||||
Assets:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||||||
Fixed maturities, available for sale:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||||||
Corporate securities
|
|
$
|
170.4
|
|
|
$
|
76.5
|
|
|
$
|
(10.7
|
)
|
|
$
|
9.1
|
|
|
$
|
20.3
|
|
|
$
|
(7.1
|
)
|
|
$
|
258.5
|
|
|
$
|
(10.9
|
)
|
Debt securities issued by foreign governments
|
|
—
|
|
|
4.0
|
|
|
—
|
|
|
(.1
|
)
|
|
—
|
|
|
—
|
|
|
3.9
|
|
|
—
|
|
||||||||
Asset-backed securities
|
|
35.9
|
|
|
9.7
|
|
|
—
|
|
|
2.2
|
|
|
26.3
|
|
|
(13.7
|
)
|
|
60.4
|
|
|
—
|
|
||||||||
Collateralized debt obligations
|
|
—
|
|
|
5.4
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
5.4
|
|
|
—
|
|
||||||||
Commercial mortgage-backed securities
|
|
1.1
|
|
|
16.9
|
|
|
—
|
|
|
.1
|
|
|
13.9
|
|
|
—
|
|
|
32.0
|
|
|
—
|
|
||||||||
Mortgage pass-through securities
|
|
.1
|
|
|
(.1
|
)
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
||||||||
Total fixed maturities, available for sale
|
|
207.5
|
|
|
112.4
|
|
|
(10.7
|
)
|
|
11.3
|
|
|
60.5
|
|
|
(20.8
|
)
|
|
360.2
|
|
|
(10.9
|
)
|
||||||||
Equity securities - corporate securities
|
|
32.0
|
|
|
5.5
|
|
|
(12.7
|
)
|
|
.4
|
|
|
—
|
|
|
—
|
|
|
25.2
|
|
|
(12.7
|
)
|
||||||||
Trading securities - commercial mortgage-backed securities
|
|
39.9
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
(39.9
|
)
|
|
—
|
|
|
—
|
|
||||||||
Liabilities:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||
Future policy benefits - embedded derivatives associated with fixed index annuity products
|
|
(1,057.1
|
)
|
|
(96.0
|
)
|
|
60.8
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
(1,092.3
|
)
|
|
60.8
|
|
(a)
|
Transfers into Level 3 are the result of unobservable inputs utilized within valuation methodologies for assets that were previously valued using observable inputs. Transfers out of Level 3 are due to the use of observable inputs in valuation methodologies as well as the utilization of pricing service information for certain assets that the Company is able to validate.
|
(b)
|
Purchases, sales, issuances and settlements, net, represent the activity that occurred during the period that results in a change of the asset or liability but does not represent changes in fair value for the instruments held at the beginning of the period. Such activity primarily consists of purchases and sales of fixed maturity and equity securities and changes to embedded derivative instruments related to insurance products resulting from the issuance of new contracts, or changes to existing contracts. In addition, such activity includes the investments received upon the recapture of reinsurance agreements with BRe on September 29, 2016. The following summarizes such activity for the year ended
December 31, 2016
(dollars in millions):
|
|
Purchases
|
|
Received in reinsurance recapture
|
|
Sales
|
|
Issuances
|
|
Settlements
|
|
Purchases, sales, issuances and settlements, net
|
||||||||||||
Assets:
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||
Fixed maturities, available for sale:
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||
Corporate securities
|
$
|
18.5
|
|
|
$
|
89.2
|
|
|
$
|
(31.2
|
)
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
76.5
|
|
Debt securities issued by foreign governments
|
4.0
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
4.0
|
|
||||||
Asset-backed securities
|
16.9
|
|
|
—
|
|
|
(7.2
|
)
|
|
—
|
|
|
—
|
|
|
9.7
|
|
||||||
Collateralized debt obligations
|
5.4
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
5.4
|
|
||||||
Commercial mortgage-backed securities
|
17.0
|
|
|
—
|
|
|
(.1
|
)
|
|
—
|
|
|
—
|
|
|
16.9
|
|
||||||
Mortgage pass-through securities
|
—
|
|
|
—
|
|
|
(.1
|
)
|
|
—
|
|
|
—
|
|
|
(.1
|
)
|
||||||
Total fixed maturities, available for sale
|
61.8
|
|
|
89.2
|
|
|
(38.6
|
)
|
|
—
|
|
|
—
|
|
|
112.4
|
|
||||||
Equity securities - corporate securities
|
3.3
|
|
|
2.2
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
5.5
|
|
||||||
Trading securities - corporate securities
|
.2
|
|
|
—
|
|
|
(.2
|
)
|
|
—
|
|
|
—
|
|
|
—
|
|
||||||
Liabilities:
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||
Future policy benefits - embedded derivatives associated with fixed index annuity products
|
(148.3
|
)
|
|
—
|
|
|
21.2
|
|
|
(28.9
|
)
|
|
60.0
|
|
|
(96.0
|
)
|
|
December 31, 2015
|
|
|
||||||||||||||||||||||||||||
|
Beginning balance as of December 31, 2014
|
|
Purchases, sales, issuances and settlements, net (b)
|
|
Total realized and unrealized gains (losses) included in net income
|
|
Total realized and unrealized gains (losses) included in accumulated other comprehensive income (loss)
|
|
Transfers into Level 3 (a)
|
|
Transfers out of Level 3 (a)
|
|
Ending balance as of December 31, 2015
|
|
Amount of total gains (losses) for the year ended December 31, 2015 included in our net income relating to assets and liabilities still held as of the reporting date
|
||||||||||||||||
Assets:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||||||
Fixed maturities, available for sale:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||||||
Corporate securities
|
$
|
365.9
|
|
|
$
|
31.0
|
|
|
$
|
(2.2
|
)
|
|
$
|
(19.5
|
)
|
|
$
|
37.4
|
|
|
$
|
(242.2
|
)
|
|
$
|
170.4
|
|
|
$
|
—
|
|
States and political subdivisions
|
35.5
|
|
|
(35.5
|
)
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
||||||||
Asset-backed securities
|
59.2
|
|
|
6.7
|
|
|
—
|
|
|
(1.4
|
)
|
|
—
|
|
|
(28.6
|
)
|
|
35.9
|
|
|
—
|
|
||||||||
Commercial mortgage-backed securities
|
1.2
|
|
|
(.1
|
)
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
1.1
|
|
|
—
|
|
||||||||
Mortgage pass-through securities
|
.4
|
|
|
(.3
|
)
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
.1
|
|
|
—
|
|
||||||||
Total fixed maturities, available for sale
|
462.2
|
|
|
1.8
|
|
|
(2.2
|
)
|
|
(20.9
|
)
|
|
37.4
|
|
|
(270.8
|
)
|
|
207.5
|
|
|
—
|
|
||||||||
Equity securities - corporate securities
|
28.0
|
|
|
4.0
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
32.0
|
|
|
—
|
|
||||||||
Trading securities - commercial mortgage-backed securities
|
28.6
|
|
|
9.5
|
|
|
—
|
|
|
1.8
|
|
|
—
|
|
|
—
|
|
|
39.9
|
|
|
1.8
|
|
||||||||
Liabilities:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||
Future policy benefits - embedded derivatives associated with fixed index annuity products
|
(1,081.5
|
)
|
|
(11.9
|
)
|
|
36.3
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
(1,057.1
|
)
|
|
36.3
|
|
(a)
|
Transfers into Level 3 are the result of unobservable inputs utilized within valuation methodologies for assets that were previously valued using observable inputs. Transfers out of Level 3 are due to the use of observable inputs in valuation methodologies as well as the utilization of pricing service information for certain assets that the Company is able to validate.
|
(b)
|
Purchases, sales, issuances and settlements, net, represent the activity that occurred during the period that results in a change of the asset or liability but does not represent changes in fair value for the instruments held at the beginning of the period. Such activity primarily consists of purchases and sales of fixed maturity and equity securities and changes to embedded derivative instruments related to insurance products resulting from the issuance of new contracts, or changes to existing contracts. The following summarizes such activity for the year ended
December 31, 2015
(dollars in millions):
|
|
Purchases
|
|
Sales
|
|
Issuances
|
|
Settlements
|
|
Purchases, sales, issuances and settlements, net
|
||||||||||
Assets:
|
|
|
|
|
|
|
|
|
|
||||||||||
Fixed maturities, available for sale:
|
|
|
|
|
|
|
|
|
|
||||||||||
Corporate securities
|
$
|
62.2
|
|
|
$
|
(31.2
|
)
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
31.0
|
|
States and political subdivisions
|
—
|
|
|
(35.5
|
)
|
|
—
|
|
|
—
|
|
|
(35.5
|
)
|
|||||
Asset-backed securities
|
13.7
|
|
|
(7.0
|
)
|
|
—
|
|
|
—
|
|
|
6.7
|
|
|||||
Commercial mortgage-backed securities
|
—
|
|
|
(.1
|
)
|
|
—
|
|
|
—
|
|
|
(.1
|
)
|
|||||
Mortgage pass-through securities
|
—
|
|
|
(.3
|
)
|
|
—
|
|
|
—
|
|
|
(.3
|
)
|
|||||
Total fixed maturities, available for sale
|
75.9
|
|
|
(74.1
|
)
|
|
—
|
|
|
—
|
|
|
1.8
|
|
|||||
Equity securities - corporate securities
|
4.0
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
4.0
|
|
|||||
Trading securities - commercial mortgage-backed securities
|
9.5
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
9.5
|
|
|||||
Liabilities:
|
|
|
|
|
|
|
|
|
|
||||||||||
Future policy benefits - embedded derivatives associated with fixed index annuity products
|
(137.8
|
)
|
|
64.4
|
|
|
(4.0
|
)
|
|
65.5
|
|
|
(11.9
|
)
|
|
Fair value at December 31, 2016
|
|
Valuation techniques
|
|
Unobservable inputs
|
|
Range (weighted average)
|
||
Assets:
|
|
|
|
|
|
|
|
||
Corporate securities (a)
|
$
|
148.5
|
|
|
Discounted cash flow analysis
|
|
Discount margins
|
|
1.35% - 27.71% (13.52%)
|
Corporate securities (b)
|
14.8
|
|
|
Recovery method
|
|
Percent of recovery expected
|
|
5% - 69% (55%)
|
|
Asset-backed securities (c)
|
24.0
|
|
|
Discounted cash flow analysis
|
|
Discount margins
|
|
2.06% - 3.64% (2.76%)
|
|
Equity security (d)
|
25.2
|
|
|
Market multiple
|
|
Projected cash flows
|
|
0.4% - 6.2% (5.9%)
|
|
Other assets categorized as Level 3 (e)
|
172.9
|
|
|
Unadjusted third-party price source
|
|
Not applicable
|
|
Not applicable
|
|
Total
|
385.4
|
|
|
|
|
|
|
|
|
Liabilities:
|
|
|
|
|
|
|
|
||
Future policy benefits (f)
|
1,092.3
|
|
|
Discounted projected embedded derivatives
|
|
Projected portfolio yields
|
|
5.15% - 5.61% (5.59%)
|
|
|
|
|
|
|
Discount rates
|
|
0.18 - 3.06% (2.07%)
|
||
|
|
|
|
|
Surrender rates
|
|
0.94% - 46.48% (13.52%)
|
(a)
|
Corporate securities - The significant unobservable input used in the fair value measurement of our corporate securities is discount margin added to a riskless market yield. Significant increases (decreases) in discount margin in isolation would result in a significantly lower (higher) fair value measurement.
|
(b)
|
Corporate securities - The significant unobservable input used in the fair value measurement of our corporate securities is percentage of recovery expected. Significant increases (decreases) in percentage of recovery expected in isolation would result in a significantly higher (lower) fair value measurement.
|
(c)
|
Asset-backed securities - The significant unobservable input used in the fair value measurement of these asset-backed securities is discount margin added to a riskless market yield. Significant increases (decreases) in discount margin in isolation would result in a significantly lower (higher) fair value measurement.
|
(d)
|
Equity securities - The significant unobservable input used in the fair value measurement of these equity securities is projected cash flows. Generally, increases (decreases) in the projected cash flows would result in higher (lower) fair value measurements.
|
(e)
|
Other assets categorized as Level 3 - For these assets, there were no adjustments to quoted market prices obtained from third-party pricing sources.
|
(f)
|
Future policy benefits - The significant unobservable inputs used in the fair value measurement of our embedded derivatives associated with fixed index annuity products are projected portfolio yields, discount rates and surrender rates. Increases (decreases) in projected portfolio yields in isolation would lead to a higher (lower) fair value measurement. The discount rate is based on the Treasury rate adjusted by a margin. Increases (decreases) in the discount rates would lead to a lower (higher) fair value measurement. Assumed surrender rates are used to project how long the contracts remain in force. Generally, the longer the contracts are assumed to be in force the higher the fair value of the embedded derivative.
|
|
Fair value at December 31, 2015
|
|
Valuation techniques
|
|
Unobservable inputs
|
|
Range (weighted average)
|
||
Assets:
|
|
|
|
|
|
|
|
||
Corporate securities (a)
|
$
|
76.9
|
|
|
Discounted cash flow analysis
|
|
Discount margins
|
|
1.65% - 9.74% (5.35%)
|
Asset-backed securities (b)
|
22.2
|
|
|
Discounted cash flow analysis
|
|
Discount margins
|
|
2.83% - 4.45% (3.50%)
|
|
Equity security (c)
|
32.0
|
|
|
Market approach
|
|
Projected cash flows
|
|
Not applicable
|
|
Other assets categorized as Level 3 (d)
|
148.3
|
|
|
Unadjusted third-party price source
|
|
Not applicable
|
|
Not applicable
|
|
Total
|
279.4
|
|
|
|
|
|
|
|
|
Liabilities:
|
|
|
|
|
|
|
|
||
Future policy benefits (e)
|
1,057.1
|
|
|
Discounted projected embedded derivatives
|
|
Projected portfolio yields
|
|
5.15% - 5.61% (5.42%)
|
|
|
|
|
|
|
Discount rates
|
|
0.00 - 3.18% (1.94%)
|
||
|
|
|
|
|
Surrender rates
|
|
1.67% - 46.56% (14.09%)
|
(a)
|
Corporate securities - The significant unobservable input used in the fair value measurement of our corporate securities is discount margin added to a riskless market yield. Significant increases (decreases) in discount margin in isolation would result in a significantly lower (higher) fair value measurement.
|
(b)
|
Asset-backed securities - The significant unobservable input used in the fair value measurement of these asset-backed securities is discount margin added to a riskless market yield. Significant increases (decreases) in discount margin in isolation would result in a significantly lower (higher) fair value measurement.
|
(c)
|
Equity security - This equity security represents an investment in a company that is constructing a manufacturing facility. The significant unobservable input is the cash flows that will be generated upon completion of the manufacturing facility. Given the nature of this investment, the best current indicator of value is the cost basis of the investment, which we believe approximates market value.
|
(d)
|
Other assets categorized as Level 3 - For these assets, there were no adjustments to quoted market prices obtained from third-party pricing sources.
|
(e)
|
Future policy benefits - The significant unobservable inputs used in the fair value measurement of our embedded derivatives associated with fixed index annuity products are projected portfolio yields, discount rates and surrender rates. Increases (decreases) in projected portfolio yields in isolation would lead to a higher (lower) fair value measurement. The discount rate is based on the Treasury rate adjusted by a margin. Increases (decreases) in the discount rates would lead to a lower (higher) fair value measurement. Assumed surrender rates are used to project how long the contracts remain in force. Generally, the longer the contracts are assumed to be in force the higher the fair value of the embedded derivative.
|
|
Withdrawal assumption
|
|
Morbidity assumption
|
|
Mortality assumption
|
|
Interest rate assumption
|
|
2016
|
|
2015
|
||||
|
|
|
|
|
|
|
|
|
|
|
|
||||
Long-term care
|
Company experience
|
|
Company experience
|
|
Company experience
|
|
6%
|
|
$
|
5,346.1
|
|
|
$
|
5,172.2
|
|
Traditional life insurance contracts
|
Company experience
|
|
Company experience
|
|
(a)
|
|
5%
|
|
2,322.1
|
|
|
2,248.7
|
|
||
Accident and health contracts
|
Company experience
|
|
Company experience
|
|
Company experience
|
|
5%
|
|
2,695.6
|
|
|
2,589.9
|
|
||
Interest-sensitive life insurance contracts
|
Company experience
|
|
Company experience
|
|
Company experience
|
|
5%
|
|
52.2
|
|
|
44.7
|
|
||
Annuities and supplemental contracts with life contingencies
|
Company experience
|
|
Company experience
|
|
(b)
|
|
4%
|
|
537.3
|
|
|
546.6
|
|
||
Total
|
|
|
|
|
|
|
|
|
$
|
10,953.3
|
|
|
$
|
10,602.1
|
|
(a)
|
Principally, modifications of: (i) the 1965 ‑ 70 and 1975 - 80 Basic Tables; and (ii) the 1941, 1958 and 1980 Commissioners' Standard Ordinary Tables; as well as Company experience.
|
(b)
|
Principally, modifications of: (i) the 1971 Individual Annuity Mortality Table; (ii) the 1983 Table "A"; and (iii) the Annuity 2000 Mortality Table; as well as Company experience.
|
|
|
2016
|
|
2015
|
||||
Fixed index annuities
|
|
$
|
5,324.5
|
|
|
$
|
4,884.4
|
|
Other annuities
|
|
4,541.8
|
|
|
4,885.1
|
|
||
Interest-sensitive life insurance contracts
|
|
1,046.4
|
|
|
992.8
|
|
||
Total
|
|
$
|
10,912.7
|
|
|
$
|
10,762.3
|
|
|
2016
|
|
2015
|
|
2014
|
||||||
Balance, beginning of year
|
$
|
1,731.8
|
|
|
$
|
1,679.5
|
|
|
$
|
1,710.1
|
|
Less reinsurance receivables
|
(130.0
|
)
|
|
(125.0
|
)
|
|
(164.1
|
)
|
|||
Net balance, beginning of year
|
1,601.8
|
|
|
1,554.5
|
|
|
1,546.0
|
|
|||
Incurred claims related to:
|
|
|
|
|
|
||||||
Current year
|
1,526.4
|
|
|
1,481.0
|
|
|
1,468.1
|
|
|||
Prior years (a)
|
96.6
|
|
|
(13.3
|
)
|
|
(39.9
|
)
|
|||
Total incurred
|
1,623.0
|
|
|
1,467.7
|
|
|
1,428.2
|
|
|||
Interest on claim reserves
|
75.3
|
|
|
71.0
|
|
|
70.5
|
|
|||
Paid claims related to:
|
|
|
|
|
|
||||||
Current year
|
837.2
|
|
|
841.8
|
|
|
848.7
|
|
|||
Prior years
|
671.3
|
|
|
649.6
|
|
|
641.5
|
|
|||
Total paid
|
1,508.5
|
|
|
1,491.4
|
|
|
1,490.2
|
|
|||
Net balance, end of year
|
1,791.6
|
|
|
1,601.8
|
|
|
1,554.5
|
|
|||
Add reinsurance receivables (payables)
|
(14.0
|
)
|
|
130.0
|
|
|
125.0
|
|
|||
Balance, end of year
|
$
|
1,777.6
|
|
|
$
|
1,731.8
|
|
|
$
|
1,679.5
|
|
(a)
|
The reserves and liabilities we establish are necessarily based on estimates, assumptions and prior years' statistics. Such amounts will fluctuate based upon the estimation procedures used to determine the amount of unpaid losses. It is possible that actual claims will exceed our reserves and have a material adverse effect on our results of operations and financial condition.
|
|
2016
|
|
2015
|
|
2014
|
||||||
Current tax expense (benefit)
|
$
|
(45.2
|
)
|
|
$
|
10.7
|
|
|
$
|
15.6
|
|
Deferred tax expense
|
173.0
|
|
|
118.6
|
|
|
143.6
|
|
|||
Valuation allowance applicable to current year income
|
(14.0
|
)
|
|
—
|
|
|
—
|
|
|||
Income tax expense calculated based on estimated annual effective tax rate
|
113.8
|
|
|
129.3
|
|
|
159.2
|
|
|||
Income tax expense on discrete items:
|
|
|
|
|
|
||||||
Tax expense related to the sale of Conseco Life Insurance Company (a)
|
—
|
|
|
—
|
|
|
14.2
|
|
|||
Change in valuation allowance
|
40.7
|
|
|
(32.5
|
)
|
|
(48.8
|
)
|
|||
IRS settlement
|
(170.4
|
)
|
|
—
|
|
|
—
|
|
|||
Other items
|
10.9
|
|
|
.2
|
|
|
(.9
|
)
|
|||
Total income tax expense (benefit)
|
$
|
(5.0
|
)
|
|
$
|
97.0
|
|
|
$
|
123.7
|
|
|
2016
|
|
2015
|
|
2014
|
|||
U.S. statutory corporate rate
|
35.0
|
%
|
|
35.0
|
%
|
|
35.0
|
%
|
Valuation allowance
|
7.6
|
|
|
(8.8
|
)
|
|
(27.9
|
)
|
Non-taxable income and nondeductible benefits, net
|
(1.1
|
)
|
|
(.2
|
)
|
|
(.9
|
)
|
State taxes
|
2.2
|
|
|
2.1
|
|
|
1.5
|
|
Impact of IRS settlement
|
(48.2
|
)
|
|
—
|
|
|
—
|
|
Impact of the sale of CLIC
|
—
|
|
|
—
|
|
|
66.3
|
|
Other items
|
3.1
|
|
|
(1.7
|
)
|
|
(3.4
|
)
|
Effective tax rate
|
(1.4
|
)%
|
|
26.4
|
%
|
|
70.6
|
%
|
|
2016
|
|
2015
|
||||
Deferred tax assets:
|
|
|
|
||||
Net federal operating loss carryforwards
|
$
|
882.9
|
|
|
$
|
916.3
|
|
Net state operating loss carryforwards
|
12.3
|
|
|
14.1
|
|
||
Tax credits
|
.7
|
|
|
55.3
|
|
||
Capital loss carryforwards
|
—
|
|
|
13.8
|
|
||
Investments
|
17.8
|
|
|
26.5
|
|
||
Insurance liabilities
|
668.4
|
|
|
600.3
|
|
||
Other
|
65.6
|
|
|
63.0
|
|
||
Gross deferred tax assets
|
1,647.7
|
|
|
1,689.3
|
|
||
Deferred tax liabilities:
|
|
|
|
|
|
||
Present value of future profits and deferred acquisition costs
|
(277.8
|
)
|
|
(305.4
|
)
|
||
Accumulated other comprehensive income
|
(344.1
|
)
|
|
(223.8
|
)
|
||
Gross deferred tax liabilities
|
(621.9
|
)
|
|
(529.2
|
)
|
||
Net deferred tax assets before valuation allowance
|
1,025.8
|
|
|
1,160.1
|
|
||
Valuation allowance
|
(240.2
|
)
|
|
(213.5
|
)
|
||
Net deferred tax assets
|
785.6
|
|
|
946.6
|
|
||
Current income taxes prepaid (accrued)
|
4.1
|
|
|
(47.8
|
)
|
||
Income tax assets, net
|
$
|
789.7
|
|
|
$
|
898.8
|
|
Balance, December 31, 2013
|
$
|
294.8
|
|
|
Decrease in 2014
|
(48.8
|
)
|
(a)
|
|
Balance, December 31, 2014
|
246.0
|
|
|
|
Decrease in 2015
|
(32.5
|
)
|
(b)
|
|
Balance, December 31, 2015
|
213.5
|
|
|
|
Increase in 2016
|
26.7
|
|
(c)
|
|
Balance, December 31, 2016
|
$
|
240.2
|
|
|
(a)
|
The
2014
reduction to the deferred tax valuation allowance primarily resulted from tax examination adjustments and the tax gain on the sale of CLIC.
|
(b)
|
The
2015
reduction to the deferred tax valuation allowance primarily resulted from higher actual and projected non-life income.
|
(c)
|
The
2016
increase to the deferred tax valuation allowance primarily resulted from additional non-life NOLs due to the settlement with the Internal Revenue Service (the "IRS").
|
|
|
Net operating loss
|
||
Year of expiration
|
|
carryforwards
|
||
2023
|
|
$
|
1,936.0
|
|
2025
|
|
85.2
|
|
|
2026
|
|
149.9
|
|
|
2027
|
|
10.8
|
|
|
2028
|
|
80.3
|
|
|
2029
|
|
213.2
|
|
|
2030
|
|
.3
|
|
|
2031
|
|
.2
|
|
|
2032
|
|
44.4
|
|
|
2033
|
|
.6
|
|
|
2034
|
|
1.7
|
|
|
Total federal NOLs
|
|
$
|
2,522.6
|
|
|
Years ended December 31,
|
||||||
|
2016
|
|
2015
|
||||
|
|
|
|
||||
Balance at beginning of year
|
$
|
234.2
|
|
|
$
|
228.7
|
|
Increase based on tax positions taken in prior years
|
3.4
|
|
|
5.5
|
|
||
Decrease in unrecognized tax benefits related to settlements with taxing authorities
|
(237.6
|
)
|
|
—
|
|
||
Balance at end of year
|
$
|
—
|
|
|
$
|
234.2
|
|
|
2016
|
|
2015
|
||||
4.500% Senior Notes due May 2020
|
$
|
325.0
|
|
|
$
|
325.0
|
|
5.250% Senior Notes due May 2025
|
500.0
|
|
|
500.0
|
|
||
Revolving Credit Agreement (as defined below)
|
100.0
|
|
|
100.0
|
|
||
Unamortized debt issuance costs
|
(12.1
|
)
|
|
(13.9
|
)
|
||
Direct corporate obligations
|
$
|
912.9
|
|
|
$
|
911.1
|
|
•
|
incur certain subsidiary indebtedness without also guaranteeing the Notes;
|
•
|
create liens;
|
•
|
enter into sale and leaseback transactions;
|
•
|
issue, sell, transfer or otherwise dispose of any shares of capital stock of any Insurance Subsidiary (as defined in the Indenture); and
|
•
|
consolidate or merge with or into other companies or transfer all or substantially all of the Company’s assets.
|
•
|
subsidiary debt;
|
•
|
liens;
|
•
|
restrictive agreements;
|
•
|
restricted payments during the continuance of an event of default;
|
•
|
disposition of assets and sale and leaseback transactions;
|
•
|
transactions with affiliates;
|
•
|
change in business;
|
•
|
fundamental changes;
|
•
|
modification of certain agreements; and
|
•
|
changes to fiscal year.
|
•
|
non-payment;
|
•
|
breach of representations, warranties or covenants;
|
•
|
cross-default and cross-acceleration;
|
•
|
bankruptcy and insolvency events;
|
•
|
judgment defaults;
|
•
|
actual or asserted invalidity of documentation with respect to the Revolving Credit Agreement;
|
•
|
change of control; and
|
•
|
customary ERISA defaults.
|
Sources:
|
|
|||
|
Notes
|
$
|
825.0
|
|
|
New Revolving Credit Agreement
|
100.0
|
|
|
|
Total sources
|
$
|
925.0
|
|
|
|
|
||
Uses:
|
|
|||
|
Repayment of Previous Senior Secured Credit Agreement
|
$
|
502.3
|
|
|
Repayment of 6.375% Notes, including redemption premium
|
292.8
|
|
|
|
Accrued interest
|
4.3
|
|
|
|
Debt issuance costs
|
16.0
|
|
|
|
General corporate purposes
|
109.6
|
|
|
|
Total uses
|
$
|
925.0
|
|
Year ending December 31,
|
|
||
2017
|
$
|
—
|
|
2018
|
—
|
|
|
2019
|
100.0
|
|
|
2020
|
325.0
|
|
|
2021
|
—
|
|
|
Thereafter
|
500.0
|
|
|
|
$
|
925.0
|
|
2017
|
$
|
32.0
|
|
2018
|
26.5
|
|
|
2019
|
13.2
|
|
|
2020
|
7.7
|
|
|
2021
|
5.0
|
|
|
Thereafter
|
5.9
|
|
|
Total
|
$
|
90.3
|
|
|
2016
|
|
2015
|
||
Benefit obligations:
|
|
|
|
||
Discount rate
|
4.25
|
%
|
|
4.50
|
%
|
Net periodic cost:
|
|
|
|
||
Discount rate
|
4.50
|
%
|
|
4.15
|
%
|
2017
|
$
|
7.0
|
|
2018
|
7.4
|
|
|
2019
|
7.5
|
|
|
2020
|
7.7
|
|
|
2021
|
7.9
|
|
|
2022 - 2026
|
43.1
|
|
|
|
Fair value
|
||||||
|
|
2016
|
|
2015
|
||||
Assets:
|
|
|
|
|
||||
Other invested assets:
|
|
|
|
|
||||
Fixed index call options
|
|
$
|
111.9
|
|
|
$
|
41.0
|
|
Interest rate futures
|
|
—
|
|
|
.1
|
|
||
Reinsurance receivables
|
|
(4.2
|
)
|
|
(5.0
|
)
|
||
Total assets
|
|
$
|
107.7
|
|
|
$
|
36.1
|
|
Liabilities:
|
|
|
|
|
||||
Future policy benefits:
|
|
|
|
|
||||
Fixed index products
|
|
$
|
1,092.3
|
|
|
$
|
1,057.1
|
|
Total liabilities
|
|
$
|
1,092.3
|
|
|
$
|
1,057.1
|
|
|
|
Measurement
|
|
December 31, 2015
|
|
Additions
|
|
Maturities/terminations
|
|
December 31, 2016
|
||||||||
Interest futures
|
|
Contracts
|
|
264
|
|
|
378
|
|
|
(642
|
)
|
|
—
|
|
||||
Fixed index annuities - embedded derivative
|
|
Policies
|
|
96,660
|
|
|
11,237
|
|
|
(7,085
|
)
|
|
100,812
|
|
||||
Fixed index call options
|
|
Notional (a)
|
|
$
|
2,379.7
|
|
|
$
|
2,452.5
|
|
|
$
|
(2,377.1
|
)
|
|
$
|
2,455.1
|
|
|
|
2016
|
|
2015
|
|
2014
|
||||||
Net investment income from policyholder and reinsurer accounts and other special-purpose portfolios:
|
|
|
|
|
|
|
||||||
Fixed index call options
|
|
$
|
29.2
|
|
|
$
|
(36.2
|
)
|
|
$
|
69.5
|
|
Embedded derivative related to reinsurance contract
|
|
—
|
|
|
—
|
|
|
(1.4
|
)
|
|||
Total
|
|
29.2
|
|
|
(36.2
|
)
|
|
68.1
|
|
|||
Net realized gains (losses):
|
|
|
|
|
|
|
||||||
Interest rate futures
|
|
(1.1
|
)
|
|
(2.7
|
)
|
|
(7.0
|
)
|
|||
Embedded derivative related to modified coinsurance agreement
|
|
.8
|
|
|
(7.0
|
)
|
|
2.0
|
|
|||
Total
|
|
(.3
|
)
|
|
(9.7
|
)
|
|
(5.0
|
)
|
|||
Insurance policy benefits:
|
|
|
|
|
|
|
||||||
Embedded derivative related to fixed index annuities
|
|
60.8
|
|
|
36.3
|
|
|
(73.5
|
)
|
|||
Total
|
|
$
|
89.7
|
|
|
$
|
(9.6
|
)
|
|
$
|
(10.4
|
)
|
|
|
|
|
|
|
|
|
|
Gross amounts not offset in the balance sheet
|
|
|
||||||||||||||
|
|
|
Gross amounts recognized
|
|
Gross amounts offset in the balance sheet
|
|
Net amounts of assets presented in the balance sheet
|
|
Financial instruments
|
|
Cash collateral received
|
|
Net amount
|
||||||||||||
December 31, 2016:
|
|
|
|||||||||||||||||||||||
|
Fixed index call options
|
|
$
|
111.9
|
|
|
$
|
—
|
|
|
$
|
111.9
|
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
111.9
|
|
|
Interest rate futures
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
||||||
December 31, 2015:
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||
|
Fixed index call options
|
|
41.0
|
|
|
—
|
|
|
41.0
|
|
|
—
|
|
|
—
|
|
|
41.0
|
|
||||||
|
Interest rate futures
|
|
.1
|
|
|
1.5
|
|
|
1.6
|
|
|
—
|
|
|
—
|
|
|
1.6
|
|
|
2016
|
|
2015
|
|
2014
|
|||
Balance, beginning of year
|
184,029
|
|
|
203,324
|
|
|
220,324
|
|
Treasury stock purchased and retired
|
(11,688
|
)
|
|
(20,582
|
)
|
|
(18,489
|
)
|
Stock options exercised
|
978
|
|
|
769
|
|
|
916
|
|
Restricted and performance stock vested (a)
|
435
|
|
|
518
|
|
|
573
|
|
Balance, end of year
|
173,754
|
|
|
184,029
|
|
|
203,324
|
|
(a)
|
In
2016
,
2015
and
2014
, such amount was reduced by
191 thousand
,
237 thousand
and
257 thousand
shares, respectively, which were tendered to the Company for the payment of required federal and state tax withholdings owed on the vesting of restricted and performance stock.
|
|
Shares
|
|
Weighted average exercise price
|
|
Weighted average remaining life (in years)
|
|
Aggregate intrinsic value
|
|||||
Outstanding at the beginning of the year
|
5,199
|
|
|
$
|
13.32
|
|
|
|
|
|
||
Options granted
|
1,706
|
|
|
17.45
|
|
|
|
|
|
|||
Exercised
|
(978
|
)
|
|
(8.70
|
)
|
|
|
|
$
|
6.1
|
|
|
Forfeited or terminated
|
(573
|
)
|
|
(20.41
|
)
|
|
|
|
|
|||
Outstanding at the end of the year
|
5,354
|
|
|
14.73
|
|
|
5.9
|
|
$
|
37.1
|
|
|
Options exercisable at the end of the year
|
2,187
|
|
|
|
|
2.7
|
|
$
|
15.1
|
|
||
Available for future grant
|
4,620
|
|
|
|
|
|
|
|
|
Shares
|
|
Weighted average exercise price
|
|
Weighted average remaining life (in years)
|
|
Aggregate intrinsic value
|
|||||
Outstanding at the beginning of the year
|
5,011
|
|
|
$
|
12.04
|
|
|
|
|
|
||
Options granted
|
1,361
|
|
|
16.45
|
|
|
|
|
|
|||
Exercised
|
(769
|
)
|
|
(8.20
|
)
|
|
|
|
$
|
4.8
|
|
|
Forfeited or terminated
|
(404
|
)
|
|
(17.70
|
)
|
|
|
|
|
|||
Outstanding at the end of the year
|
5,199
|
|
|
13.32
|
|
|
4.8
|
|
$
|
38.4
|
|
|
Options exercisable at the end of the year
|
2,399
|
|
|
|
|
2.5
|
|
$
|
15.3
|
|
||
Available for future grant
|
6,882
|
|
|
|
|
|
|
|
|
Shares
|
|
Weighted average exercise price
|
|
Weighted average remaining life (in years)
|
|
Aggregate intrinsic value
|
|||||
Outstanding at the beginning of the year
|
5,579
|
|
|
$
|
10.64
|
|
|
|
|
|
||
Options granted
|
1,014
|
|
|
19.10
|
|
|
|
|
|
|||
Exercised
|
(917
|
)
|
|
(5.47
|
)
|
|
|
|
$
|
3.8
|
|
|
Forfeited or terminated
|
(665
|
)
|
|
(20.07
|
)
|
|
|
|
|
|||
Outstanding at the end of the year
|
5,011
|
|
|
12.04
|
|
|
4.3
|
|
$
|
32.1
|
|
|
Options exercisable at the end of the year
|
2,030
|
|
|
|
|
2.7
|
|
$
|
12.1
|
|
||
Available for future grant
|
8,571
|
|
|
|
|
|
|
|
|
2016
|
|
2015
|
|
2014
|
||||||
|
Grants
|
|
Grants
|
|
Grants
|
||||||
Weighted average risk-free interest rates
|
1.4
|
%
|
|
1.7
|
%
|
|
1.6
|
%
|
|||
Weighted average dividend yields
|
1.6
|
%
|
|
1.5
|
%
|
|
1.3
|
%
|
|||
Volatility factors
|
36
|
%
|
|
85
|
%
|
|
51
|
%
|
|||
Weighted average expected life (in years)
|
6.3
|
|
|
6.3
|
|
|
4.8
|
|
|||
Weighted average fair value per share
|
$
|
5.48
|
|
|
$
|
10.83
|
|
|
$
|
7.65
|
|
|
|
|
|
Options outstanding
|
|
Options exercisable
|
||||||||||
Range of exercise prices
|
|
Number outstanding
|
|
Remaining life (in years)
|
|
Average exercise price
|
|
Number exercisable
|
|
Average exercise price
|
||||||
$6.45 - $7.51
|
|
922
|
|
|
1.6
|
|
$
|
7.29
|
|
|
922
|
|
|
$
|
7.29
|
|
$10.88 - $16.22
|
|
860
|
|
|
3.2
|
|
11.09
|
|
|
846
|
|
|
11.02
|
|
||
$16.42 - $19.15
|
|
3,572
|
|
|
7.7
|
|
17.52
|
|
|
419
|
|
|
19.08
|
|
||
|
|
5,354
|
|
|
|
|
|
|
2,187
|
|
|
|
|
Shares
|
|
Weighted average grant date fair value
|
|||
Non-vested shares, beginning of year
|
95
|
|
|
$
|
15.66
|
|
Granted
|
401
|
|
|
18.17
|
|
|
Vested
|
(126
|
)
|
|
16.53
|
|
|
Forfeited
|
(1
|
)
|
|
16.80
|
|
|
Non-vested shares, end of year
|
369
|
|
|
18.10
|
|
|
Total shareholder return awards
|
|
Operating return on equity awards
|
|
Pre-tax operating income awards
|
|||
Awards outstanding at December 31, 2013
|
382
|
|
|
204
|
|
|
470
|
|
Granted in 2014
|
142
|
|
|
142
|
|
|
—
|
|
Additional shares issued pursuant to achieving certain performance criteria (a)
|
—
|
|
|
—
|
|
|
142
|
|
Shares vested in 2014
|
—
|
|
|
—
|
|
|
(434
|
)
|
Forfeited
|
(5
|
)
|
|
(3
|
)
|
|
(2
|
)
|
Awards outstanding at December 31, 2014
|
519
|
|
|
343
|
|
|
176
|
|
Granted in 2015
|
258
|
|
|
258
|
|
|
—
|
|
Additional shares issued pursuant to achieving certain performance criteria (a)
|
85
|
|
|
—
|
|
|
85
|
|
Shares vested in 2015
|
(260
|
)
|
|
—
|
|
|
(260
|
)
|
Forfeited
|
(53
|
)
|
|
(52
|
)
|
|
(1
|
)
|
Awards outstanding at December 31, 2015
|
549
|
|
|
549
|
|
|
—
|
|
Granted in 2016
|
254
|
|
|
254
|
|
|
—
|
|
Additional shares issued pursuant to achieving certain performance criteria (a)
|
87
|
|
|
65
|
|
|
—
|
|
Shares vested in 2016
|
(261
|
)
|
|
(239
|
)
|
|
—
|
|
Forfeited
|
(59
|
)
|
|
(59
|
)
|
|
—
|
|
Awards outstanding at December 31, 2016
|
570
|
|
|
570
|
|
|
—
|
|
|
2016
|
|
2015
|
|
2014
|
||||||
Net income for diluted earnings per share
|
$
|
358.2
|
|
|
$
|
270.7
|
|
|
$
|
51.4
|
|
Shares:
|
|
|
|
|
|
|
|
||||
Weighted average shares outstanding for basic earnings per share
|
176,638
|
|
|
193,054
|
|
|
212,917
|
|
|||
Effect of dilutive securities on weighted average shares:
|
|
|
|
|
|
|
|||||
Stock options, restricted stock and performance units
|
1,685
|
|
|
2,112
|
|
|
2,505
|
|
|||
Warrants (a)
|
—
|
|
|
—
|
|
|
2,233
|
|
|||
Dilutive potential common shares
|
1,685
|
|
|
2,112
|
|
|
4,738
|
|
|||
Weighted average shares outstanding for diluted earnings per share
|
178,323
|
|
|
195,166
|
|
|
217,655
|
|
(a)
|
All outstanding warrants were repurchased in September 2014 as further discussed above. Accordingly, the warrants have no dilutive effect in periods beginning after September 30, 2014.
|
|
2016
|
|
2015
|
|
2014
|
||||||
Direct premiums collected
|
$
|
3,942.7
|
|
|
$
|
3,769.6
|
|
|
$
|
3,856.2
|
|
Reinsurance assumed
|
33.8
|
|
|
38.4
|
|
|
34.5
|
|
|||
Reinsurance ceded
|
(132.9
|
)
|
|
(142.8
|
)
|
|
(187.9
|
)
|
|||
Premiums collected, net of reinsurance
|
3,843.6
|
|
|
3,665.2
|
|
|
3,702.8
|
|
|||
Change in unearned premiums
|
6.2
|
|
|
5.9
|
|
|
9.1
|
|
|||
Less premiums on interest-sensitive life and products without mortality and morbidity risk which are recorded as additions to insurance liabilities
|
(1,386.7
|
)
|
|
(1,241.9
|
)
|
|
(1,295.4
|
)
|
|||
Premiums on traditional products with mortality or morbidity risk
|
2,463.1
|
|
|
2,429.2
|
|
|
2,416.5
|
|
|||
Fees and surrender charges on interest-sensitive products
|
138.0
|
|
|
126.8
|
|
|
213.2
|
|
|||
Insurance policy income
|
$
|
2,601.1
|
|
|
$
|
2,556.0
|
|
|
$
|
2,629.7
|
|
|
2016
|
|
2015
|
|
2014
|
||||||
Commission expense
|
$
|
110.5
|
|
|
$
|
103.8
|
|
|
$
|
99.4
|
|
Salaries and wages
|
231.0
|
|
|
205.2
|
|
|
242.4
|
|
|||
Other
|
454.8
|
|
|
430.2
|
|
|
461.0
|
|
|||
Total other operating costs and expenses
|
$
|
796.3
|
|
|
$
|
739.2
|
|
|
$
|
802.8
|
|
|
2016
|
|
2015
|
|
2014
|
||||||
Balance, beginning of year
|
$
|
449.0
|
|
|
$
|
489.4
|
|
|
$
|
679.3
|
|
Amortization
|
(62.2
|
)
|
|
(69.1
|
)
|
|
(76.2
|
)
|
|||
Effect of reinsurance transaction
|
—
|
|
|
—
|
|
|
5.0
|
|
|||
Amounts related to CLIC prior to being sold
|
—
|
|
|
—
|
|
|
(15.5
|
)
|
|||
Amounts related to changes in unrealized investment gains (losses) on fixed maturities, available for sale
|
15.0
|
|
|
28.7
|
|
|
(103.2
|
)
|
|||
Balance, end of year
|
$
|
401.8
|
|
|
$
|
449.0
|
|
|
$
|
489.4
|
|
|
2016
|
|
2015
|
|
2014
|
||||||
Balance, beginning of year
|
$
|
1,083.3
|
|
|
$
|
770.6
|
|
|
$
|
968.1
|
|
Additions
|
242.7
|
|
|
246.4
|
|
|
242.8
|
|
|||
Amortization
|
(191.1
|
)
|
|
(190.9
|
)
|
|
(171.2
|
)
|
|||
Effect of reinsurance transaction
|
—
|
|
|
—
|
|
|
24.0
|
|
|||
Amounts related to CLIC prior to being sold
|
—
|
|
|
—
|
|
|
(37.6
|
)
|
|||
Amounts related to changes in unrealized investment gains (losses) on fixed maturities, available for sale
|
(90.2
|
)
|
|
257.2
|
|
|
(255.5
|
)
|
|||
Balance, end of year
|
$
|
1,044.7
|
|
|
$
|
1,083.3
|
|
|
$
|
770.6
|
|
|
2016
|
|
2015
|
|
2014
|
|
||||||
Cash flows from operating activities:
|
|
|
|
|
|
|
||||||
Net income
|
$
|
358.2
|
|
|
$
|
270.7
|
|
|
$
|
51.4
|
|
|
Adjustments to reconcile net income to net cash from operating activities:
|
|
|
|
|
|
|
|
|||||
Amortization and depreciation
|
275.0
|
|
|
283.4
|
|
|
274.2
|
|
|
|||
Income taxes
|
(11.7
|
)
|
|
92.9
|
|
|
119.7
|
|
|
|||
Insurance liabilities
|
332.8
|
|
|
297.4
|
|
|
398.2
|
|
|
|||
Accrual and amortization of investment income
|
(124.2
|
)
|
|
(27.6
|
)
|
|
(148.3
|
)
|
|
|||
Deferral of policy acquisition costs
|
(242.7
|
)
|
|
(246.4
|
)
|
|
(242.8
|
)
|
|
|||
Net realized investment (gains) losses
|
(8.3
|
)
|
|
36.6
|
|
|
(36.7
|
)
|
|
|||
Payment to reinsurer pursuant to long-term care business reinsured
|
—
|
|
|
—
|
|
|
(590.3
|
)
|
|
|||
Loss on sale of subsidiary, (gain) loss on reinsurance transactions and transition expenses
|
75.4
|
|
|
9.0
|
|
|
239.8
|
|
|
|||
Cash and cash equivalents received upon recapture of reinsurance
|
73.6
|
|
|
—
|
|
|
—
|
|
|
|||
Loss on extinguishment or modification of debt
|
—
|
|
|
32.8
|
|
|
.6
|
|
|
|||
Other
|
31.4
|
|
|
(4.9
|
)
|
|
56.0
|
|
|
|||
Net cash from operating activities
|
$
|
759.5
|
|
|
$
|
743.9
|
|
|
$
|
121.8
|
|
(a)
|
(a)
|
Cash flows from operating activities reflect outflows in the 2014 period due to the payment to reinsurer to transfer certain long-term care business.
|
Investments
|
$
|
139.4
|
|
(a) (b)
|
Cash
|
7.7
|
|
|
|
Present value of future profits and deferred acquisition costs
|
29.0
|
|
(b)
|
|
Reinsurance receivables
|
(155.9
|
)
|
(b)
|
|
Other liabilities
|
5.9
|
|
(b)
|
|
Gain on reinsurance transaction (classified as "Loss on sale of subsidiary, (gain) loss on reinsurance transactions and transition expenses")
|
26.1
|
|
|
|
Income tax expense
|
9.2
|
|
|
|
Gain on reinsurance transaction (net of income taxes)
|
$
|
16.9
|
|
|
|
2016
|
|
2015
|
|
2014
|
||||||
Stock options, restricted stock and performance units
|
$
|
23.0
|
|
|
$
|
17.1
|
|
|
$
|
15.6
|
|
Market value of investments recaptured in connection with the termination of reinsurance agreements with BRe
|
431.1
|
|
|
$
|
—
|
|
|
$
|
—
|
|
|
2016
|
|
2015
|
||||
Statutory capital and surplus
|
$
|
1,956.8
|
|
|
$
|
1,739.2
|
|
Asset valuation reserve
|
253.3
|
|
|
196.9
|
|
||
Interest maintenance reserve
|
486.9
|
|
|
476.0
|
|
||
Total
|
$
|
2,697.0
|
|
|
$
|
2,412.1
|
|
Net cash proceeds
|
|
$
|
224.9
|
|
Net assets being sold:
|
|
|
||
Investments
|
|
3,863.8
|
|
|
Cash and cash equivalents
|
|
164.7
|
|
|
Accrued investment income
|
|
42.7
|
|
|
Present value of future profits
|
|
15.5
|
|
|
Deferred acquisition costs
|
|
37.6
|
|
|
Reinsurance receivables
|
|
307.4
|
|
|
Income tax assets, net
|
|
84.4
|
|
|
Other assets
|
|
2.8
|
|
|
Liabilities for insurance products
|
|
(3,201.3
|
)
|
|
Other liabilities
|
|
(199.1
|
)
|
|
Investment borrowings
|
|
(383.4
|
)
|
|
Accumulated other comprehensive income
|
|
(240.5
|
)
|
|
Net assets being sold
|
|
494.6
|
|
|
Loss before taxes
|
|
(269.7
|
)
|
|
Tax expense related to the sale
|
|
14.2
|
|
|
Valuation allowance release related to the tax on the sale
|
|
(14.2
|
)
|
|
Valuation allowance increase related to the decrease in projected future taxable income
|
|
19.4
|
|
|
Net loss
|
|
$
|
(289.1
|
)
|
|
2016
|
|
2015
|
|
2014
|
||||||
Revenues:
|
|
|
|
|
|
||||||
Bankers Life:
|
|
|
|
|
|
||||||
Insurance policy income:
|
|
|
|
|
|
||||||
Annuities
|
$
|
22.0
|
|
|
$
|
22.4
|
|
|
$
|
26.0
|
|
Health
|
1,244.1
|
|
|
1,251.0
|
|
|
1,287.1
|
|
|||
Life
|
393.0
|
|
|
375.3
|
|
|
338.6
|
|
|||
Net investment income (a)
|
936.8
|
|
|
884.7
|
|
|
957.3
|
|
|||
Fee revenue and other income (a)
|
34.4
|
|
|
27.7
|
|
|
29.3
|
|
|||
Total Bankers Life revenues
|
2,630.3
|
|
|
2,561.1
|
|
|
2,638.3
|
|
|||
Washington National:
|
|
|
|
|
|
|
|
||||
Insurance policy income:
|
|
|
|
|
|
|
|
||||
Annuities
|
2.9
|
|
|
3.0
|
|
|
4.0
|
|
|||
Health
|
627.9
|
|
|
615.4
|
|
|
597.6
|
|
|||
Life
|
25.0
|
|
|
25.4
|
|
|
24.4
|
|
|||
Net investment income (a)
|
259.3
|
|
|
253.6
|
|
|
276.1
|
|
|||
Fee revenue and other income (a)
|
1.3
|
|
|
1.3
|
|
|
1.1
|
|
|||
Total Washington National revenues
|
916.4
|
|
|
898.7
|
|
|
903.2
|
|
|||
Colonial Penn:
|
|
|
|
|
|
|
|
||||
Insurance policy income:
|
|
|
|
|
|
|
|
||||
Health
|
2.6
|
|
|
3.0
|
|
|
3.6
|
|
|||
Life
|
278.8
|
|
|
260.5
|
|
|
242.4
|
|
|||
Net investment income (a)
|
44.2
|
|
|
43.0
|
|
|
41.7
|
|
|||
Fee revenue and other income (a)
|
1.1
|
|
|
1.0
|
|
|
1.0
|
|
|||
Total Colonial Penn revenues
|
326.7
|
|
|
307.5
|
|
|
288.7
|
|
|||
Long-term care in run-off:
|
|
|
|
|
|
|
|
||||
Insurance policy income - health
|
4.8
|
|
|
—
|
|
|
—
|
|
|||
Net investment income (a)
|
9.4
|
|
|
—
|
|
|
—
|
|
|||
Total Long-term care in run-off revenues
|
14.2
|
|
|
—
|
|
|
—
|
|
|||
Corporate operations:
|
|
|
|
|
|
|
|
||||
Net investment income
|
16.6
|
|
|
11.3
|
|
|
14.9
|
|
|||
Fee revenue and other income
|
10.0
|
|
|
8.6
|
|
|
6.7
|
|
|||
Total corporate revenues
|
26.6
|
|
|
19.9
|
|
|
21.6
|
|
|||
Total revenues
|
3,914.2
|
|
|
3,787.2
|
|
|
3,851.8
|
|
|
2016
|
|
2015
|
|
2014
|
||||||
Expenses:
|
|
|
|
|
|
||||||
Bankers Life:
|
|
|
|
|
|
||||||
Insurance policy benefits
|
$
|
1,620.6
|
|
|
$
|
1,588.4
|
|
|
$
|
1,667.6
|
|
Amortization
|
176.5
|
|
|
187.1
|
|
|
174.7
|
|
|||
Interest expense on investment borrowings
|
13.2
|
|
|
8.8
|
|
|
7.9
|
|
|||
Other operating costs and expenses
|
422.1
|
|
|
407.2
|
|
|
401.2
|
|
|||
Total Bankers Life expenses
|
2,232.4
|
|
|
2,191.5
|
|
|
2,251.4
|
|
|||
Washington National:
|
|
|
|
|
|
|
|
||||
Insurance policy benefits
|
561.7
|
|
|
546.6
|
|
|
536.2
|
|
|||
Amortization
|
59.1
|
|
|
55.2
|
|
|
64.6
|
|
|||
Interest expense on investment borrowings
|
3.7
|
|
|
2.0
|
|
|
1.7
|
|
|||
Other operating costs and expenses
|
189.0
|
|
|
183.4
|
|
|
189.5
|
|
|||
Total Washington National expenses
|
813.5
|
|
|
787.2
|
|
|
792.0
|
|
|||
Colonial Penn:
|
|
|
|
|
|
|
|
||||
Insurance policy benefits
|
201.9
|
|
|
189.0
|
|
|
173.2
|
|
|||
Amortization
|
15.3
|
|
|
14.4
|
|
|
15.3
|
|
|||
Interest expense on investment borrowings
|
.6
|
|
|
.1
|
|
|
—
|
|
|||
Other operating costs and expenses
|
107.2
|
|
|
98.4
|
|
|
99.4
|
|
|||
Total Colonial Penn expenses
|
325.0
|
|
|
301.9
|
|
|
287.9
|
|
|||
Long-term care in run-off:
|
|
|
|
|
|
|
|
||||
Insurance policy benefits
|
17.6
|
|
|
—
|
|
|
—
|
|
|||
Other operating costs and expenses
|
.5
|
|
|
—
|
|
|
—
|
|
|||
Total Long-term care in run-off expenses
|
18.1
|
|
|
—
|
|
|
—
|
|
|||
Corporate operations:
|
|
|
|
|
|
|
|
||||
Interest expense on corporate debt
|
45.8
|
|
|
45.0
|
|
|
43.9
|
|
|||
Interest expense on investment borrowings
|
—
|
|
|
.2
|
|
|
.1
|
|
|||
Other operating costs and expenses
|
69.1
|
|
|
38.6
|
|
|
49.1
|
|
|||
Total corporate expenses
|
114.9
|
|
|
83.8
|
|
|
93.1
|
|
|||
Total expenses
|
3,503.9
|
|
|
3,364.4
|
|
|
3,424.4
|
|
|||
Pre-tax operating earnings by segment:
|
|
|
|
|
|
|
|
||||
Bankers Life
|
397.9
|
|
|
369.6
|
|
|
386.9
|
|
|||
Washington National
|
102.9
|
|
|
111.5
|
|
|
111.2
|
|
|||
Colonial Penn
|
1.7
|
|
|
5.6
|
|
|
.8
|
|
|||
Long-term care in run-off
|
(3.9
|
)
|
|
—
|
|
|
—
|
|
|||
Corporate operations
|
(88.3
|
)
|
|
(63.9
|
)
|
|
(71.5
|
)
|
|||
Pre-tax operating earnings
|
$
|
410.3
|
|
|
$
|
422.8
|
|
|
$
|
427.4
|
|
(a)
|
It is not practicable to provide additional components of revenue by product or services.
|
|
2016
|
|
2015
|
|
2014
|
||||||
Total segment revenues
|
$
|
3,914.2
|
|
|
$
|
3,787.2
|
|
|
$
|
3,851.8
|
|
Net realized investment gains (losses)
|
8.3
|
|
|
(36.6
|
)
|
|
33.9
|
|
|||
Revenues related to certain non-strategic investments and earnings attributable to VIEs
|
52.6
|
|
|
36.3
|
|
|
33.2
|
|
|||
Fee revenue related to transition and support services agreements
|
10.0
|
|
|
25.0
|
|
|
15.0
|
|
|||
Revenues of CLIC prior to being sold
|
—
|
|
|
—
|
|
|
210.8
|
|
|||
Consolidated revenues
|
3,985.1
|
|
|
3,811.9
|
|
|
4,144.7
|
|
|||
|
|
|
|
|
|
||||||
Total segment expenses
|
3,503.9
|
|
|
3,364.4
|
|
|
3,424.4
|
|
|||
Insurance policy benefits - fair value changes in embedded derivative liabilities
|
(11.3
|
)
|
|
(15.7
|
)
|
|
48.5
|
|
|||
Amortization related to fair value changes in embedded derivative liabilities
|
1.7
|
|
|
3.8
|
|
|
(12.5
|
)
|
|||
Amortization related to net realized investment gains (losses)
|
.7
|
|
|
(.5
|
)
|
|
1.0
|
|
|||
Expenses related to certain non-strategic investments and expenses (earnings) attributable to VIEs
|
54.6
|
|
|
43.0
|
|
|
41.2
|
|
|||
Fair value changes and amendment related to agent deferred compensation plan
|
(3.1
|
)
|
|
(15.1
|
)
|
|
26.8
|
|
|||
Loss on extinguishment or modification of debt
|
—
|
|
|
32.8
|
|
|
.6
|
|
|||
Loss on sale of subsidiary, (gain) loss on reinsurance transactions and transition expenses
|
75.4
|
|
|
9.0
|
|
|
239.8
|
|
|||
Expenses related to transition and support services agreements
|
10.0
|
|
|
22.5
|
|
|
12.4
|
|
|||
Expenses of CLIC prior to being sold
|
—
|
|
|
—
|
|
|
187.4
|
|
|||
Consolidated expenses
|
3,631.9
|
|
|
3,444.2
|
|
|
3,969.6
|
|
|||
Income before tax
|
353.2
|
|
|
367.7
|
|
|
175.1
|
|
|||
Income tax expense:
|
|
|
|
|
|
||||||
Tax expense on period income
|
127.8
|
|
|
129.5
|
|
|
159.2
|
|
|||
Valuation allowance for deferred tax assets and other tax items
|
(132.8
|
)
|
|
(32.5
|
)
|
|
(35.5
|
)
|
|||
Net income
|
$
|
358.2
|
|
|
$
|
270.7
|
|
|
$
|
51.4
|
|
|
2016
|
|
2015
|
||||
Assets:
|
|
|
|
||||
Bankers Life
|
$
|
19,876.4
|
|
|
$
|
19,067.8
|
|
Washington National
|
7,555.7
|
|
|
7,948.5
|
|
||
Colonial Penn
|
1,022.9
|
|
|
985.4
|
|
||
Long-term care in run-off
|
656.2
|
|
|
—
|
|
||
Corporate operations
|
2,864.0
|
|
|
3,123.4
|
|
||
Total assets
|
$
|
31,975.2
|
|
|
$
|
31,125.1
|
|
Liabilities:
|
|
|
|
||||
Bankers Life
|
$
|
17,144.9
|
|
|
$
|
16,612.0
|
|
Washington National
|
6,096.9
|
|
|
6,665.1
|
|
||
Colonial Penn
|
898.5
|
|
|
869.3
|
|
||
Long-term care in run-off
|
562.2
|
|
|
—
|
|
||
Corporate operations
|
2,785.8
|
|
|
2,840.2
|
|
||
Total liabilities
|
$
|
27,488.3
|
|
|
$
|
26,986.6
|
|
Segment
|
Present value of future profits
|
|
Deferred acquisition costs
|
|
Insurance liabilities
|
||||||
2016
|
|
|
|
|
|
||||||
Bankers Life
|
$
|
95.5
|
|
|
$
|
646.2
|
|
|
$
|
15,702.8
|
|
Washington National
|
266.8
|
|
|
299.9
|
|
|
5,586.7
|
|
|||
Colonial Penn
|
39.5
|
|
|
98.6
|
|
|
809.6
|
|
|||
Long-term care in run-off
|
—
|
|
|
—
|
|
|
554.7
|
|
|||
Total
|
$
|
401.8
|
|
|
$
|
1,044.7
|
|
|
$
|
22,653.8
|
|
2015
|
|
|
|
|
|
||||||
Bankers Life
|
$
|
114.9
|
|
|
$
|
718.2
|
|
|
$
|
15,234.1
|
|
Washington National
|
290.2
|
|
|
280.0
|
|
|
6,126.2
|
|
|||
Colonial Penn
|
43.9
|
|
|
85.1
|
|
|
782.9
|
|
|||
Total
|
$
|
449.0
|
|
|
$
|
1,083.3
|
|
|
$
|
22,143.2
|
|
2016
|
1st Qtr.
|
|
2nd Qtr.
|
|
3rd Qtr.
|
|
4th Qtr.
|
||||||||
Revenues
|
$
|
960.4
|
|
|
$
|
1,003.9
|
|
|
$
|
1,015.9
|
|
|
$
|
1,004.9
|
|
Income before income taxes
|
$
|
40.5
|
|
|
$
|
82.7
|
|
|
$
|
49.3
|
|
|
$
|
180.7
|
|
Income tax expense (benefit)
|
(5.0
|
)
|
|
22.8
|
|
|
30.7
|
|
|
(53.5
|
)
|
||||
Net income
|
$
|
45.5
|
|
|
$
|
59.9
|
|
|
$
|
18.6
|
|
|
$
|
234.2
|
|
Earnings per common share:
|
|
|
|
|
|
|
|
||||||||
Basic:
|
|
|
|
|
|
|
|
||||||||
Net income
|
$
|
.25
|
|
|
$
|
.34
|
|
|
$
|
.11
|
|
|
$
|
1.35
|
|
Diluted:
|
|
|
|
|
|
|
|
||||||||
Net income
|
$
|
.25
|
|
|
$
|
.33
|
|
|
$
|
.11
|
|
|
$
|
1.34
|
|
|
|
|
|
|
|
|
|
||||||||
2015
|
1st Qtr.
|
|
2nd Qtr.
|
|
3rd Qtr.
|
|
4th Qtr.
|
||||||||
Revenues
|
$
|
978.3
|
|
|
$
|
959.5
|
|
|
$
|
904.5
|
|
|
$
|
969.6
|
|
Income before income taxes
|
$
|
82.3
|
|
|
$
|
72.7
|
|
|
$
|
52.4
|
|
|
$
|
160.3
|
|
Income tax expense
|
29.5
|
|
|
25.9
|
|
|
18.6
|
|
|
23.0
|
|
||||
Net income
|
$
|
52.8
|
|
|
$
|
46.8
|
|
|
$
|
33.8
|
|
|
$
|
137.3
|
|
Earnings per common share:
|
|
|
|
|
|
|
|
||||||||
Basic:
|
|
|
|
|
|
|
|
||||||||
Net income
|
$
|
.26
|
|
|
$
|
.24
|
|
|
$
|
.18
|
|
|
$
|
.74
|
|
Diluted:
|
|
|
|
|
|
|
|
||||||||
Net income
|
$
|
.26
|
|
|
$
|
.24
|
|
|
$
|
.18
|
|
|
$
|
.73
|
|
|
December 31, 2016
|
||||||||||
|
VIEs
|
|
Eliminations
|
|
Net effect on
consolidated
balance sheet
|
||||||
Assets:
|
|
|
|
|
|
||||||
Investments held by variable interest entities
|
$
|
1,724.3
|
|
|
$
|
—
|
|
|
$
|
1,724.3
|
|
Notes receivable of VIEs held by insurance subsidiaries
|
—
|
|
|
(204.2
|
)
|
|
(204.2
|
)
|
|||
Cash and cash equivalents held by variable interest entities
|
189.3
|
|
|
—
|
|
|
189.3
|
|
|||
Accrued investment income
|
3.0
|
|
|
(.1
|
)
|
|
2.9
|
|
|||
Income tax assets, net
|
6.4
|
|
|
(1.3
|
)
|
|
5.1
|
|
|||
Other assets
|
13.1
|
|
|
(1.8
|
)
|
|
11.3
|
|
|||
Total assets
|
$
|
1,936.1
|
|
|
$
|
(207.4
|
)
|
|
$
|
1,728.7
|
|
Liabilities:
|
|
|
|
|
|
|
|
|
|||
Other liabilities
|
$
|
81.8
|
|
|
$
|
(6.4
|
)
|
|
$
|
75.4
|
|
Borrowings related to variable interest entities
|
1,662.8
|
|
|
—
|
|
|
1,662.8
|
|
|||
Notes payable of VIEs held by insurance subsidiaries
|
203.3
|
|
|
(203.3
|
)
|
|
—
|
|
|||
Total liabilities
|
$
|
1,947.9
|
|
|
$
|
(209.7
|
)
|
|
$
|
1,738.2
|
|
|
December 31, 2015
|
||||||||||
|
VIEs
|
|
Eliminations
|
|
Net effect on
consolidated
balance sheet
|
||||||
Assets:
|
|
|
|
|
|
||||||
Investments held by variable interest entities
|
$
|
1,633.6
|
|
|
$
|
—
|
|
|
$
|
1,633.6
|
|
Notes receivable of VIEs held by insurance subsidiaries
|
—
|
|
|
(204.3
|
)
|
|
(204.3
|
)
|
|||
Cash and cash equivalents held by variable interest entities
|
364.4
|
|
|
—
|
|
|
364.4
|
|
|||
Accrued investment income
|
3.3
|
|
|
—
|
|
|
3.3
|
|
|||
Income tax assets, net
|
26.0
|
|
|
(1.9
|
)
|
|
24.1
|
|
|||
Other assets
|
1.4
|
|
|
(1.5
|
)
|
|
(.1
|
)
|
|||
Total assets
|
$
|
2,028.7
|
|
|
$
|
(207.7
|
)
|
|
$
|
1,821.0
|
|
Liabilities:
|
|
|
|
|
|
|
|
|
|||
Other liabilities
|
$
|
196.6
|
|
|
$
|
(7.2
|
)
|
|
$
|
189.4
|
|
Borrowings related to variable interest entities
|
1,676.4
|
|
|
—
|
|
|
1,676.4
|
|
|||
Notes payable of VIEs held by insurance subsidiaries
|
204.0
|
|
|
(204.0
|
)
|
|
—
|
|
|||
Total liabilities
|
$
|
2,077.0
|
|
|
$
|
(211.2
|
)
|
|
$
|
1,865.8
|
|
|
2016
|
|
2015
|
|
2014
|
||||||
Revenues:
|
|
|
|
|
|
||||||
Net investment income – policyholder and reinsurer accounts and other special-purpose portfolios
|
$
|
78.9
|
|
|
$
|
62.1
|
|
|
$
|
47.2
|
|
Fee revenue and other income
|
6.4
|
|
|
1.6
|
|
|
1.1
|
|
|||
Total revenues
|
85.3
|
|
|
63.7
|
|
|
48.3
|
|
|||
Expenses:
|
|
|
|
|
|
||||||
Interest expense
|
53.1
|
|
|
38.8
|
|
|
30.1
|
|
|||
Other operating expenses
|
1.5
|
|
|
2.0
|
|
|
1.2
|
|
|||
Total expenses
|
54.6
|
|
|
40.8
|
|
|
31.3
|
|
|||
Income before net realized investment losses and income taxes
|
30.7
|
|
|
22.9
|
|
|
17.0
|
|
|||
Net realized investment losses
|
(20.4
|
)
|
|
(6.4
|
)
|
|
(2.2
|
)
|
|||
Income before income taxes
|
$
|
10.3
|
|
|
$
|
16.5
|
|
|
$
|
14.8
|
|
|
Amortized
cost
|
|
Estimated
fair
value
|
||||
|
(Dollars in millions)
|
||||||
Due in one year or less
|
$
|
20.5
|
|
|
$
|
20.0
|
|
Due after one year through five years
|
846.5
|
|
|
853.1
|
|
||
Due after five years through ten years
|
841.6
|
|
|
851.2
|
|
||
Total
|
$
|
1,708.6
|
|
|
$
|
1,724.3
|
|
|
Amortized
cost
|
|
Estimated
fair
value
|
||||
|
(Dollars in millions)
|
||||||
Due in one year or less
|
$
|
10.5
|
|
|
$
|
9.9
|
|
Due after one year through five years
|
175.2
|
|
|
172.5
|
|
||
Due after five years through ten years
|
55.8
|
|
|
55.3
|
|
||
Total
|
$
|
241.5
|
|
|
$
|
237.7
|
|
ITEM 9.
|
CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE.
|
(a)
|
1.
|
Financial Statements. See Index to Consolidated Financial Statements on page
119
for a list of financial statements included in this Report.
|
|
2.
|
Financial Statement Schedules:
|
|
|
Schedule II ‑‑ Condensed Financial Information of Registrant (Parent Company)
|
|
|
Schedule IV ‑‑ Reinsurance
|
3.
|
Exhibits. See Exhibit Index immediately preceding the Exhibits filed with this report.
|
|
By:
|
/s/ Edward J. Bonach
|
|
|
Edward J. Bonach
|
|
|
Chief Executive Officer
|
|
|
|
Signature
|
Title (Capacity)
|
Date
|
/s/ EDWARD J. BONACH
|
Director and Chief Executive Officer
|
February 21, 2017
|
Edward J. Bonach
|
(Principal Executive Officer)
|
|
|
|
|
/s/ ERIK M. HELDING
|
Executive Vice President
|
February 21, 2017
|
Erik M. Helding
|
and Chief Financial Officer
|
|
|
(Principal Financial Officer)
|
|
|
|
|
/s/ JOHN R. KLINE
|
Senior Vice President
|
February 21, 2017
|
John R. Kline
|
and Chief Accounting Officer
|
|
|
(Principal Accounting Officer)
|
|
|
|
|
/s/ ELLYN L. BROWN
|
Director
|
February 21, 2017
|
Ellyn L. Brown
|
|
|
|
|
|
/s/ ROBERT C. GREVING
|
Director
|
February 21, 2017
|
Robert C. Greving
|
|
|
|
|
|
/s/ MARY R. HENDERSON
|
Director
|
February 21, 2017
|
Mary R. Henderson
|
|
|
|
|
|
/s/ CHARLES J. JACKLIN
|
Director
|
February 21, 2017
|
Charles J. Jacklin
|
|
|
|
|
|
/s/ DANIEL R. MAURER
|
Director
|
February 21, 2017
|
Daniel R. Maurer
|
|
|
|
|
|
/s/ NEAL C. SCHNEIDER
|
Director
|
February 21, 2017
|
Neal C. Schneider
|
|
|
|
|
|
/s/ FREDERICK J. SIEVERT
|
Director
|
February 21, 2017
|
Frederick J. Sievert
|
|
|
|
|
|
/s/ MICHAEL T. TOKARZ
|
Director
|
February 21, 2017
|
Michael T. Tokarz
|
|
|
ASSETS
|
|||||||
|
2016
|
|
2015
|
||||
Fixed maturities, available for sale, at fair value (amortized cost: 2016 - $-; 2015 - $5.0)
|
$
|
—
|
|
|
$
|
5.0
|
|
Cash and cash equivalents - unrestricted
|
106.1
|
|
|
128.9
|
|
||
Equity securities at fair value (cost: 2016 - $166.5; 2015 - $247.3)
|
167.9
|
|
|
254.9
|
|
||
Trading securities
|
—
|
|
|
1.0
|
|
||
Investment in wholly-owned subsidiaries (eliminated in consolidation)
|
5,220.3
|
|
|
4,809.2
|
|
||
Income tax assets, net
|
99.5
|
|
|
58.5
|
|
||
Receivable from subsidiaries (eliminated in consolidation)
|
2.0
|
|
|
3.8
|
|
||
Other assets
|
1.8
|
|
|
3.1
|
|
||
Total assets
|
$
|
5,597.6
|
|
|
$
|
5,264.4
|
|
|
|
|
|
||||
LIABILITIES AND SHAREHOLDERS' EQUITY
|
|||||||
Liabilities:
|
|
|
|
||||
Notes payable
|
$
|
912.9
|
|
|
$
|
911.1
|
|
Payable to subsidiaries (eliminated in consolidation)
|
128.4
|
|
|
135.9
|
|
||
Other liabilities
|
69.4
|
|
|
78.9
|
|
||
Total liabilities
|
1,110.7
|
|
|
1,125.9
|
|
||
Commitments and Contingencies
|
|
|
|
||||
Shareholders' equity:
|
|
|
|
||||
Common stock and additional paid-in capital ($0.01 par value, 8,000,000,000 shares authorized, shares issued and outstanding: 2016 - 173,753,614; 2015 - 184,028,511)
|
3,213.8
|
|
|
3,388.6
|
|
||
Accumulated other comprehensive income
|
622.4
|
|
|
402.8
|
|
||
Retained earnings
|
650.7
|
|
|
347.1
|
|
||
Total shareholders' equity
|
4,486.9
|
|
|
4,138.5
|
|
||
Total liabilities and shareholders' equity
|
$
|
5,597.6
|
|
|
$
|
5,264.4
|
|
|
2016
|
|
2015
|
|
2014
|
||||||
Revenues:
|
|
|
|
|
|
||||||
Net investment income
|
$
|
15.6
|
|
|
$
|
16.9
|
|
|
$
|
12.7
|
|
Net realized investment gains
|
17.7
|
|
|
3.5
|
|
|
11.1
|
|
|||
Intercompany losses (eliminated in consolidation)
|
—
|
|
|
(1.5
|
)
|
|
(1.0
|
)
|
|||
Total revenues
|
33.3
|
|
|
18.9
|
|
|
22.8
|
|
|||
Expenses:
|
|
|
|
|
|
||||||
Interest expense
|
45.8
|
|
|
45.2
|
|
|
44.0
|
|
|||
Intercompany expenses (eliminated in consolidation)
|
.9
|
|
|
.4
|
|
|
.3
|
|
|||
Operating costs and expenses
|
48.2
|
|
|
21.0
|
|
|
66.6
|
|
|||
Loss on extinguishment of debt
|
—
|
|
|
32.8
|
|
|
.6
|
|
|||
Total expenses
|
94.9
|
|
|
99.4
|
|
|
111.5
|
|
|||
Loss before income taxes and equity in undistributed earnings of subsidiaries
|
(61.6
|
)
|
|
(80.5
|
)
|
|
(88.7
|
)
|
|||
Income tax benefit on period income
|
(54.6
|
)
|
|
(37.9
|
)
|
|
(34.1
|
)
|
|||
Loss before equity in undistributed earnings of subsidiaries
|
(7.0
|
)
|
|
(42.6
|
)
|
|
(54.6
|
)
|
|||
Equity in undistributed earnings of subsidiaries (eliminated in consolidation)
|
365.2
|
|
|
313.3
|
|
|
106.0
|
|
|||
Net income
|
$
|
358.2
|
|
|
$
|
270.7
|
|
|
$
|
51.4
|
|
|
|
|
|
|
|
|
2016
|
|
2015
|
|
2014
|
||||||
Cash flows from operating activities
|
$
|
(114.0
|
)
|
|
$
|
(55.1
|
)
|
|
$
|
(66.7
|
)
|
Cash flows from investing activities:
|
|
|
|
|
|
||||||
Sales of investments
|
305.0
|
|
|
66.5
|
|
|
229.8
|
|
|||
Sales of investments - affiliated*
|
—
|
|
|
16.0
|
|
|
18.3
|
|
|||
Maturities and redemptions of investments - affiliated*
|
—
|
|
|
8.3
|
|
|
—
|
|
|||
Purchases of investments
|
(198.4
|
)
|
|
(68.6
|
)
|
|
(320.1
|
)
|
|||
Purchases of investments - affiliated*
|
—
|
|
|
(3.4
|
)
|
|
(30.7
|
)
|
|||
Net sales of trading securities
|
12.0
|
|
|
11.8
|
|
|
9.9
|
|
|||
Dividends received from consolidated subsidiary, net of capital contributions of $200.0 in 2016, nil in 2015 and $18.8 in 2014*
|
92.5
|
|
|
269.7
|
|
|
423.5
|
|
|||
Net cash provided by investing activities
|
211.1
|
|
|
300.3
|
|
|
330.7
|
|
|||
Cash flows from financing activities:
|
|
|
|
|
|
||||||
Issuance of notes payable, net
|
—
|
|
|
910.0
|
|
|
—
|
|
|||
Payments on notes payable
|
—
|
|
|
(797.1
|
)
|
|
(62.9
|
)
|
|||
Expenses related to extinguishment or modification of debt
|
—
|
|
|
(17.8
|
)
|
|
(.6
|
)
|
|||
Issuance of common stock
|
8.4
|
|
|
6.3
|
|
|
5.0
|
|
|||
Payments to repurchase common stock and warrants
|
(206.7
|
)
|
|
(361.5
|
)
|
|
(376.5
|
)
|
|||
Common stock dividends paid
|
(54.8
|
)
|
|
(52.0
|
)
|
|
(51.0
|
)
|
|||
Investment borrowings - repurchase agreements, net
|
—
|
|
|
(20.4
|
)
|
|
20.4
|
|
|||
Issuance of notes payable to affiliates*
|
217.1
|
|
|
234.4
|
|
|
257.8
|
|
|||
Payments on notes payable to affiliates*
|
(83.9
|
)
|
|
(104.8
|
)
|
|
(100.7
|
)
|
|||
Net cash used by financing activities
|
(119.9
|
)
|
|
(202.9
|
)
|
|
(308.5
|
)
|
|||
Net increase (decrease) in cash and cash equivalents
|
(22.8
|
)
|
|
42.3
|
|
|
(44.5
|
)
|
|||
Cash and cash equivalents, beginning of the year
|
128.9
|
|
|
86.6
|
|
|
131.1
|
|
|||
Cash and cash equivalents, end of the year
|
$
|
106.1
|
|
|
$
|
128.9
|
|
|
$
|
86.6
|
|
|
2016
|
|
2015
|
|
2014
|
||||||
Life insurance inforce:
|
|
|
|
|
|
||||||
Direct
|
$
|
27,048.1
|
|
|
$
|
25,807.0
|
|
|
$
|
25,029.0
|
|
Assumed
|
128.7
|
|
|
137.4
|
|
|
147.1
|
|
|||
Ceded
|
(3,604.0
|
)
|
|
(3,780.8
|
)
|
|
(3,660.1
|
)
|
|||
Net insurance inforce
|
$
|
23,572.8
|
|
|
$
|
22,163.6
|
|
|
$
|
21,516.0
|
|
Percentage of assumed to net
|
.5
|
%
|
|
.6
|
%
|
|
.7
|
%
|
|
2016
|
|
2015
|
|
2014
|
||||||
Insurance policy income:
|
|
|
|
|
|
||||||
Direct
|
$
|
2,553.0
|
|
|
$
|
2,524.3
|
|
|
$
|
2,558.2
|
|
Assumed
|
34.0
|
|
|
38.5
|
|
|
35.0
|
|
|||
Ceded
|
(123.9
|
)
|
|
(133.6
|
)
|
|
(176.7
|
)
|
|||
Net premiums
|
$
|
2,463.1
|
|
|
$
|
2,429.2
|
|
|
$
|
2,416.5
|
|
Percentage of assumed to net
|
1.4
|
%
|
|
1.6
|
%
|
|
1.4
|
%
|
3.1
|
Amended and Restated Certificate of Incorporation of CNO Financial Group, Inc., incorporated by reference to Exhibit 3.1 of our Quarterly Report on Form 10-Q for the quarter ended June 30, 2016.
|
3.2
|
Amended and Restated Bylaws of CNO Financial Group, Inc. dated as of February 28, 2013, incorporated by reference to Exhibit 3.2 of our Current Report on Form 8-K filed February 28, 2013.
|
3.3
|
Certificate of Designations of Series C Junior Participating Preferred Stock of CNO Financial Group, Inc., incorporated by reference to Exhibit 3.1 of our Current Report on Form 8-K filed November 13, 2014.
|
4.1
|
Second Amended and Restated Section 382 Rights Agreement, dated as of November 13, 2014, between the Corporation and American Stock Transfer & Trust Company, LLC, as Rights Agent, which includes the Certificate of Designations for the Series C Junior Participating Preferred Stock as Exhibit A, the Form of Right Certificate as Exhibit B and the Summary of Rights to Purchase Preferred Shares as Exhibit C, incorporated by reference to Exhibit 4.1 of our Current Report on Form 8-K filed November 13, 2014, as amended by the First Amendment to Rights Agreement, dated as of April 22, 2015, between the Corporation and the Rights Agent, incorporated by reference to Exhibit 4.1 of our Quarterly Report on Form 10-Q for the quarter ended March 31, 2015.
|
4.2
|
Form of specimen stock certificate, incorporated by reference to Exhibit 4.1 of our Current Report on Form 8-K filed May 12, 2010.
|
4.3
|
Indenture, dated as of May 19, 2015, between CNO Financial Group, Inc. and Wilmington Trust, National Association, as trustee (the “Trustee”), incorporated by reference to Exhibit 4.1 of our Current Report on Form 8-K filed May 19, 2015.
|
4.4
|
First Supplemental Indenture, dated as of May 19, 2015, between the Corporation and the Trustee, relating to the 4.500% Senior Notes due 2020 and the 5.250% Senior Notes due 2025, incorporated by reference to Exhibit 4.2 of our Current Report on Form 8-K filed May 19, 2015.
|
4.5
|
Form of 4.500% Senior Notes due 2020 (included in Exhibit 4.4).
|
4.6
|
Form of 5.250% Senior Notes due 2025 (included in Exhibit 4.4).
|
10.1
|
Underwriting Agreement dated as of May 14, 2015, between CNO Financial Group, Inc. and Goldman, Sachs & Co. and RBC Capital Markets LLC, as representatives of the several underwriters named therein, incorporated by reference to Exhibit 1.1 of our Current Report on Form 8-K filed May 19, 2015.
|
10.2
|
Credit Agreement, dated as of May 19, 2015, by and among CNO Financial Group, Inc., the lenders from time to time party thereto, and KeyBank National Association, as administrative agent for the lenders, incorporated by reference to Exhibit 10.1 of our Current Report on Form 8-K dated May 19, 2015.
|
10.3
|
Letter of agreement dated as of August 3, 2007 between CNO Services, LLC (formerly Conseco Services, LLC) and John R. Kline, incorporated by reference to Exhibit 10.11 of our Quarterly Report on Form 10-Q for the quarter ended September 30, 2007.
|
10.4
|
CNO Financial Group, Inc. Amended and Restated Long-Term Incentive Plan, incorporated by reference to Exhibit 10.13 of our Quarterly Report on Form 10-Q for the quarter ended September 30, 2011.
|
10.5
|
Form of stock option agreement under Amended and Restated Long-Term Incentive Plan, incorporated by reference to Exhibit 10.1 of our Quarterly Report on Form 10-Q for the quarter ended March 31, 2014.
|
10.6
|
Form of restricted stock agreement under Amended and Restated Long-Term Incentive Plan, incorporated by reference to Exhibit 10.2 of our Quarterly Report on Form 10-Q for the quarter ended March 31, 2014.
|
10.7
|
Form of performance unit award agreement (TSR) under the Amended and Restated Long-Term Incentive Plan, incorporated by reference to Exhibit 10.3 of our Quarterly Report on Form 10-Q for the quarter ended March 31, 2014.
|
10.8
|
Form of performance unit award agreement (ROE) under the Amended and Restated Long-Term Incentive Plan, incorporated by reference to Exhibit 10.4 of our Quarterly Report on Form 10-Q for the quarter ended March 31, 2014.
|
10.9
|
Form of stock option agreement for 2015 under Amended and Restated Long-Term Incentive Plan, incorporated by reference to Exhibit 10.1 of our Quarterly Report on Form 10-Q for the quarter ended March 31, 2015.
|
10.10
|
Form of restricted stock agreement for 2015 under Amended and Restated Long-Term Incentive Plan, incorporated by reference to Exhibit 10.2 of our Quarterly Report on Form 10-Q for the quarter ended March 31, 2015.
|
10.11
|
Form of performance unit award agreement (TSR) for 2015 under the Amended and Restated Long-Term Incentive Plan, incorporated by reference to Exhibit 10.3 of our Quarterly Report on Form 10-Q for the quarter ended March 31, 2015.
|
10.12
|
Form of performance unit award agreement (ROE) for 2015 under the Amended and Restated Long-Term Incentive Plan, incorporated by reference to Exhibit 10.4 of our Quarterly Report on Form 10-Q for the quarter ended March 31, 2015.
|
10.13
|
Form of amendment to outstanding stock option agreements under the Amended and Restated Long-Term Incentive Plan, incorporated by reference to Exhibit 10.5 of our Quarterly Report on Form 10-Q for the quarter ended March 31, 2015.
|
10.14
|
Form of amendment to outstanding restricted stock agreements under the Amended and Restated Long-Term Incentive Plan, incorporated by reference to Exhibit 10.6 of our Quarterly Report on Form 10-Q for the quarter ended March 31, 2015.
|
10.15
|
Form of amendment to outstanding performance unit award agreements under the Amended and Restated Long-Term Incentive Plan, incorporated by reference to Exhibit 10.7 of our Quarterly Report on Form 10-Q for the quarter ended March 31, 2015.
|
10.16
|
Form of Indemnification Agreement among the Corporation, CDOC, Inc., CNO Services, LLC (formerly Conseco Services, LLC) and each director of the Corporation, incorporated by reference to Exhibit 10.16 of our Annual Report on Form 10-K for the year ended December 31, 2008.
|
10.17
|
Closing Agreement on Final Determination Covering Specific Matters, incorporated by reference to Exhibit 10.14 of our Current Report on Form 8-K filed September 14, 2004.
|
10.18
|
2015 Pay for Performance Incentive Plan, incorporated by reference to Exhibit 10.1 of our Current Report on Form 8-K filed March 12, 2015.
|
10.19
|
Closing Agreement on Final Determination Covering Specific Matters, incorporated by reference to Exhibit 10.21 of our Current Report on Form 8-K filed August 1, 2006.
|
10.20
|
Deferred Compensation Plan amended and restated effective January 1, 2017.
|
10.21
|
Amended and Restated Employment Agreement dated as of May 31, 2016 between CNO Services, LLC and Susan L. Menzel, incorporated by reference to Exhibit 10.21 of our Quarterly Report on Form 10-Q for the quarter ended June 30, 2016.
|
10.22
|
Amended and Restated Employment Agreement dated as of December 18, 2014 between CNO Services, LLC and Christopher J. Nickele, incorporated by reference to Exhibit 10.17 of our Annual Report on Form 10-K for the year ended December 31, 2014.
|
10.23
|
Amended and Restated Employment Agreement dated as of January 5, 2015 between CNO Financial Group, Inc. and Scott R. Perry, incorporated by reference to Exhibit 10.18 of our Annual Report on Form 10-K for the year ended December 31, 2014.
|
10.24
|
Amended and Restated Employment Agreement dated as of December 18, 2014 between CNO Financial Group, Inc. and Edward J. Bonach, incorporated by reference to Exhibit 10.20 of our Annual Report on Form 10-K for the year ended December 31, 2014.
|
10.25
|
Amended and Restated Employment Agreement dated as of September 30, 2016 between 40|86 Advisors, Inc. and Eric R. Johnson, incorporated by reference to Exhibit 10.25 of our Quarterly Report on Form 10-Q for the quarter ended September 30, 2016.
|
10.26
|
Amended and Restated Employment Agreement dated as of January 12, 2015 between CNO Services, LLC and Matthew J. Zimpfer, incorporated by reference to Exhibit 10.22 of our Annual Report on Form 10-K for the year ended December 31, 2014.
|
10.27
|
Amended and Restated Employment Agreement dated as of January 6, 2015 between CNO Services, LLC and Bruce Baude, incorporated by reference to Exhibit 10.23 of our Annual Report on Form 10-K for the year ended December 31, 2014, as amended by Amendment dated July 30, 2015, incorporated by reference to Exhibit 10.1 of our Quarterly Report on Form 10-Q for the quarter ended June 30, 2015.
|
10.28
|
Coinsurance and Administration Agreement between Conseco Insurance Company and Reassure American Life Insurance Company, incorporated by reference to Exhibit 10.34 of our Quarterly Report on Form 10-Q for the quarter ended June 30, 2007.
|
10.29
|
Employment Agreement dated as of April 6, 2016 between CNO Financial Group, Inc. and Gary C. Bhojwani, incorporated by reference to Exhibit 10.1 of our Current Report on Form 8-K filed April 12, 2016.
|
10.30
|
Employment Agreement dated as of April 8, 2016 between CNO Financial Group, Inc. and Erik M. Helding, incorporated by reference to Exhibit 10.2 of our Current Report on Form 8-K filed April 12, 2016.
|
10.31
|
CNO Board of Directors Deferred Compensation Plan.
|
12.1
|
Computation of Ratio of Earnings to Fixed Charges and Preferred Dividends.
|
21
|
Subsidiaries of the Registrant.
|
23.1
|
Consent of PricewaterhouseCoopers LLP.
|
31.1
|
Certification Pursuant to the Securities Exchange Act Rule 13a-14(a)/15d-14(a), as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
|
31.2
|
Certification Pursuant to the Securities Exchange Act Rule 13a-14(a)/15d-14(a), as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
|
32.1
|
Certification Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
|
32.2
|
Certification Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
|
101.INS
|
XBRL Instance Document.
|
101.SCH
|
XBRL Taxonomy Extension Schema Document.
|
101.CAL
|
XBRL Taxonomy Extension Calculation Linkbase Document.
|
101.DEF
|
XBRL Taxonomy Extension Definition Linkbase Document.
|
101.LAB
|
XBRL Taxonomy Extension Label Linkbase Document.
|
101.PRE
|
XBRL Taxonomy Extension Presentation Linkbase Document.
|
10.3
|
Letter of agreement dated as of August 3, 2007 between CNO Services, LLC (formerly Conseco Services, LLC) and John R. Kline, incorporated by reference to Exhibit 10.11 of our Quarterly Report on Form 10-Q for the quarter ended September 30, 2007.
|
10.4
|
CNO Financial Group, Inc. Amended and Restated Long-Term Incentive Plan, incorporated by reference to Exhibit 10.13 of our Quarterly Report on Form 10-Q for the quarter ended September 30, 2011.
|
10.5
|
Form of stock option agreement under Amended and Restated Long-Term Incentive Plan, incorporated by reference to Exhibit 10.1 of our Quarterly Report on Form 10-Q for the quarter ended March 31, 2014.
|
10.6
|
Form of restricted stock agreement under Amended and Restated Long-Term Incentive Plan, incorporated by reference to Exhibit 10.2 of our Quarterly Report on Form 10-Q for the quarter ended March 31, 2014.
|
10.7
|
Form of performance unit award agreement (TSR) under the Amended and Restated Long-Term Incentive Plan, incorporated by reference to Exhibit 10.3 of our Quarterly Report on Form 10-Q for the quarter ended March 31, 2014.
|
10.8
|
Form of performance unit award agreement (ROE) under the Amended and Restated Long-Term Incentive Plan, incorporated by reference to Exhibit 10.4 of our Quarterly Report on Form 10-Q for the quarter ended March 31, 2014.
|
10.9
|
Form of stock option agreement for 2015 under Amended and Restated Long-Term Incentive Plan, incorporated by reference to Exhibit 10.1 of our Quarterly Report on Form 10-Q for the quarter ended March 31, 2015.
|
10.10
|
Form of restricted stock agreement for 2015 under Amended and Restated Long-Term Incentive Plan, incorporated by reference to Exhibit 10.2 of our Quarterly Report on Form 10-Q for the quarter ended March 31, 2015.
|
10.11
|
Form of performance unit award agreement (TSR) for 2015 under the Amended and Restated Long-Term Incentive Plan, incorporated by reference to Exhibit 10.3 of our Quarterly Report on Form 10-Q for the quarter ended March 31, 2015.
|
10.12
|
Form of performance unit award agreement (ROE) for 2015 under the Amended and Restated Long-Term Incentive Plan, incorporated by reference to Exhibit 10.4 of our Quarterly Report on Form 10-Q for the quarter ended March 31, 2015.
|
10.13
|
Form of amendment to outstanding stock option agreements under the Amended and Restated Long-Term Incentive Plan, incorporated by reference to Exhibit 10.5 of our Quarterly Report on Form 10-Q for the quarter ended March 31, 2015.
|
10.14
|
Form of amendment to outstanding restricted stock agreements under the Amended and Restated Long-Term Incentive Plan, incorporated by reference to Exhibit 10.6 of our Quarterly Report on Form 10-Q for the quarter ended March 31, 2015.
|
10.15
|
Form of amendment to outstanding performance unit award agreements under the Amended and Restated Long-Term Incentive Plan, incorporated by reference to Exhibit 10.7 of our Quarterly Report on Form 10-Q for the quarter ended March 31, 2015.
|
10.18
|
2015 Pay for Performance Incentive Plan, incorporated by reference to Exhibit 10.1 of our Current Report on Form 8-K filed March 12, 2015.
|
10.20
|
Deferred Compensation Plan amended and restated effective January 1, 2017.
|
10.21
|
Amended and Restated Employment Agreement dated as of May 31, 2016 between CNO Services, LLC and Susan L. Menzel, incorporated by reference to Exhibit 10.21 of our Quarterly Report on Form 10-Q for the quarter ended June 30, 2016.
|
10.22
|
Amended and Restated Employment Agreement dated as of December 18, 2014 between CNO Services, LLC and Christopher J. Nickele, incorporated by reference to Exhibit 10.17 of our Annual Report on Form 10-K for the year ended December 31, 2014.
|
10.23
|
Amended and Restated Employment Agreement dated as of January 5, 2015 between CNO Financial Group, Inc. and Scott R. Perry, incorporated by reference to Exhibit 10.18 of our Annual Report on Form 10-K for the year ended December 31, 2014.
|
10.24
|
Amended and Restated Employment Agreement dated as of December 18, 2014 between CNO Financial Group, Inc. and Edward J. Bonach, incorporated by reference to Exhibit 10.20 of our Annual Report on Form 10-K for the year ended December 31, 2014.
|
10.25
|
Amended and Restated Employment Agreement dated as of September 30, 2016 between 40|86 Advisors, Inc. and Eric R. Johnson, incorporated by reference to Exhibit 10.25 of our Quarterly Report on Form 10-Q for the quarter ended September 30, 2016.
|
10.26
|
Amended and Restated Employment Agreement dated as of January 12, 2015 between CNO Services, LLC and Matthew J. Zimpfer, incorporated by reference to Exhibit 10.22 of our Annual Report on Form 10-K for the year ended December 31, 2014.
|
10.27
|
Amended and Restated Employment Agreement dated as of January 6, 2015 between CNO Services, LLC and Bruce Baude, incorporated by reference to Exhibit 10.23 of our Annual Report on Form 10-K for the year ended December 31, 2014, as amended by Amendment dated July 30, 2015, incorporated by reference to Exhibit 10.1 of our Quarterly Report on Form 10-Q for the quarter ended June 30, 2015.
|
10.29
|
Employment Agreement dated as of April 6, 2016 between CNO Financial Group, Inc. and Gary C. Bhojwani, incorporated by reference to Exhibit 10.1 of our Current Report on Form 8-K filed April 12, 2016.
|
10.30
|
Employment Agreement dated as of April 8, 2016 between CNO Financial Group, Inc. and Erik M. Helding, incorporated by reference to Exhibit 10.2 of our Current Report on Form 8-K filed April 12, 2016.
|
10.31
|
CNO Board of Directors Deferred Compensation Plan.
|
No information found
* THE VALUE IS THE MARKET VALUE AS OF THE LAST DAY OF THE QUARTER FOR WHICH THE 13F WAS FILED.
FUND | NUMBER OF SHARES | VALUE ($) | PUT OR CALL |
---|
DIRECTORS | AGE | BIO | OTHER DIRECTOR MEMBERSHIPS |
---|
No information found
No Customers Found
Suppliers
Supplier name | Ticker |
---|---|
Johnson & Johnson | JNJ |
Pfizer Inc. | PFE |
Merck & Co., Inc. | MRK |
Abbott Laboratories | ABT |
Bristol-Myers Squibb Company | BMY |
AbbVie Inc. | ABBV |
Amgen Inc. | AMGN |
Price
Yield
Owner | Position | Direct Shares | Indirect Shares |
---|